var title_f22_45_23248="Airway view of glottis and esophagus";
var content_f22_45_23248=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F78195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F78195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Airway view of the glottis and esophagus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 293px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Airway view during laryngoscopy. The glottis has a vertical orientation with vocal cords appearing as white structures superiorly and arytenoid cartilages posteriorily&nbsp;(black arrow). The esophagus has a horizontal orientation and appears slitlike inferiorly (white arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Joshua Nagler, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_45_23248=[""].join("\n");
var outline_f22_45_23248=null;
var title_f22_45_23249="Toxic shock syndrome - macular erythema";
var content_f22_45_23249=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F61786&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F61786&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Toxic shock syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Macular erythema is present on the arm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_45_23249=[""].join("\n");
var outline_f22_45_23249=null;
var title_f22_45_23250="Diagnosis of celiac disease";
var content_f22_45_23250=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62181&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62181&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 571px\">",
"   <div class=\"ttl\">",
"    Diagnosis of celiac disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 551px; height: 614px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     EMA: antiendomysial antibodies; tTG: tissue transglutaminase.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_45_23250=[""].join("\n");
var outline_f22_45_23250=null;
var title_f22_45_23251="Zanca radiographic view";
var content_f22_45_23251=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F72101&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F72101&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Zanca radiographic view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 385px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The patient in the photograph above is positioned for a Zanca view. Note the upward angle of the x-ray beam.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott Koehler, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_45_23251=[""].join("\n");
var outline_f22_45_23251=null;
var title_f22_45_23252="Metronidazole (topical): Pediatric drug information";
var content_f22_45_23252=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Metronidazole (topical): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?13/25/13717?source=see_link\">",
"    see \"Metronidazole (topical): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?0/5/95?source=see_link\">",
"    see \"Metronidazole (topical): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8770975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      MetroCream&reg;;",
"     </li>",
"     <li>",
"      MetroGel-Vaginal&reg;;",
"     </li>",
"     <li>",
"      MetroGel&reg;;",
"     </li>",
"     <li>",
"      MetroLotion&reg;;",
"     </li>",
"     <li>",
"      Noritate&reg;;",
"     </li>",
"     <li>",
"      Rosadan&reg;;",
"     </li>",
"     <li>",
"      Vandazole&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8770976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      MetroCream&reg;;",
"     </li>",
"     <li>",
"      Metrogel&reg;;",
"     </li>",
"     <li>",
"      MetroLotion&reg;;",
"     </li>",
"     <li>",
"      Nidagel&trade;;",
"     </li>",
"     <li>",
"      Noritate&reg;;",
"     </li>",
"     <li>",
"      Rosasol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10529884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Topical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10529892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/25/13717?source=see_link\">",
"      see \"Metronidazole (topical): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adolescents:",
"     <b>",
"      Bacterial vaginosis or vaginitis due to",
"      <i>",
"       Gardnerella, Mobiluncus",
"      </i>",
"      :",
"     </b>",
"     Vaginal: One applicatorful (~5 g gel contains ~37.5 mg of metronidazole) intravaginally once daily at bedtime for 5 days (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Acne rosacea:",
"     </b>",
"     Topical: Apply a thin film once daily (1% product) or twice daily (0.75% product) to affected areas",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Bacterial vaginosis or vaginitis due to",
"      <i>",
"       Gardnerella",
"      </i>",
"      ,",
"      <i>",
"       Mobiluncus",
"      </i>",
"      :",
"     </b>",
"     Vaginal: One applicatorful (~5 g gel contains ~37.5 mg of metronidazole)  intravaginally 1-2 times/day for 5 days; apply once in morning and evening if using twice daily; apply at bedtime if using once daily",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8771215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical: 0.75% (45 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     MetroCream&reg;: 0.75% (45 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Noritate&reg;: 1% (60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rosadan&reg;: 0.75% (45 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical: 0.75% (45 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     MetroGel&reg;: 1% (55 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rosadan&reg;: 0.75% (45 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, vaginal: 0.75% (70 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     MetroGel-Vaginal&reg;: 0.75% (70 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vandazole&reg;: 0.75% (70 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical: 0.75% (59 mL, 60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     MetroLotion&reg;: 0.75% (59 mL) [contains benzyl alcohol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8770978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10529893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intravaginal: Use only",
"     <b>",
"      vaginal gel",
"     </b>",
"     intravaginally; fill applicator with medication; insert the applicator high into the vagina and press the plunger to release the medication; clean the applicator with warm soapy water and rinse well. Do not apply to the eye",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical: Wash affected areas with a mild cleanser; wait 15-20 minutes, then apply a thin film of drug to the affected area and rub in. Do not apply to the eye.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F12782289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical cream, gel, lotion: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaginal gel: Store at 15&deg;C to 30&deg;C (59&deg;C to 86&deg;C); do not freeze.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10529885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical: Treatment of inflammatory lesions and erythema of rosacea (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaginal gel: Treatment of bacterial vaginosis (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8771050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Topical:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Acne, burning, contact dermatitis, dryness, erythema, irritation, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea, unusual/metallic taste, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Allergic reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Peripheral neuropathy, tingling/numbness of extremities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Eye irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Vaginal:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Appetite decreased, cramping, diarrhea, gastrointestinal discomfort, nausea and/or vomiting, unusual/metallic taste",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary:",
"     <i>",
"      Candida",
"     </i>",
"     cervicitis/vaginitis, pelvic discomfort, vaginal discharge, vulva/vaginal irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abdominal bloating, abdominal gas, darkened urine, depression, fatigue, itching, rash, thirst, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10529886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to metronidazole, nitroimidazole derivatives, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10529889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hepatic impairment due to potential accumulation. May cause tearing of the eye; avoid contact with the eyes. In the event of accidental contact, wash eye out immediately. Use with caution in patients with blood dyscrasias and CNS disease. Prolonged use may result in fungal or bacterial superinfection. Approximately 10% of women treated with the vaginal gel developed",
"     <i>",
"      Candida",
"     </i>",
"     vaginitis during or immediately after treatment. Disulfiram-like reaction to ethanol has been reported with systemic metronidazole and may occur with the vaginal gel; consider avoidance of alcoholic beverages during therapy with vaginal gel. Do not administer the vaginal gel to patients who have taken disulfiram within the past 2 weeks.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10529887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Has been shown to be carcinogenic in rodents",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; aseptic meningitis, encephalopathy, seizures, and neuropathies (peripheral and optic) have been reported with systemic therapy, especially with increased doses and chronic treatment; peripheral neuropathy has also been reported with topical products; monitor and consider discontinuation of therapy if signs/symptoms occur.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8771053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8771054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): MetroNIDAZOLE (Topical) may enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disulfiram: MetroNIDAZOLE (Topical) may enhance the adverse/toxic effect of Disulfiram.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mebendazole: May enhance the adverse/toxic effect of MetroNIDAZOLE (Topical). Particularly the risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis may be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: MetroNIDAZOLE (Topical) may enhance the adverse/toxic effect of Ritonavir. A disulfiram-like reaction could occur due to the alcohol contained in Kaletra (lopinavir/ritonavir) oral solution.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: MetroNIDAZOLE (Topical) may enhance the adverse/toxic effect of Tipranavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8771029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8771030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Metronidazole crosses the placenta and rapidly distributes into the fetal circulation following oral administration. Although there have been a few reports of facial anomalies after",
"     <i>",
"      in utero",
"     </i>",
"     exposure, most studies with systemic metronidazole have not found an increased risk adverse fetal or neonatal outcomes. Refer to the Metronidazole (Systemic) monograph for details. The amount of metronidazole available systemically following topical application is less in comparison to oral doses. Oral metronidazole is preferred for the treatment of symptomatic bacterial vaginosis in pregnant patients (consult current CDC guidelines).",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10529891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduced to a product which interacts with DNA to cause a loss of helical DNA structure and strand breakage, resulting in inhibition of protein synthesis and cell death in susceptible organisms",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F12782290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Topical: Concentrations achieved systemically after application of the 1 g topical gel and cream are &lt;1% of those obtained after a 250 mg oral dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Vaginal gel: ~50% of oral dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Topical gel: 6-10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Topical cream: 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Vaginal gel: 6-12 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F12782291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/5/95?source=see_link\">",
"      see \"Metronidazole (topical): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Wash hands and area before applying. Apply medication thinly. Wash hands after applying. Avoid contact with eyes. Do not cover with occlusive dressing. Report severe skin irritation or if condition does not improve to prescriber. Cosmetics may be used after application (wait at least 5 minutes after using lotion). Avoid vaginal intercourse during treatment with vaginal gel. Avoid alcohol consumption during treatment with vaginal gel.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/45/23252/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2012 Report of the Committee on Infectious Diseases",
"      </i>",
"      , 29th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2012.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16018 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-A3F5C7E4D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_45_23252=[""].join("\n");
var outline_f22_45_23252=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770975\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770976\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10529884\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10529892\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771215\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770978\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10529893\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12782289\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10529885\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771050\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10529886\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10529889\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10529887\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771053\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771054\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771029\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771030\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10529891\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12782290\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12782291\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16018\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16018|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/7/34936?source=related_link\">",
"      Metronidazole (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/48/19205?source=related_link\">",
"      Metronidazole (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/48/20231?source=related_link\">",
"      Metronidazole (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/25/13717?source=related_link\">",
"      Metronidazole (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/5/95?source=related_link\">",
"      Metronidazole (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_45_23253="Genital lesions chancroid";
var content_f22_45_23253=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F60163&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F60163&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The genital lesions of chancroid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_45_23253=[""].join("\n");
var outline_f22_45_23253=null;
var title_f22_45_23254="Bosutinib: Drug information";
var content_f22_45_23254=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bosutinib: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?23/10/23717?source=see_link\">",
"    see \"Bosutinib: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F15367319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bosulif&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F14965011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Tyrosine Kinase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F15034523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+CML):",
"     </b>",
"     Oral: 500 mg once daily; continue until disease progression or unacceptable toxicity.",
"     <b>",
"      Note:",
"     </b>",
"     If complete hematologic response is not achieved by week 8 or complete cytogenetic response is not achieved by week 12, in the absence of grade 3 or higher adverse reactions, consider increasing the dose from 500 mg once daily to 600 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Missed doses:",
"     </i>",
"     If a dose is missed beyond 12 hours, skip the dose and resume the usual dose the following day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F15034524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15034526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling; based on pharmacokinetics, the need for dosage adjustment is not likely in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;25 mL/minute (creatinine clearance had no meaningful impact on bosutinib exposure).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15034527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Pre-existing impairment (mild, moderate, or severe):",
"     </b>",
"     Reduce dose to 200 mg once daily (this dose is predicted to result in an AUC similar to that of patients with normal hepatic function, however, there is no efficacy data for this dose in CML patients with hepatic impairment).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Hepatotoxicity during treatment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     ALT or AST &gt;5 times ULN:  Withhold treatment until recovery to &le;2.5 times ULN and resume at 400 mg once daily thereafter. If recovery to &le;2.5 times ULN takes &gt;4 weeks:  Discontinue bosutinib.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     ALT or AST &gt;3 times ULN in conjunction with bilirubin elevation &gt;2 times ULN and alkaline phosphatase &lt;2 times ULN: Discontinue bosutinib.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F15034525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hematologic toxicity:",
"     </b>",
"     ANC &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     or platelets &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Withhold treatment until ANC &ge;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     <b>",
"      and",
"     </b>",
"     platelets &ge;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; if recovery occurs within 2 weeks, resume treatment at the same dose. If ANC and platelets remain low for &gt;2 weeks, upon recovery, resume treatment with the dose reduced by 100 mg. If cytopenia recurs, withhold until recovery and resume treatment with the dose reduced by an additional 100 mg.  Doses &lt;300 mg daily have not been evaluated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Nonhematologic toxicity:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Diarrhea:",
"     </i>",
"     Grade 3 or 4 (&ge;7 stools/day increase over baseline): Withhold treatment until recovery to &le; grade 1; may resume at 400 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Other clinically significant nonhematologic toxicity, moderate or severe:",
"     </i>",
"     Withhold treatment until resolved, then consider resuming at 400 mg once daily; may re-escalate dose to 500 mg once daily if clinically appropriate.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F15367320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bosulif&reg;: 100 mg, 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F15034461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F15034528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with food. Swallow tablet whole; do not crush or break.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F14965013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Treatment of chronic, accelerated or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) patients resistant or intolerant to prior therapy",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F15034460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Bosutinib may be confused with bortezomib, bosentan, dasatinib, imatinib, nilotinib, ponatinib",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medical Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F15237078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Edema (14%; grades 3/4: &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fever (26%), fatigue (24%), headache (20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash (35%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Bicarbonate decreased (31%), hypermagnesemia (25%; grades 3/4: 12%), hypomagnesemia (19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (82%; grades 3/4: 8%), nausea (46%; grades 3/4: 1%), vomiting (39%; grades 3/4: 32%), abdominal pain (37%; grades 3/4: 2%), appetite decreased (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Thrombocytopenia (41%; grades 3/4: 29% to 33%), anemia (27%; grades 3/4: 13% to 19%), neutropenia (17%; grades 3/4: 12% to 23%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: ALT increased (17%; grades 3/4: 7% to 9%), AST increased (14%; grades 3/4: 3% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (14%), back pain (11%), weakness (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Cough (20%), dyspnea (12%), respiratory tract infection (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Chest pain (&lt;10%), pericardial effusion (&lt;10%; grades 3/4: &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (10%), pain (&lt;10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Pruritus (10%), acne (&lt;10%), urticaria (&lt;10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Dehydration (&lt;10%), hypophosphatemia (grades 3/4: 7%), uric acid increased (grades 3/4: 6%), hypocalcemia (grades 3/4: 3% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Abnormal taste (&lt;10%), gastritis (&lt;10%), lipase increased (grades 3/4: 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Neutropenic fever (&lt;10%), INR increased (grades 3/4: 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Abnormal hepatic function (&lt;10%), hepatotoxicity (&lt;10%), bilirubin increased (grades 3/4: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: CPK increased (&lt;10%), myalgia (&lt;10%), bone pain (4%), muscle spasm (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Otic: Tinnitus (&lt;10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Creatinine increased (&lt;10%), renal failure (&lt;10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Nasopharyngitis (10%), bronchitis (&lt;10%), pleural effusion (&lt;10%; grades 3/4: &lt;2%), pneumonia (&lt;10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Hypersensitivity reactions (&lt;10%), influenza (&lt;10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylactic shock, erythema multiforme, exfoliative rash, fixed drug eruption, gastrointestinal hemorrhage, hemorrhage, pancreatitis, pericarditis, pulmonary edema, pulmonary hypertension, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, respiratory failure",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F15034466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to bosutinib or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F15034474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Anemia, neutropenia, and thrombocytopenia may occur. May require treatment interruption, dose reduction, or discontinuation. Monitor blood counts weekly during first month, then monthly thereafter (or as clinically indicated).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fluid retention/edema: Fluid retention, manifesting as pericardial effusion, pleural effusion, pulmonary edema and/or peripheral edema may occur; may be severe. Monitor and manage appropriately; may require treatment interruption, dose reduction, or discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal toxicity: Diarrhea, nausea, vomiting, and abdominal pain may occur. Monitor; may require treatment interruption, dose reduction, or discontinuation. For patients experiencing diarrhea (all grades), the median time to onset was 2 days; median duration (per event) was 1 day; manage diarrhea with antidiarrheals and/or fluid replacement.  Nausea and vomiting may be managed with antiemetics and/or fluid replacement.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Bosutinib exposure is increased in patients with hepatic impairment; dose reduction is recommended. Hepatotoxicity has been reported during treatment; dose reductions may be necessary. Monitor liver function. ALT and AST elevations may occur, usually with an onset in the first 3 months of treatment (median onset was ~30-33 days; median duration was 21 days). Once case of drug-induced liver injury has been reported; full recovery occurred after discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP3A4 inducers/inhibitors: Avoid concurrent use with strong or moderate CYP3A4 inducers; may decrease bosutinib levels/effects. Avoid concurrent use with strong or moderate CYP3A4 and/or P-gp inhibitors; may increase bosutinib levels/effect.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal medications: Proton pump inhibitors (PPIs) may decrease bosutinib effects; consider using short acting antacids or H",
"     <sub>",
"      2",
"     </sub>",
"     antagonists instead of PPIs.  Separate administration of antacids or H",
"     <sub>",
"      2",
"     </sub>",
"     antagonists from bosutinib by at least 2 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F15255889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F15255887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of Bosutinib. Management: Administer antacids more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May decrease the serum concentration of Bosutinib. Management: Administer histamine H2 receptor antagonists more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Modafinil: May decrease the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May decrease the serum concentration of Bosutinib. Management: Consider alternatives to proton pump inhibitors, such as antacids or H2 receptor antagonists.  Administer alternative agents more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F15034495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Grapefruit juice may increase imatinib plasma concentration. Management: Avoid grapefruit juice.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: St John's wort may increase metabolism and decrease imatinib plasma concentration. Management: Avoid St John's wort.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F15034462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F15034463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. Based on the mechanism of action, bosutinib may cause fetal harm if administered in pregnancy.  Females of reproductive potential should use effective contraception during bosutinib treatment and for at least 30 days after completion of treatment.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F15034464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F15034465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, the decision to discontinue bosutinib or discontinue breast-feeding should take into account the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F15034530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Bosulif Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (120): $9817.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (30): $9817.50",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F15034531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelets (weekly during first month, then monthly thereafter, or as clinically indicated); hepatic enzymes (monthly for first 3 months or as clinically indicated; monitor more frequently with transaminase elevations); diarrhea episodes; fluid/edema status",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F15034498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     BCR-ABL tyrosine kinase inhibitor (TKI); inhibits BCR-ABL kinase that promotes CML. Also inhibits SRC family (including SRC, LYN, and HCK). Bosutinib has minimal activity against c-KIT and platelet-derived growth factor receptor (PDGFR), which are nonspecific targets associated with toxicity in other TKIs (Cortes, 2012). Bosutinib has activity in 16 of 18 imatinib-resistant BCR-ABL mutations, with the exceptions of the T315I and V299L mutants (Cortes, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F15034500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Median time to complete hematologic response (in responders): 2 weeks (Cortes, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Median time to major cytogenetic response (in responders): 12.3 weeks (Cortes, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Median time to first complete cytogenic response: 12.9 weeks (Cortes, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Slow (Abbas, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 6080 &plusmn; 1230 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 94% to plasma proteins",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic via CYP3A4, primarily to inactive metabolites oxydechlorinated (M2) bosutinib and",
"     <i>",
"      N",
"     </i>",
"     -desmethylated (M5) bosutinib, also to bosutinib",
"     <i>",
"      N",
"     </i>",
"     -oxide (M6)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 22-27 hours (Cortes, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces (91%); urine (3%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abbas R, Hug BA, Leister C, et al, &ldquo;A Phase I Ascending Single-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Bosutinib (SKI-606) in Healthy Adult Subjects,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 2012, 69(1):221-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/45/23254/abstract-text/21691746/pubmed\" id=\"21691746\" target=\"_blank\">",
"        21691746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Abbas R, Hug BA, Leister C, et al, &ldquo;A Randomized, Crossover, Placebo- and Moxifloxacin-Controlled Study to Evaluate the Effects of Bosutinib (SKI-606), A Dual Src/Abl Tyrosine Kinase Inhibitor, on Cardiac Repolarization in Healthy Adult Subjects,&rdquo;",
"      <i>",
"       Int J Cancer",
"      </i>",
"      , 2012, 131(3):E304-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/45/23254/abstract-text/22065400/pubmed\" id=\"22065400\" target=\"_blank\">",
"        22065400",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Abbas R, Hug BA, Leister C, et al, &ldquo;Effect of Ketoconazole on the Pharmacokinetics of Oral Bosutinib in Healthy Subjects,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2011, 51(12):1721-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/45/23254/abstract-text/21148045/pubmed\" id=\"21148045\" target=\"_blank\">",
"        21148045",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cortes JE, Kantarjian HM, Br&uuml;mmendorf TH, et al, &ldquo;Safety and Efficacy of Bosutinib (SKI-606) in Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Imatinib,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(17):4567-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/45/23254/abstract-text/21865346/pubmed\" id=\"21865346\" target=\"_blank\">",
"        21865346",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cortes JE, Kim DW, Kantarjian HM, et al, &ldquo;Bosutinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(28):3486-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/45/23254/abstract-text/22949154/pubmed\" id=\"22949154\" target=\"_blank\">",
"        22949154",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Khoury HJ, Cortes JE, Kantarjian HM, et al, &ldquo;Bosutinib is Active in Chronic Phase Chronic Myeloid Leukemia After Imatinib and Dasatinib and/or Nilotinib Therapy Failure,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2012, 119(15):3403-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/45/23254/abstract-text/22371878/pubmed\" id=\"22371878\" target=\"_blank\">",
"        22371878",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Redaelli S, Piazza R, Rostagno R, et al, &ldquo;Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(3):469-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/45/23254/abstract-text/19075254/pubmed\" id=\"19075254\" target=\"_blank\">",
"        19075254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Remsing Rix LL, Rix U, Colinge J, et al, &ldquo;Global Target Profile of the Kinase Inhibitor Bosutinib in Primary Chronic Myeloid Leukemia Cells,&rdquo;",
"      <i>",
"       Leukemia",
"      </i>",
"      , 2009, 23(3):477-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/45/23254/abstract-text/19039322/pubmed\" id=\"19039322\" target=\"_blank\">",
"        19039322",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trask PC, Cella D, Besson N, et al, &ldquo;Health-Related Quality of Life of Bosutinib (SKI-606) in Imatinib-Resistant or Imatinib-Intolerant Chronic Phase Chronic Myeloid Leukemia,&rdquo;",
"      <i>",
"       Leuk Res",
"      </i>",
"      , 2012, 36(4):438-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/45/23254/abstract-text/22036634/pubmed\" id=\"22036634\" target=\"_blank\">",
"        22036634",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86371 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-340D2F8564-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_45_23254=[""].join("\n");
var outline_f22_45_23254=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15367319\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14965011\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15034523\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15034524\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15034526\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15034527\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15034525\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15367320\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15034461\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15034528\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14965013\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15034460\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15237078\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15034466\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15034474\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15255889\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15255887\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15034495\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15034462\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15034463\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15034464\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15034465\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15034530\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570453\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15034531\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15034498\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15034500\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/86371\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/86371|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?23/10/23717?source=related_link\">",
"      Bosutinib: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_45_23255="Captopril and hydrochlorothiazide: Drug information";
var content_f22_45_23255=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Captopril and hydrochlorothiazide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?26/54/27493?source=see_link\">",
"    see \"Captopril and hydrochlorothiazide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F145466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin-Converting Enzyme (ACE) Inhibitor;",
"     </li>",
"     <li>",
"      Diuretic, Thiazide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F145453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypertension, CHF: May be substituted for previously titrated dosages of the individual components; alternatively, may initiate as follows: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Initial: Single tablet (captopril 25 mg/hydrochlorothiazide 15 mg) taken once daily; daily dose of captopril should not exceed 150 mg; daily dose of hydrochlorothiazide should not exceed 50 mg",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F145454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to dosing in individual monographs.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F145455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May respond to smaller or less frequent doses.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustments provided in manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F145438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral: 25/15: Captopril 25 mg and hydrochlorothiazide 15 mg; 25/25: Captopril 25 mg and hydrochlorothiazide 25 mg; 50/15: Captopril 50 mg and hydrochlorothiazide 15 mg; 50/25: Captopril 50 mg and hydrochlorothiazide 25 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F145427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F145440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of hypertension",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F145464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F145443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to captopril, any other ACE inhibitor, hydrochlorothiazide, sulfonamide-derived drugs, or any component of the formulation; angioedema or serious hypersensitivity related to previous treatment with an ACE inhibitor; concomitant use with aliskiren in patients with diabetes mellitus; anuria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2529316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angioedema: At any time during treatment (especially following first dose) angioedema may occur rarely with ACE inhibitors; it may involve the head and neck (potentially compromising airway) or the intestine (presenting with abdominal pain). African-Americans and patients with idiopathic or hereditary angioedema may be at an increased risk. Prolonged frequent monitoring may be required, especially if tongue, glottis, or larynx are involved as they are associated with airway obstruction. Patients with a history of airway surgery may have a higher risk of airway obstruction. Aggressive early and appropriate management is critical. Use is contraindicated with  previous angioedema associated with ACE inhibitor therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cholestatic jaundice: A rare toxicity associated with ACE inhibitors includes cholestatic jaundice, which may progress to fulminant hepatic necrosis; discontinue if marked elevation of hepatic transaminases or jaundice occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cough: An ACE inhibitor cough is a dry, hacking, nonproductive one that usually occurs within the first few months of treatment and should generally resolve within 1-4 weeks after discontinuation of the ACE inhibitor. Other causes of cough should be considered (eg, pulmonary congestion in patients with heart failure) and excluded prior to discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte disturbances: Hyperkalemia may occur with ACE inhibitors; risk factors include renal dysfunction, diabetes mellitus, and concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts. Use cautiously, if at all, with these agents and monitor potassium closely. Thiazide diuretics may cause hypokalemia, hypochloremic alkalosis, hypomagnesemia, and hyponatremia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Anaphylactic/anaphylactoid reactions can occur with ACE inhibitors. Severe anaphylactoid reactions may be seen during hemodialysis (eg, CVVHD) with high-flux dialysis membranes (eg, AN69), and rarely, during low density lipoprotein apheresis with dextran sulfate cellulose. Rare cases of anaphylactoid reactions have been reported in patients undergoing sensitization treatment with hymenoptera (bee, wasp) venom while receiving ACE inhibitors. Hypersensitivity reactions may also occur with hydrochlorothiazide; risk is increased in patients with a history of allergy or bronchial asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can occur with ACE inhibitors (usually with the first several doses); effects are most often observed in volume-depleted patients; correct volume depletion prior to initiation; close monitoring of patient is required especially with initial dosing and dosing increases; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Although dose reduction may be necessary, hypotension is not a reason for discontinuation of future ACE inhibitor use especially in patients with heart failure where a reduction in systolic blood pressure is a desirable observation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neutropenia/agranulocytosis: Captopril has been associated with rare cases of agranulocytosis, neutropenia, or leukopenia with myeloid hypoplasia. Patients with renal impairment are at high risk of developing neutropenia. Patients with both renal impairment and collagen vascular disease (eg, systemic lupus erythematosus) are at an even higher risk of developing neutropenia. Closely monitor CBC with differential for the first 3 months of therapy and periodically thereafter in these patients. Onset of neutropenia is usually within 3 months of captopril initiation. Neutrophil count generally returns to baseline within 2 weeks of discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Hydrochlorothiazide may cause acute transient myopia and acute angle-closure glaucoma, typically occurring within hours to weeks following initiation; discontinue therapy immediately in patients with acute decreases in visual acuity or ocular pain. Risk factors may include a history of sulfonamide or penicillin allergy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Photosensitization may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal function deterioration: May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfa allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. Discontinue if signs of hypersensitivity are noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic stenosis: Use with caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Initiation of therapy in patients with ischemic heart disease or cerebrovascular disease warrants close observation due to the potential consequences posed by falling blood pressure (eg, MI, stroke). Fluid replacement, if needed, may restore blood pressure; therapy may then be resumed. Discontinue therapy in patients whose hypotension recurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Collagen vascular disease: Use with caution in patients with collagen vascular disease especially with concomitant renal impairment; may be at increased risk for hematologic toxicity. Hydrochlorothiazide can cause systemic lupus erythematosus (SLE) exacerbation or activation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use hydrochlorothiazide with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gout: In certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated by hydrochlorothiazide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use caution in patients with severe hepatic impairment; in cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypercalcemia: Thiazide diuretics may decrease renal calcium excretion; consider avoiding use in patients with hypercalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercholesterolemia: Use with caution in patients with moderate or high cholesterol concentrations; increased cholesterol and triglyceride levels have been reported with thiazides.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Parathyroid disease: Thiazide diuretics reduce calcium excretion; pathologic changes in the parathyroid glands with hypercalcemia and hypophosphatemia have been observed with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal artery stenosis: Use captopril with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use ACE inhibitors with caution in pre-existing renal insufficiency; dosage adjustment may be needed. Avoid rapid dosage escalation which may lead to further renal impairment. Patients with renal impairment may be at increased risk for hematologic toxicity. Avoid hydrochlorothiazide in severe renal disease (ineffective). Contraindicated in anuric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angiotensin receptor blockers (ARBs) and renin inhibitors: Concomitant use of an ARB or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Based on human data, ACEIs can cause injury and death to the developing fetus when used in the second and third trimesters. ACEIs should be discontinued as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgery: Use with caution before, during, or immediately after major surgery. Cardiopulmonary bypass, intraoperative blood loss or vasodilating anesthesia increases endogenous renin release. Use of ACE inhibitors perioperatively will blunt angiotensin II formation and may result in hypotension.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F145461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F145434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Thiazide Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of ACE Inhibitors. Aliskiren may enhance the hypotensive effect of ACE Inhibitors. Aliskiren may enhance the nephrotoxic effect of ACE Inhibitors. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of ACE Inhibitors. Management: Separate fosinopril administration from antacids by at least 2 hours. US and Canadian recommendations for use of other ACE- inhibitors with antacids may vary. Consult appropriate labeling. Monitor for decreased therapeutic effects of ACE-inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprotinin: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: ACE Inhibitors may enhance the myelosuppressive effect of AzaTHIOprine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benazepril: Hydrochlorothiazide may enhance the hypotensive effect of Benazepril. Hydrochlorothiazide may enhance the nephrotoxic effect of Benazepril. Benazepril may decrease the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: Thiazide Diuretics may decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of ACE Inhibitors. Canagliflozin may enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): ACE Inhibitors may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Thiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DPP-IV Inhibitors: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ferric Gluconate: ACE Inhibitors may enhance the adverse/toxic effect of Ferric Gluconate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gold Sodium Thiomalate: ACE Inhibitors may enhance the adverse/toxic effect of Gold Sodium Thiomalate. An increased risk of nitritoid reactions has been appreciated.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Icatibant: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Dextran Complex: ACE Inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions.  Management: Follow iron dextran recommendations closely regarding both having resuscitation equipment and trained personnel on-hand prior to iron dextran administration and the use of a test dose prior to the first therapeutic dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of ACE Inhibitors. Management: Administer angiotensin-converting enzyme inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Thiazide Diuretics may decrease the excretion of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: ACE Inhibitors may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an ACE inhibitor.  Monitor patient response to lithium closely following addition or discontinuation of concurrent ACE inhibitor treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Loop Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: ACE Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Thiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF.  The effects are likely dose-related.  100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: ACE Inhibitors may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ACEIs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: May enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Thiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.  Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: Thiazide Diuretics may enhance the hypercalcemic effect of Toremifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valsartan: Hydrochlorothiazide may enhance the hypotensive effect of Valsartan. Valsartan may increase the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Thiazide Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F145435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C/D (2nd and 3rd trimesters) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F145446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F145457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F1623912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F145445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Captopril-Hydrochlorothiazide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25-15 mg (100): $92.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25-25 mg (100): $92.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-15 mg (100): $159.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-25 mg (100): $159.29",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6179303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure; BUN, serum creatinine, and electrolytes; in patients with renal impairment and/or collagen vascular disease, closely monitor CBC with differential for the first 3 months of therapy and periodically thereafter.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F145447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acediur (IT);",
"     </li>",
"     <li>",
"      Aceplus (IT, NL);",
"     </li>",
"     <li>",
"      Acezide (GB);",
"     </li>",
"     <li>",
"      Addcomp (DE);",
"     </li>",
"     <li>",
"      Capozid (DK);",
"     </li>",
"     <li>",
"      Capozide (BB, BM, BS, BZ, CH, GY, ID, IE, JM, MX, NL, NZ, PE, PH, PK, RU, SR, TT, VE, ZA);",
"     </li>",
"     <li>",
"      Capozide Forte (AT);",
"     </li>",
"     <li>",
"      Capozit (KP);",
"     </li>",
"     <li>",
"      Caprizide (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Captea (FR);",
"     </li>",
"     <li>",
"      Captopress (GR);",
"     </li>",
"     <li>",
"      Captopril-H (IN);",
"     </li>",
"     <li>",
"      Captoprilan-D (DO);",
"     </li>",
"     <li>",
"      Ecazide (CN, FR);",
"     </li>",
"     <li>",
"      Jutacor Comp (AE, BH, CY, DE, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Lopiretic (PT);",
"     </li>",
"     <li>",
"      Lopril-D (BR);",
"     </li>",
"     <li>",
"      Zapto-Co (ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F145430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Captopril is a competitive inhibitor of angiotensin-converting enzyme (ACE); prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This results in lower levels of angiotensin II which causes an increase in plasma renin activity and a reduction in aldosterone secretion. Hydrochlorothiazide inhibits sodium reabsorption in the distal tubules causing increased excretion of sodium and water as well as potassium and hydrogen ions.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F145442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl ):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/45/23255/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/45/23255/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaplan NM and Sever PS, &ldquo;Combination Therapy: A Key to Comprehensive Patient Care,&rdquo;",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 1997, 10(7 Pt 2):127S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/45/23255/abstract-text/9231887/pubmed\" id=\"9231887\" target=\"_blank\">",
"        9231887",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miller DR, Oliveria SA, Berlowitz DR, et al, &ldquo;Angioedema Incidence in US Veterens Initiating Angiotensin-Converting Enzyme Inhibitors,&rdquo;",
"      <i>",
"       Hypertension",
"      </i>",
"      , 2008, 51(6):1-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/45/23255/abstract-text/18413488/pubmed\" id=\"18413488\" target=\"_blank\">",
"        18413488",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moser M and Black HR, &ldquo;The Role of Combination Therapy in the Treatment of Hypertension,&rdquo;",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 1998, 11(6 Pt 2):73S-8S, 95S-100S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/45/23255/abstract-text/9655566/pubmed\" id=\"9655566\" target=\"_blank\">",
"        9655566",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8671 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D34A3220F9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_45_23255=[""].join("\n");
var outline_f22_45_23255=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708659\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145466\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145453\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145454\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145455\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682478\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145438\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145427\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145440\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145464\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145443\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2529316\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145461\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145434\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145435\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145446\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145457\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1623912\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145445\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6179303\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145447\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145430\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145442\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8671\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8671|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/54/27493?source=related_link\">",
"      Captopril and hydrochlorothiazide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_45_23256="Asbestosis Photomicrograph";
var content_f22_45_23256=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F81274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F81274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Asbestosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 281px; height: 188px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photomicrograph illustrates a relatively acellular fibrosing interstitial pneumonia in a patient with asbestosis. Alveolar septa are thickened by dense collagen deposition (arrow) resembling that seen in usual intersititial pneumonia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey L Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal lung",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 240px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADwAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwC1PrWua5pMdx4Ks0SN2Kvdamvl4/65oeWxnqeM9M1n+JdKsINVtoruzTW9Y1G3JuLzUJjFDGMbGMSLgKvcnqABXeb3Y/MSTjAyegqRfLZdrqrqAQcqDgEYIAPtXgRr8r91WX9bvd/gvI3Ukjg/E3iHQdL0XSLVNauZYLC4gi1K40mbzJkieGTo4PClgBwchRjqRUVz4l+HiItz4d1ax07VbOMC0ntLOUvJk4CSJt/eg55zkg8itC60TR9KigsL7xFerI7ptAtoEKLlioban+rJBBycN0qODw1Gnjmyv9JtrXQbW0tzBJLCkbyzDccNGNrKj5+UksG2npW8HT3bkt3vZP101vtttuOST2f4HVTajrMvhWxurXSvK1i7RIZbWZSfJduGkIz90D5sE55GazPDfhWw8P8AjS1jtnuZ7q20ySWC9knzJcSmQrK0y/e2gFQvbrySOIPGPiG6F1H4Z0OK4GqXsbETJKN0WTgBl5YKc8u20Acgmq+tW+qeF9RkvtCsdMutPESmIzyAXLyhMNGrs25lBG4Lz941nCEmuVNLmvZfl1+6/mHwxv3PRkkPnFZDsbBABP3sdSKfKiPE8bltkilWGe317GuCt9K1vSWGv6cYrrWrm1VtWtJEMrSEYOy3GflIBIwDzgYzW/oOtWviXw+NR0q6QCUPHuUEmCUAjDBgDkHnBFYypq14u6/r+l3/AAIcLanRONyDa3Ixy3cCpocuURE3MeiqMk1wl5beM721S2ttUt9Na3gYvftGrrfT7htUJkmNABnceSSeMVi+MdK+IGteHbfTodb0W2cYa4a2EqSXJHXJVcf8BXqT0pqhG+s0vv8A8v662HynoHi7UtR0K0huo9OeewRs3tyhVjbxZA3BM5brk47CuU1248HatJb3V43ibWYpSEitrWWZ4GLDjITADY569q5fSpV8OxX+hXWh6mNXS0SS0gsmLQXU4BDOSH3cnDfPyB1A6V1fw10bV9EuTdXLXWn6Z9j8iHS5Z97iUsGeZlX5UBxgKDkZPSt1SjSi3fXydr/i35aaGjSirjJoNT8XRz2dn4bg03TbRn0+zle3Md3FCirlldvlQHoMZ6fjVfUNAmh8SeG9It9L1eZDA08zalqANvhUYeVK0Ybc2QGI5HNekNJuI8xidvI3EkA1574+vksNft5NL1GePxNJbo8NjcTbbPyg/wB5t3y5yG4X5j9KmlOTlypWVn3+96hGbk7I6KbRL1rqOC28OeEYbKOLKyAOH3jlU+VcgAkk9Qa0fDOhJpazTXl02oahOAZTIP3MX+zEh6D3PJ4zV6yuVu9Pt7jzLZvMGGaGUNFvGchWPUDFR2d9bahbifTruC6g3lPMgkDqWHUZHcVjKU5Jrp1MnK2hoCQszlmLEEBj+GaqazeSWWk3VzaIZJYE8xUWMyEgEZ+Uctxngc1z99Hq0d9qE9hdeTE8iQxjyxIWDAfOc9NrFuByelb1u06QRRTv5lwkY8yZUKK/q3t/Sk6Sik7piemp5Zdad4nhutc8SyOTZTxQXdr/AGrp5n8tlzsIiRiY9o6Dafmxkd69X0OG0sNN82DzIku1+2XMt2+JCSu5mkJ+7jn5ei1HPqNvZRST397b2sScs804XAPGeTzk8fWuX1mS68d6HdaZpIuNP0e5cQ3OpXMJV54errDGcNzwNx461rJyqpKSsu/3ff8A1oiubm8h2lafYeKdct9YttPvf7DjujqXnXzsBdXO3bG8KE5WMZLYIAJA9K7iSZ/tEhkARMAo+7AP97I7c964az8OReGNKNxf+NfEBsLABIHeVIY7aPhQpGCGPOMkdxgd61IfDmmSwK0Woa1Pbyssnz6pJJHMM5G7PUc9AQKU4qWrbtstP83v/WisObjsmb7qGYZIHHG054pS2QR+HvVG0ubUEwQRG2CthY2TYrZyfl9e/wCVTFwcnPU54rJ07GfMTRSAq2AfUCqupatFp8qo0NxcXLW8k0UUEZJcJj5N3RWYkAZpjNnkcMOpqul9KswhkyrPuKZPB24yPrg04x7oW5NLd6tP5Mf9kS2cbxMZ3e6j82JiBtUbSRwc5OfpmqWqy6nZ6VMuhpbXPiG6jzEt5dgIkmBubB5ZF64A+vWrk80nkN5LgS/wkjcPyJGaxbiJ9TvTDcajOrpBskOnQLFNAXOQfOOSgIxhQORyeK2jG/RJfP8Ar8RIdJJd6d4OlvvGt601xbxZnisWMcckmRsVQo3Es2FA965zXLTWtE8B6NLqRgv0F2smr21/M0gjWXhYw452occDPPqK6h7BLp5UudSvJzbzpPBnaDaEIVHOPnzySW5yKittEtkulur+7vNYvI4/KSS9K7Av+zEoCg+/JPrW1OooO773tby2Xbff0ttq7om0vVIbXxRe+GVZVeOJbvTo1UkNbHAOGJ7PuGOuK2LjK582Mbhycr09/rWZqFlZaj5Zv7WGd4s+WzoN0eRg7WGCAQeRnFcH8QNVg0CG207w9ZILyR11C9WEPst7ZDhpmTOCxwMZ646GsY0VVkkt+v8Anf8ArUd09EekNOSqZY4xwe34VnT39woj8ixeSdyxETOFyoOM7jwCe2feuR8P+KrjWNOj/wCEO0hb20thsnfUrs20xlOSSEKnIAwc5AOcdq6XT7V7OxiiuZRcXOMzTEkmRvXJ5OOn4UOh7N+993+dnoS3bcYFv7vVJ7i+It9MFusUWnkq7PKfvPKRkcYwoU9zmofFN7dW3hq/fTRcC4EYRTaxh3jUkAsqnqQOlXWkVZVj/wCWjJvAA7A45NJvKvleD6jrRbVO3+QKVnc8d0R9TvoojZeItTlbT7gyFr5Gfe7D5Y9uQB3BD4AYdcV6poOmmxtJpWmW6vLlhJdTBt5D4yEPJwBzxx3rM8Z2dt/wjuuammmw3GoR2rP5yqUkfGPvOuD079apz+EtB1LT7aSyil0qRxHPFd2DMkycZzjOCTnvXRVmqsbttL0T7PyNXJS6WOraUdR0zUMk2V5zj1FcLoPiW50eW907xOL6SC3mK2+otaviSME/PI3OcnGMfTmtu3122ezW5u3eFpnPkWogkM4TPBaMAsCcE8gcEVDw8lpa5jJOO5qzhS3Kgg9vaqWoana2AhNyzgzyCGJVUlncjgDHT6ninPPdzR5t7B7cEgbr1lUkY+8EQk/gcGuJ8ZXF7LpdrK2oiQfaRB5cCBI5Vc7T5Y5ZpeAcE4wDVUaCnNRb/r8RanVXyf2pbz2V9YbLeVQv78JIcHrjBO1sdD7186ap4XW01q9tJ5XtJ5Hc2yMCkaoG6sx7BR2zmvVvHHix/DtzaaP59y13LGEkuJPkUDbzKJMHc2c8Adc1w8l9aa9qsF74s1y/uLS1Cw21vYR/vnGM7S7AANzyeeWrsw1OVOPOl7r7f1+ZrSvazOy+Ft3c3HhPN3ePeGGdo4pssTsHTGRn6A0VTuvHmk6ZZ2lpoumXWk2MUbO73sH8K5ULEu753ZhyxPHNFEqVSrJzjpf+umhnyqLtJf19x6bbeItOmhnaf7TayWh23kUkJP2ZsdGZcrn6GqLeKm1IrZ6BYavJezny0uzZkW9vzzKznjA5OO+MVD4Pv7SPT1g8N2Fzb6fFHNerNfXDJFE7MdwmO3KnjdgbuKis/iTZPLaweIo/7NknjaSKRXaWPaOASCNy7iPlBHI5OK4PY6y5IXt5/pv8r/f135bI6GbQ9Pls7q3khMouJEluJnY75pExtcnPGDyAMAeleb/EPSbrTpE0nQri4l07WD5s2kbi5km3cOhxu28AkZ4I54r1W3uLO8O2wv7G9YAkrbXCO/AyRtBzmucsLnWdbsrXW5LKx0FLG48+1nuL7Jlt2TD+YgXlCp7EYI6cZrOjOcZavT1tr0/Lpqh0puLu1deexWtPDuoadaK0Wu3E2vK/myXDgGCeQAKBImNxUIAo+YDjOKmvLy+0XUby/nzqWqXdlHBYrHYsIopVk5QbSTzv3Egg4X0qnpHinUvE2q6ja6BptlZwwgmO61KY7WHAG0Rk7jnJ4OBgA8mukS28UoY1Or+HbMOQryR2ckkn0jDsFLfWtnzRfLUt6P5Pom7eRnfW7F8VaXO3h+6tNR8XTWCjcr3UCRW6Sn+GMA+vIGGyeD7VR+E+hW2ieD7SaKw+yahfAzXG5nMhG4lA+7+IA84AHNa+m6XDYvJPetLql7PKGkubuJXJOMKFQDagGOw/GpfEuvWXh7TpNR1q4ZP4liUb5pjn+BMgnHcnis+Ztezjrd+n4f1stEF3ayNXI3ZPt2rmPiPq0Np4fk07MX2/UQVgDXotTHtORJvxwAwA7ZPGapWHxF0a/lijtLHW5DLIkce60Ee8sD93c3OMHIFXY9Cvte8RR69feZpEf9ny2UFjndOxcEb5xkqACSVUexNNQ9nJSnpbX59PMqMbP3i/4G0waJ4bghmtreHU5VEt7JAd3nSH/loGyc5B6jg1vAtxkc452muK+G/iK11G0/4R4yLBfaLALIkj5LwRkq0kR9AR0PJzn2rtW37GEbLvPQkZC/UVE0+d824qiaepKDxjJJPArM1vRtK1qeybUbd2vLGRZ7aeByksRDZ+Vh2z2OaTxLe3Ol6SbuzSOVlYAhm+cL32qeGP1Iq/aOzRxyNFJD5yCXY2Ny5H8WOM/SiMWkpInVanNP8ADfwxO4kvY9QvZCdzPcXbHzP9khcAAY7Y962VtrzTntE0+XTNP0K3WSS8t47f9445OYz/AA4A69frWozsijI6nHFcz4rmu0mjT+xdQ1KxUrIP7P2GQuCd27eQMYx8o6561ac6krN39f8Ag6DU21Z7Eni7UNV0/wAGT63pscQgihS5laQnz7eMkZZFxtkfacjcRg+tT6fpOl6xoml3kk+o6lDLGl3FLe3Db33LlS6qQOh+70FZGvpAktjP4xttUltprkSuhvzLb2gPKLIiIu8DhSuDz64q7qvirQrTT4xouoQS3M4MVtFZws5j2Yz+6wDhR/D17VtGM7KME7t7rb70Jx0ujS0rw1oek3st3YaPaRXLYxIVMhHHUBiQPwFbUru+Xcl3A6luT+NRpISIASxklVcArgk4z0/pWdqWu29oZFtbW91hoVL3CaUizmAAgYbBHzf7A5wCeKwtKbvuyW29zO8XXF3YXtpqD6Pea3oiWksN1ZWyrKySbg6y+UfvDAIyOnpTvCetXOsapdPf6bf6TNHaxmGymZTEYjjDDADFugPAAORzU994lWxdg+ja+7LGsw8ixMnBOMDBxuB6rnimxu95rA12KG00i3tIXhnvNVCo1yCPljYg/LGGIJOeuAK1StC0orbf8e/y2KSujoZHJJVucYODzg1GzbuM1leEzqUnhixfXWlbUX3mVnG0kF22kDHC7cYzzjGa1CqhwT90H1rGUeVtdiHpuRvKoZIy215NxRD1bA5I9h3PvTbl4oI0e5Kx7AWVmGMcc4/CsqGw1aC/1a9W8tDcXc48lpkaUwWq42RhRgDncx9zzmnXUD2Np5ltAdSRpXkvVuG3TXG8EEoPuhs4wvAxxVcivv8A1/Wg7a2H21xd3l3K9vJCltFyhMW8Tb0BUg5HCnk469OMVNpNiun2ZiZxPPJK89xPsCGaVjksQPQYUegArO0jVJkuLPT7nRrmyN0Hlt1aVXMVuhxulXjyz2wM59a3I5EmRZIXR1IP3Tz17jt9DVSjbS2ny/ruEroRjlemQRxmmnqCCPb6U914GD+faquo3NtZWU91e3EVtbQrmSWY4VcnA/EkgD3NTYnd2BpF87y2AyRke9YfjpNXuvCd/b+HordtQZCf3hCsVAP3Tg729FPHNZV98QNC0mKabxCb/Sp0z5Vtd2+2eZP7yICeOT1x0NaK+LNK+wS34GoGyRVdZEs3YOGUEFSMg9QPrVqlNNPl/AtXT0PLNM1nxb8PfDenWdylnqsZ3SmCL95cW8H3iSB8wwSclgQOADXqXhfWv7atElY27uEy7QnhT2BHODgjjNc34r1e08TXem6dpmlalcagbiM/a1i8pBCwPmLJIuSY8HDKe/T1rp/B3huDwvoradbyowe4kmLpHsX5sYUd8AAda6a/Lyc042k/6/ruOVrW6mk5xJHEMkyBmyAcDHr6Vn67fQ6Ro11f3kipDEhK7m2mRscKvqx5wAO1c/r174m1jXIbHwlctZ6Uu6O7vVVMxyqeCCc5X0AAzW7p2jtZ6jFf32p32rajEG8qe6cbY2YYdkjACqTzg9QDjNYKCjZyfy6/PsS423OZ0rT5/F8UOq6958GjsA1hpQdl+UH/AFkxGMkkH5cdK7CU7s8jA9Knkd5HZ3Yl26k9TULnC5Aziic3N9ktl2/rq+vUjYg+0KlwLYS5nMfmmLOSEzjJHbnp+NBlkGSGIZ/vN3PsT3rkdcV9B1trvQfDd7f308JU3O4m3RS4ZweSdxOPpjim6TqHi3XD56ix0K025VJrFp5CwONvzsOD64FP2N1zJ6ef+SuynHS51RGF6cegrmtWmg0nVvDiywPPDNPOkflxb2ilCja5x2AZh+Oe1QWus6udbnsJLq3uhazCCWaW1+yRyyuMqi4LHI6D8/St5baZL+a4ujGJSghjiiyVjTq3zHBYs3sOAKrldJ+92++6/wCDchqyOG+KdlreuaVb6bpGnK1hFKs09xMyfPx8qx87hjnOOuR6Vi2fg/w+0BGr6PfoiAK7w2s0JD8ZKDLbl7ZPOa9XI5Xuc/lUZDKnBIwcsc/59KI1+WPIl925UajSscVZadZWlrbXuleFL/UlkYxganchZIFT7rCOTOAccdDRXTSqF6ZK/wB73oolNSd5K/rzf5gqj2/4Bj+FdfvdP13UNOuJLS20XSIHuJrKdQs1rG2WWNGBO+UcBge/ANdZD4oSfWbezmsb2Frzd9llmiUF0ChmeRTzGuCoyf6VbtND0iGK2Eek2CmBFRf3YYjaQw+Y8sQecnnPNcR420Zo9ejs9IN/Jqnim4P2iV5T5MUaldxcAZZcdicDB9a54qlWltbT/h3+b6328zq5lJ7nV3+k+GdRmMmo2ug3Ekcu4uRGHEjf3iuCScd+uK5/XLafxV4pGhS2Hm+HobcGNlYrBHIUJSSbAB+XgCMEcYJ9Kgj0e98A+EL24hh8MMIZWlmv5DLubkBWCEfe5wFHdu1dlpmoSeI9Ee7sDc6fu4Q3CKzAkAh9mTkEEYzg1SXIrxd1sn2emqX9eZN7O+5laRf23hm2bw8NOuri5sYllhj063eaORZGztQtjZ8xyQTxnPsNZJde1G3lePw/b6dNDIpjF/frmQj73CocDHfOaS2sNdlmtzqviFls4QB9m06PyvtBzyZGbkAjIwuMetYev30vhW4QS69qWq3pkWG10iNEyC2WVpto3FAO/BIAo5FN2jZv5/8AA+d9PMhPW/UdqM09pdXWn3d7earr11bmJLHS0b7LZIxws7gkNwTySeewrb8O+H10aS6urjyZNTvIY7e4aEs0IiQYVY9+WCnqcnk1RuPC95qmovqo8QzWd5InlkaQhihlVePvPlyDjB/StG2SfQvDkdtFZi4v2M0sVukv32yWwXP3Rgjk8U5tcvLGW+62/wAtFb9WPyQ0eEvDZkjkbRbeSVOksjuzevdsdeeAK3t5jkV05wRj+lZ2jS6pLZtLrsOmQXLMRGmnyPIuzA5Zm6nPpWgSVbBGR6VhNuWknf53JcnfU8o1fRJPCHjHSJrfzLvQ7q7M8FsztGFnLY8uRuQSM5U4BboelesQzfalne2BVhtLF02kgeufTJH509Wb5lIO0gZU8g49qyvFWinxFpi6fJczW6tOkhmhG5lC5OGB4YHpg55wcVonGTSlp3f62/q5c6zq25tbEOlzS+JLzU5JVjPhu3ufKtSh2yTzR4EmSOsYbkEY5B7V0u4EgdCB2HFcXa23jDSvFFhPqOsR6p4YbetxBZ6aFkgAQ7AyoNxUcZZe/UYrrLW4t76CK6sp47m1kG6OaNsq46ZH405q2q1Xlt+KWumpnLUsY4PGfwxSDaVJO0ANwXIHPrk0ENtaR2UIilmd+AAPUngcVyevR2XiXTLO+0cXupraiU24tEVreVyAAW83CHaehHPJ61Cjf0CKvo2W/GOvafb+FNSnt9atVcRAjyHZhISceVleSWGR8pB96v8AhFIJfDunX1tpkOnCYNNHEIPLcAkjeQcsC455JPPJrgrCz8SS3McXijVprXS0ltI3S3YMsTAZ2NwFXBALPyCWwDXdjRo9LihEGo3yLFdC63NcE+fn+BwOHQjj8sVvOMYR5b63v+HyLkuVWTGeJ5Lm60+4tbG/fSXUqZNTH/LsOOQO4PQ4xgGpNIsksJrLTbazSzsFVpYFtj5aFicdiSzN1ySc0/8AtW3tvPmmEtxJtO6PhV2gfMvoox1z+tYOhebIkVpbvahwjxrDtbzrBvmYMDn5FwdoB578Ukvdfb+tf6/zuknYm8VStq1tqGmadrz2MP2YpH5TYLTI68rIOSFAIIHU8VF441G01TwwNHXF9q9+0UEFqsXmOTuUm4ZDwYwASSeM1o+DNPs7a2TUrGBIxOmIypDKRnG6Nh0QgD5RlcjI9ahl1SLRfiLDb6lFbx2+uReVa6nhi6MuD5EjdACc7QvU4Jqo6StFX5dem6/4YbaWi6HR2dnDpllb2NoXMNugjDSOXZ8dWLEknJzT2PZug9aWMSbQZUMb5IZdwOMH1qrqN7Z6bayXWp3UNpaREB5ZTgKT0HHPNYpOT7tmDv0K+orFuEsgU3NvHJLAzHBXjDkHp93r7VBp99aa1ZFdE1mxe5lBwYmDtDg53MhwQOOpHQ1BrGlQ+M/Cstlfpeadb3ZDxtkeaFB+V2Tphuuw54xn0rgjYeIr7xfeW+sSQ3H2yAadcukcO6WHeo3tJFh49+wHawPcDgGt6dKM003Zr+vn+H46XHU7rwJNbXmgy6hDJ52o3FzJHqEzSCR3ljYqAWHGwD7oAAAPTOa2mhHmSTBVWRx87AAFvqe9ZWh3FrcwSaRocUlhFpkjWzWptfLWPB42ngNnBO4euTWjp0pvdPguAQTKD2IKnJBBB7ggj8KmprJvb+tP+B5EPQmXkA59sVyHjXVVuLhfCdjpUWsalqcLFVmb/R7YqckyEc7lwGwMY4Oa6u6WTyHFuSj8AHbnGeMgVwPiLwpeSw6lJbtby6o3ywpDctGGHOZJN5YMwPUHgjgU6Kje7e35/h67mlNK92bC+BvDb/Zm1bRLDVL9IUjmvLlXZp2AwWPzd+tIPh54IQ7h4VswSMYWecL/AN878Y9qb4P1PUl0bTLTV7a5uJI4cz6w8yOsj4J4UcjH3efQV0pZHLKjqWXBODyM8jP1FKTqwk/efyf+T/AmTaM/R9E0jQ4JINB0yHToZCWdIWY7icZzuJPYcVl+Odek8PaDNPBbtNPL+4jdfnaBm4Egj/jAz0zwcetdE2FXPIwK4nXozr/irT/DrytAlsF1K7mXG6RVPywoO2f4ieMYpUkpTvPVbv0FF3d2ULPRbvwJe2c8+pXepaddMUvpY7f5gwH7tpFGTjkgYJ9Oetb914m08XemWlm/2y8vHCPbwn57UEZDS5xtHY9SPSuimlcTPcKziTlsocHPXis/UbOy1m1WLVbWO9ttwlCOxU7v725SDn8ap1PaNSqLXyt+Wn5ofPfclIKllOMjjr/Ko5MDPHTms281E6EJn1KIx6BGAy6gJfM+zDgBJVOXPPAYZ461Jo2r2Ov6al9pUwmtXYrnGCGHYjsehx71PLK3N0/r+rEPct8qQBxzwBUTHcxBJznknmpmAIyOciosbsZyRmpDdHD/ABYS0tvDEd/LZv8A2sbmNbae3y8sJX5mfAI3gAAHjuOa0/BipF4Q0kRtIVeHePMfewyScE1DpLQJ451f+0Sh1xyWtPMjO9LQAKNjfd2nngc9ck10MhY/MfmPc1vKTjTVJ+T/AA2Xl+twm1axF2POf60jANkcY6dOtLLnB2KN3YE00EsvPTHPHB+ntXPJEIzroYk9jyO/FFPuRsUySuPKUFmdmAUDuSe1FbwV0DNaLX7KTTmurJbnUHA+WOzhaTe+cbQwG3rkZ6cVj+NbjWHgSbw/oviMapETEksIWOPYSCSwIO8ZA4GCRnPFa9pqzaW6abHoWsRadZWUfz21uXiibosUeMmUk4BYdO/c1ga34wbVbyz0/wAJXU9xdRyJPqCWLA3KQ5IaJP8AbGCSR0wBnJFc1OD57xjp5vT52OyK1ViS9sLxvDMOoalo174m1ho8NZXaALbuzbWVLdMKAAMkjLdOeOOd+Fyvo15rOrazPc2WkpmDbbW7G3hcclJxgujJkKCcfU1X1D4paNBcSwLF4gtRC4jt7aDVGi2bWIJY5AGQSSDzkYrQsfE2rzx3d2+g+M4dHgdnklF4cT9OGwgYkgjoTj14rqhCpJOLW/ml8lrby/zNJRcYO63O+1/VjaaZcNpEttcasYVa0gTMzSMwymFXJ5XJBPHGTxmsLRvBk8Vrcz6xftBfaiim+jtv3srf3g1y+WywwGC4XAGMVNp174c8GF9I0mxvDqMwSa5igjMsqo2SvmzH5QFXOFyMYPc5O3Lqck1ksmhaXf3zykrFJPCbWDg8lnfnb16ZzWfvw0irJ9XbXtvol1X5nNeysizd2UU8NtDBJNZ28LqVjs38oFB/yzz12+w61zviXSdF0i9s/Es++zlFxHHdSGV2WeEna+5Cfmwp7flWjY6j4gW/aDWPDiLbqxxfWF2siKnYmNvn/r7Vk6vG/wDa2na7Aya9pJmcSSXMZeHRiFG2SMZxyfvcHGOxpQUoStzfc9/K6utfP7r2Khds7QBWX9zzEQDGAMZXscduKzfEF1Pp8NpLbmGa6luEt47ByBJdliARGeoKg7jxjHWqNvZ6rIXudY8WBoroqIF0xPsysCCQwflx9QckZ5qZPD9jLcRXS3t8+q26Okeo+eJZYt67TjcNuceozxzWajGL1d/k/wBbfPr21DRbnQGH955cfzckDB61XvNQs9ODyX95Fb28Z2yTOwCocfd929FHPIqrLpuoXEcMV3ro+zoNriytfJkuRtwTI5JKH/rn79Kp23gnwzDMJxpMU8o5Rrp2mCHIJIDcA5AOaIRh9p/cv87fk/0JdrFGxeXxhcz32n3mq2OiIv2dZbe4EMguFJ3jGMj5SvzA5B+X1FXtch1jTNEtdP8ACNtAirIi/abiYF0XO6aRt/33bnnqWYmrdxos8lzqU9lrt9YyXxV5Vggi8tWGB5iqw4cgYLc5/KrVtpwE5lvb67v9o3bZ2EcEZA5kEKAKD7sSR61q5q6atZdNf+Bf+tOgadDHgbStY0yG7lN1JDeSs8VpqzvPEAOCiKflbJUHLZxnit9bj+0L4wwC5MVrhGR4zHGQB2BHQYwMcV5/4m8c3NhdaG3hXS1m0e+uEhXVLmAlJ1LbSkEZwx25yDxnHHFdvqFzo9s8y6trenTG2ASV5rmOPucZQNxznilUg1Z2et7dWv6+8o5vVdeh8Qyaxp2gtfXyRWb27bot9mZyTmKRSuMY/jJwDitDwlLb2cOn6TCszRafZwBmkl3mGRsbVYkknjOMcDGBUt94g022trTQ9C1aws5p3YKtg6TPbRhWkd1VchGPAUsMZfIBrC8B6pZLo8mvT2V7cSTyzSzXEcbSixiUknfIQPMPy7jtBOR+FXGL5Hpp0/zf4/1vTV47G7DrU9u2szwSabBpMF81vJqDSZaNgBuZwPlIDHA3H6ntVLxdbx2enJY6VZLq15rIl3xSMC942FO+SQkHyhwWC9RgV0Nve6PcaBcX1vJYvoEqzXE06oPIYEkyM4I6k9c85681UsrY63rGl61PYSWdlZWrNZi4fEkskg27lVTgIEAAJ67uOlTCSUua1rfnbTs99+2+hN7G3BALS0gtVcusEaxKxG0EAAcDoq8cAcAcVjePbiytfBup3GqIr2lsFlBcORG5YKr/ACEMMFuoIrcwTzjAxwK5L4o28l/4esLRLFtRhvLz7O9uLoW0cgMbFd7n0IBUHgkDPappr3437kRu2bl5epovh21nmluNWn8tYIGhjJkvZvLLqAB93IUkk9ACSa818KeKIPFXiSz1TxVNYWlssBltbaZTFb7xIV/dyHHmkEAneSuW46V6ZpOnfZbCCK/vLvUbgRgO14VBGUCMuxPlAxkd+pwea4+/+HGlWmh3a6bcXUJiinkMcaLK8mQSkcSn5YwPmGAMtuycnmt6EqSvGe76/wBf5FRt3NLxh460/Q4b+K3la71KCFm8qFNwTKnZLu+6yKQQQOcjHrXnuv3Wsaf440uwvtcnF/qtvEtldW9slp5js2fmyMhlbIUtwMnjk1UubOx0nwfc/wBnyxy3Vq8dz5tlCALdPLB+cH7+F2hgflDMcjNc5ocvirxNDDZ6xp0sltdlJbTV7618x7ZZHI85WyDjP3QOBkkYroVKNJ2j87/p/X6G0IKMbns+g/2rpWpah/ampWc6RP5X2e4vUlvWbf8AM0r8YYqAQgwoHAArpl1axE7wz+dHOoV5IxGTgPyD7knIHqa80i0OE2Gm3n2m2TVDNNc3sMlvG97qLqQQ0Sr82QAGVD94HPcmr1/8UVjtdMhm0mw/t5pCkiXNwIbe12scHLfNk44GeO9YyoupK0Fd/d/W39bEOm2uYr+MviGllb3KxK76jaSNE1pBcL5SjpuuGAzhc/cU5yOayvANn4wZb3aGhsAm5Jrw7AZcggAH5wmOvHPHNK/xplsr9IX0/QY7i8k/4/Y9/lxfNhhMDyTxng8Utx8RvEUUc63Fl4UTUbp0kmeC7DvMvIUfKxXOF4OcgfWupUKsVyRgl6vf5eQ4uy5UkdibmbT9d0PTNXvrCOXVY5Li7gFsiR2xClm2MPvfMMAHr8x5rehu7E3UUC3Vqt7cRCQW6zKzuoXhgoOSMDOfTpXEWniCXWtdi8Q6WlnaaW6RQ313qDKWtTtwYw5+aFeAAcbWbuKseNdOk8O61FrWlw2umNdMlpLf3axvFaDBbzFYjKl8FSCdp3DpgVySp3koS0dvx87fLu/mzOUbnT+J71tL8Ma3qEW4TWdm8kbLglXyFDc8HBOefSuO0KfUPC91cpdeHtT1O0wsl54ghgEs06lA+4kEl0BYnPoQOMVvp4x0G40yeDW7iKG7uIZYpLVIHeCfKn5I3GVkJ4+UEn9KsfD+TWF8H6YNdgls7+JSghddjRxg/uwR/u4/lUKLhTlzR69b/h3tb019CPh0ZHa+KNFvzEILqeCSWEzot5bPbbowMl1LgAgDnI7c1Npd3HqM93DZnzAmySNo/mSWJ1yroRww7ZGRmrPiHTbTX4Y49WRpvJLGOQNteLcNrBWHIDDgjuK5Dwx4ej02HT9N1TXNR+1r5sMdkLnYk8CsHKxqvMSZVScHJ244qIRi0+/3/dsNqLjdHUa5pA1TSb3S7yNhFdwmFlZtp9ev4ZrlNHvr/SNNitF8P2FlpFvJt+3RSeRbyAkBdinLNIx7/drfm8M6K0UsZsWVJJWmJE8hKuf7pJyoxxgcY4puoaBp99rFvqE4m3whP9HSYpAxQ/IWQcZH696cZRWj1Xp/k/68+gpKzTM+fWNbF1cxWnhK8eGMFo5rm6SATfNgYBBKnvhucVZgi1u8hWTUZbfSFXhre1IuZJGz1MhG0JjsBkn2rZd92dwwSeOetRuSvPpQpq2kV+P6tr8CLnH6lqF7beMdIsb25trrTITK5lFsVntyUOd23gpnAJAwOM81Jp+r6nq0kj6bo8cVgkjxGe/n2M5UcFUXnBOOTV5vCmgE35TS4op79WjmnjJDfNzlf7vPPHXvSeHNUl1XTXe4jeK7tp3tLhHXB3pgbsehGDWnuuN0r2010+dl/W3ccpKydinLdar/AGTE8+mOt/HKpkgtnDRyJ/EFc8fg1Vtf1i9tyyabpmoZFk8iNJbkAT5wi4x846D5ema6RvujqRwSM1mvqNvba/cw3d9FbhbVJR50oQBcsWwD1wBk47VHMm/hvb1JjZ9DlNe1G1Dxf2jezNNZQefq+lnDQoPKB8sngElzxnOSKK5nUoNFn1vVtUSyt9Rg1GcZkdS32NVIzIfaQDIY9AaK9CnQTj70L/evya/HU6I8sVZux6p4e1y7OsXC30d7b6hqk6i0066jeNYraMEeaGwRuI5bGATiuomks7EXWoNHZWh2/wCkXgjWN2QHgM4wTzXnuuwXtyloLTUbzTb2WSW9sDK/l/Zoiqh437GRmOQvRdxrqtLtbt5LS/8AEGpWt1Paqwhgt4wIlJUDzGJ5klwCc4AHOK8qpTjpPv8Ap28tLa+uul3NaXILrS7LUvEls40OD+zHX7XfXV1Y7RdTLxEihsE8MzM2PrWhp17a65cXVxuc3Vm72joJiy7A3XbwOvHTjpVyO7huIxJDMsyE4Vw2Q30PevPPH2j3ml64PFPhdZbfUjEY7mSNBKqZwNwjx94jgsKSa2eltv8Ag+v+QU4urJRvr0PS3hguIJIbm0t7mCT/AFsU0YZJP94d6y7Lw7aabceboUs+kuRtMau01sVznBgZsfiCDXnHhb4ra7q3iS00+XSrCdLuQQDyVZGjYcM2MnGOWJPHFetW7XJ3rcxQK6sRvgYsjj155Bpe/FNd/wCtuoq1GdF2kYOpSavcSaok1u6GxKfZZtNRil2HH8Kuc707nJXmq+m+A9ItRLNO1xcX0gkHmFhEFD/eyqfIzHk7sd+nSusxjd2PSnKhyDgEdznOapVZRXLF29P6/r0M+fsZml6Tp+mF0hglLOxJaaUykE+megx0A7VqrGif6tEQHk7BjJ9ainV3TbG+xs9e9TEiNFDNzwOe9ZuTk7tibbF6j0x09qljAdxGNokxnBPb1/Wqep3tvp2n3N7fymG0gTfJJjcVHsO59B3rD0q3XxPNBrGsLBPpsMjx6dZLnbKg6SXAOCX77OAMc5qkm1foNRVrvYy/Efi6xvNVk0Wx1aK0hSFbqTVLMNdujBtojSOP7xycHnI9MVZFr/atnax+KLzxnMoeSd9PGkPCLjceFkeJWG0EfdLcA812MCx2yGO0iitoz83l28SxKffCgc1IJHDDBYHuN38619okrRVvuv8AfbT+rWDn0sjMaTxJqnh3URdR6Vo+qXNs8cECSNcmBiCATIpVQcHjaOD61yWh2Wo2k2l6PqGgafY2d65hj+zx25ZikYaR5FYPkZIxhsnnivQDzwTg9cVhXFrqMnim8u7W0tpIoLeO1try4YgWUzKxdkXB8x8MpOMDGBnOcTTlZOKStv8Ap/W/4lRmU/8AhX+jT6hPe6vLeapNKqIA7LBGiI25UVI1HGeuSa6+GUxMnlIscUeBHEoxGgHQKOwrk9QOq6Bq+m6jea/dajpM8q2moQTQKkVuHACzJt+6A2M7ietdVflNPt7ue8Zo4LRHlnk2ltqoCzHA5OAD0605tySu7r8Pu0/IiXN3ON1TSvDvh6O6v9ev9UvdPaWa9j0u5ufMilkYF5FVAB5mT82GyAean+FBhk8KS3NvFdwwXE7XAhnVo4oHbloIVbkRoAvPQkkis/VLm78cS6RFoCfZbKNP7UW5nYCQvlkjTy+2QC2CeQRVC1g8UaU2q3fhgrOYmS0uYbxJn824B+/GzHDZLZZuBwACcVs6d48spWk+703/AF/4c2SvC19T08DfhV3En+7XJ+K9W0vVPDl9aafq9u+pJOIbRbaRTOl2jrwidSRnBOMYJ5qHUdR8WaR4dxaWJhvkmVRqOr3kZZ1LAkrFFkk4yNo6LzyRXkWg6/Npes2NvZavNqVvYCVlXTbMCTyiWLMxdAzN8x6YIAB5xVUMPKV5p3tt8vv/AKuTGlfVn0cSZNzAq7A+XJsYEeYMbgcdDnt2qJdjOArAP/sn3ryPwp4k0T4c+AtKlm1MalHrN/JeXEmJBKqZCNsDD5mQhdwOCd3GcVuf8Jrca1qHn+Bbe3ura3tXuHv9Sjkhily5G2JB8x5BG5uMg9MGsfYS1stO702/4IpU3ewzV10nVvGupWerTXX9jf2S1rdmCP8Adq7SM2GYf6tlA3d9xI/HzRZLnxH4jh03w7Jdafps1pG8EIvGbYsbIqlV6LJ8ikhjj0A4zb8c+KLxNWisLLSpYvEVzqbXNzBflZ4hhdsCKBkDIw/PGec4r0D4QeC7/wAO6bdXniCVn1C/bebZ0XbESckjH0X06fSvRXLhqftJb2Vlf/L779vUpy5djiNY8BeM2N/eG2W61VYHj+1Fle4c7srITncZAowu0cdqq+Cvhfd67pap4n086YqOWa7l3JOwJyWIb7428DoPWvcLPUpN1y0xiPlS+WdpJdOOFf8A2vp2q5eXkghY20EdxIm3zGmOI4VPd/4ifRRyfasvr1ZLlSSfdGbnd6o81uvhr4Q1XQ3kOuzTQRDyZbiIBowyncVUdevYHNQxfA/wxFaRSRalIbdkDOZYQwkBI+ZTuGOOlelafbeXdTRXc011dxQRSebMAAVJIyqjheR0H51zPxR8cWPg60jtWiW+164USWunjkEdnk9FGCcdTjsOahYmvOfLCTf3f5Apyb0PGpdOHg7xZq+iPq0MdmlpJMtvdTb45FWTcISBxlxzjqCPxr2XwTPeW1xd+HdSsGudDeHz7Wa4PnKquqs1s5P3lAbKk+hxXjvgXwl4l1bWZfFepQWV/wD2hJPaTGZ97ROy4ZlVf4wrZUe2a9f0SeOz0yHXdSuGs9N0qzks/KkkVI3UvmJ3JP3ygA28kZ7nit8VPnhyuzf69Pnp+JpU0WpevPB+nT30N1pf2rR5IkWNV0yXyU2Ancu3Bxu4BIwTgVW1LULnTvHdhbWlybq3v1YXGmLKkkloAAVnAJ3BOSCPbI61hifxX4okBhsyNKhmCyzWt6bZJCTlvIkIJkUKRzgc8V2dro+naFa3Nl4es4bQI/zALlyTg/Mx+Y5BB64rjneDtN8z103t69f63MmujZPdymECTY7oGy+zllXuQByT6AdTXNaVqTav4r1iS8gjih0NVjtZtmxkSZcuJmzy3y52HG0dea19f17TvDkNrJqks6NcNst4YIjNLM46qijqfyFcvqNl5WozG7tmk1vVkuLqw0GCJSIRs5muTuw0jLzz0OQM1NKOl312f5/hdN7IUVfQ7NWVhlSrKeQynIPuKhlGW4A5rG+GrJP4K0+CKQPJYobadQxfyXDH5SxA9fp1AJxmt2e3uJIWW0IS4JG0suVIzyDnHXkZ7VE4qE3FvZk2ZAeB6+lZl9rmlWN9b2N5fxW95OcRRyKwDH3fG0fQms1te1+8by9D0GO1vpYZJ7O21dW33EanaXAXARgeitnPXNcfBruj6o0Bhn1jWJLeFYdSMzpFaxbnwXILY8wsQowTxznitqdDm+L8P6tvpvvoUond6vdWmlQJJJdxRtPP5cUO/c00mRlIwvO7JHB455rnfEep3fh7VDqU80NpYX5JNsy+dK8safcCL93fwN4yBgZ61ee3bQNLvtSs9H0mwjtWBEpnNxHaqCEcnau7dg9Og9cdeM+JnjOxvL200nSJzFBdxFhfjO5o2ziPgbkU4yxH5HFEU1pFX3XT16XX53NaVJSlZ/D1MvUfiX4jvr2NNK0qG3eIec1tkzHYBku5GMr14wMe5r0aO20XXJPMMkF/cXMUMspiJ2EqPlKE9OCwwO3WvK7eyuvD9vdaNeRbNSuY1i2wzqHt1IU8MRtZWBBK8n02kV7K9jpd7pkdh5Vvd2lsqwLtODGVULlWGCrD1FJtKKcdPNfL+lr8zXFQhSaUdDJ8Vf2fpujX89/ILCG4jWLfCoR1Cn5Sg77Tz0ornfEHw50/U9aW/vNQv5LWFEjS0dy+AMcFyScd+nWiuzDToU4+9KXy0OPm+Z6BqttdS3mmXcGkRatLbMwWZnAaBWHLrnjPsfw5q5Jaz3EsRS1SHzObjz0DbDjl0wcnPTAxkdadeaTHePZ3L3V9BdWjGSEWswCO/UqYjxIDjG0889RWTqA/4SDw6mrf2rNaNZ75hHaXZtovlPzLcYUspCggr2z3rxo+9az8uvn52/I6i7N4i0aDXU0Q3kA1Yt5b2sUTERsFz8xC7VGPU1shFk+SSR1RxgmJ9rYPoR0+tcVDqVroOnwa3aXDz6BGxm1GGCBXVY5E/dy27kKSoYBWDFj83rxWx4K1WPxNpM+sQsws7y6f7FArfNHCgC4cY4csCTgkYI5rScEldbfr9yt39OplKNh/huO+SWJL3T4kuYhLDJcyKomWMOfLUMuSQVK/eIOAc9q6EblGQAR+lc5ZRabB4wuY7O41ObUpo/OugJmktY8YAV/4VfHQcmt+5ZI7K4kuJza26RsXuAwTyhjqCeM+g5+lOolzaLfy/r5Et82ol5NcQhXt7Ge8UfNJ5TICiDkt8xAJ9AKbpd7Fqen2t/aB/st1GJovMG1yD0yvbis3/hH7O8ntr3UrjVbwhUkFtdTkQO20BXeDAG7HbgZPIzWzEFVVSJFRE4CqMAD2FS+Wytv/AF/WyEyK7SaWSKOGRoU3bnZV6/7JNWkj+dERC56Duc1ja7c31npszxPZ28mMRT3EpSBH5I8044U4xnjkgdTVfX7XVNV+Hd9aXEXla3dWWx47E8JIcZ2ZPIx2zyO9Pluldre3/BKSbsWNbjudbvLvQbULHpyQq17qSsGaNzysEanh2OAWzwF461uIXWMCaZp5V5aVwAX9yBxWB4O1HU9Vk1CO802G0s4ZUSxKo8UjRleA6OOW4BLA47VqaXf2mpwvPp9/a3sQbaGtXDKvsfQ/Wk01pbYc7rQ0CcEEcmgcrgdOnFZ+t6pZ6Jpcuoak8iWkW0OyRM5GTgcAZxk9aoReLvDklubiHWbaWEP5ZZEkcBsZwSF681SpzkrxTfyMzoMA8DOO1VIdPhh8QXmrxu5uLy1jtJI8/IQjEh8f3sHb9B703SruPUrm5ks7y3ubUorQRxAh1VSVd2BAOC3A7cVfXcShPA53ADr6c/n+dJ3i7BqY/jRbKbwbrseqLI9iLRnlEblGyvKlT2IbHJ49a5Xw94d/tK/TRrjxD4wvI7aAXdy8k3kwxeZGCR9p6yD5hhR05OeDXc6veSafYzXEcSSHHlqZmCQoxB+aZieIx3wC3oDXO+HPDo1TTru58UR299JNOoWCBHis02qRmFd2SrbiOQM+ldFKfLTetvx1/rrdFRulcteC7G2aa41G3Sf7JDEulWEjzljcwwkq07DgfMRgH0BPeuo3nbjPTgcnikjUIiRxokcUarGiIu1VUcBQOgAHaooSSpMi4OT+I96wnLmdwb5nc57xj4RHia70y7fUbi2bTvMe3jjUFTM2AJST0Ze3BrHv4NL0jxxZWOlajOdcci/isUcOC+wq0jHGNxG4nJGcGupN2w8YxWVu8jn7Hm8KIdtufvRHf0Dkbht9OeK4XX/BWpX3jDU9YsdljDbNF9nxP5ELRxqNwdgCQwLMwP3SAc9a6aMm1yTlZW0+b/p+nYuPusz/AIbeFNKuNbWW7tp72aC5mt45JgTawyAFhHFz8xO7ezHCk4Ap3xB8UWPhKe5tLTXYZXvbT7G6Q4Y2MA3AuhQbd7HK7ewUZ7Vs/F/XF8NeD9Ns9MvbERTjyJMSie4aMAH92g+U7j1Y4AGABzx4RcQahrCw6Db6XGCbkBVhi/49y3zHYVJJLAjcGyuQuMdu3DUniH7aXw9vR/1/mU5tta6mj4X0KLxN4rii8OPdTAtHG895IG4I+eRVABUADgnPYV9Nfapts6SQbJI5jbWmCW89EUfO3Ax7gcVw3ww0KXwXot1FdOViuZfItbVX3XDShjvQkZGBkDI7gk4AFdhqLpaQ3NpY2aanfxbZbmJ7jy0jjY5LFmOABjKqME4FY42t7WoorVLb8Lu/4GDd9CRYFgWGTesshaSSJmQHa2ATnHJA4A70sk8Vlp5vtaeGKKJS0pIJXJ5YherE9uM9KzbK9vokiub55b66njcwwWNmGCrnIXJYdRgktjoQCalbzZru3uwq3U0ab/mkHktOfu7ST8sa9c+vJzXI4a2kxblaK/vtPvVvDBDCk9k+xNVn2bth3iSUjIXA4CjJwTnmvFNF8J6jqng7XfGl5eGfU5rx/NCDzXEORuaM4++C3AzjbnPOBWj8WNbg8Z6nDoenvLK6sGDuG3Mf+Wki9QqYBCqcZzk9q3/BniSw8HySQTrqdrp7XWx4o4N0doiRn90y4JaRshiQF+6eflIPowpyp0+eK97TTy7fNHRGMqa5luYksmheFLzU9MtdaltZVs2N9KGeCUHCBFQ46gkHABY564zixrY1az8F6dpk9jPDPDGn9o3sMTPHBby52Snfk+c4xuZQdqnHU4r1q+0+21y8g1KCSSJEg2xajbRoZWDHO1WdWAXGMkDPbNQWvhjS7OyeGzk1CKRt/wDpX2pjMCwwcE/KRz0IxnnFY/Wo6OW/6/16/hrLra3Zl6Lp+tQaQdKsL6RLeM+Ut5LIZ7iNtoCxAYACDGW53DdxUeg2GuaHa3ENo+n31/vUX1vcSziFJiTlopCC2SuMqR/CMVe0nR9V057vTrjWku9IuDJIsxUx3ql+GVWHy4ChRuA6knA4q3a6NplqdLNvalm01GjtWlkZygJ5J5wzc/eIJ+lYTnurp38t/XZ/19+bmjC8JT6re65rWqalb28nlXYtYnlDIkHlZVkgTbng9XzyfStyy06KG21BCN76hNLPdSjhpS5Py567VHyqOwFaDln+/uPpnpUbDgkdRxWcpczulbb8CXK5zOo+D9OnW2aweXTriJDFJcRku1xGQQI5AThgCcjjIxXEalZTeFTZ2GqeMr3ULt7hr22t4UleeeNQVCGQvtGOSQc9K9YYnP0/Wsa+Gh+HFv8AW7q3traWZgzzeXukd8YCR+jH0GM961pV5p2bb8tP1uNS6MgTT9S1fQmOsalOt3chzGYV8l44JB/qnGfvAZGRXHeJtBFp5Z1FVFpJLaubiC28mJzErp5U5TP94Nv28n0rvINZiu4IbuyttSvLWaIPHJbwoUcHoSzOCCOQQRkelZ15retPetZ6d4curXyZcTT3jq8cse3P7vYcbicdTgc048zdrafJWKhUlHU4XxJrceparfaaYr6+uhIIrGDTsxRKV+VXEn3uScHcu3HO45rPHgu88LaSp1SSOOeaRpYreKVEaKNOZj5uMsUypVV45616hFBrEquL/U4dOt5Uy0Wk2qx3CEgZQzNuGM9SF7cEUsGn2cEU0QjknSXO9ryRrh2B6gs+ePYYHtVKcadkv8/8kvknfuVLEu1kedLpngfSbs6rb62Ly9khK27ySvLD5z8By2Cd45OGx716NZ2sdhp9vZwNvihjCBiNpf1bA7nrT0SGOHZbw28UfDBYolVc+uAMZ96S4ZlgbywGkxwOgNYVKnMlHX5v/gLzMZzc9SrcEsygFSRztbvRTJgTgnAzyT6H0FFEEmiCp42t7mbxD4XmtrC9vPsks0im1O3ypSoCMW6Lg4OSCMDv0q3bWWmeCPh7OmvyCeFVaW/YNzdSv1QZ6luF9xXVRg84bj0Fcr8QRYzaJLaX+n3GqzzqWtNOgVg7soO+UuOFRQRlj0xxz05YTc+Wn08t92/wu/zO7mukkcFc+LbjWfA92viTTr26sGlWCz0+3h+yWgXnYzyBcvh8BVXAOCTk8ib4eajrNjdan4asbmyjdUjuUtIVMsiOxHmRxNnqq4DA5IIJ9TUGtaf4X8Iabpdxqr67rurbA2+0v2jit84YrEzHIUHoRkkjORXe+F1tm8OaO1hILHSZIc22nW67W3uzM37/ADvd8ZBAPOOfSutKMVdrTppZfd/mlfubVKkeVqC0b1/r/hzR0y70vS9NfS/CsP210kYpaxyHa8zH5nllPAAOSxz2wOcVNb6D50dnL4quYNZ1C1mM8ZVClvG3G3ZH/sgAZbPf1rZGI0WJY0jiBz5aIFBJ5JIHc9SfXk0iqhzwCAORWDm221169fv/AK8zj5kth7ytIDI0gfqWfOee5NQ2dxHd2dtc2+9oLhBIhZSpKkZGQeR9KwPEq3ul+D9QltZRceW4eSNYQXkhLfNGueA2Dw2Dj0roL6JomtYYw0Q2gKoJcLgDgt3x0yaTiktP6t/w4rFXXtG07XtP+xaxaC5td6yeWzMo3DOCcEZ6nirkMccEMUUEYjgjQRqi9FUcAc/SpOwBPFRzh9p2HDDmp5na3QPIkdg67Xyy+5NZ2gaXpmgW7abpNvHbRuxnKAkl88FiT17CryAlVyAPUetQzkRTpMYy8r/u1wCfrmiLe1w8i+NroVlQOjqUdGGQwPUEHqKm06Q6fbrb6cFtbdMkRQjaMk5J46n3qorK0rKu1tvBIOcH0PoatIpJAHXsBRutSdjC8e21vdafDq17e6hYXmnuJEvrGBppQh+8joo+ZDgZz0xn1q94b8Q6X4ltFn0i8N00aAyrImyZewMi4AXPJHY1g+NfFlxpN+2k6YZre9eMYvVKk72U4hiU/ekwAT6A1ifDO/XTLq+fxHc2p8barZmUl7gsJgmdiO4wsZPA2jJ+XOe1daoydHmfTb+rbdd/lqaKN467mx4/8O6tq2sJqmnJNOumWXn2lq7qUlvN/wDDHn/nnkHd1zhcHmuZ+G18+g6tqW24tk8Isryu9zK/mwuPlijRW+ckgAbSueD6VR0Pxh8QtOiml1CPTpbCxYO8PlbWnjIBJjmyQTk4BOctkda6i78RWdr47iiTw7Pb6rdENPeSWW4Sy7MeX5pH7sxtjMq5Hc1r7Golyy1ST2fpv+nZvttopNR5Gtyx4n+IcMDJbaJaXVxbzx4XXUiaW1tpdwByuBu2ZGeRycY4o8Haj4uvp7mTWbqSdHl3WaxaesLmHJBZ0LAqxwMKenXNczB4i8Rprlpb3OkTyAziSGw09/LtI4tocF227CQ4J7bmyD143LSWCwvtM1LRoY9XtLZZRcTXEjySvJJnKrKTsLl85IBwOBgU3RjFcqir99H+PS+3Z9CXHlL/AIe1OVpr6bSruOErfq2qT3KkzSBOCi7vkHXhgCCoODmuZ8X/ABEOn6sll4W160v7J1kCW2oQtGLeXJDPLKQNyMCwUHruHsaxvEV5p1zdSaFPqGnWF/cW6S6ndtGs1uzFgQm1ThCjbDhew5zjFM8M/DLVrlhB4hney8PTxi5u+oF2/Y9N2c87SQOhFdMaFJL2lV/Lv/n5JdN97ESavZC6b4L1jWr22aJLIalZRy2l8gj22LQvsIy46ybXYFFORtQjHOe8XRdK+Hd1bxeEo7ibUZovs7NOweQoc7F+X7iluSSOQuAcnNXfErTWHw41y20G3VLWw0u5zcOBGzHyifMATA39ST3NeJ+BNW1ay8R+EJxd6rpUGoI0U13qMnmw3DMuAYwFyvOSCxwDg9jnP2sqt7vTt39evorGerVz3+OUWtwRp2XvLONkO8BvIEpywOPl85yBwPujrjvlyuAZIEUzytNvuGSIszS5wQ7fxMDxtXj2FYl7q+l6Jp2n2ukrfPYxTPJbi2iM81zKxy85U8gY6OeuflA4NcvrHxKfTtPMGji5h1Rh5dvbxbZJBgeozsVj/Cvzdcms4YectYr7/wBf609Sorsek20ls2ry6bezSG/aIFrC2wsvlnGTMxIUA8fKCSM1zfxD16LQrK5sb17NRcMCbW3xi2tsAbN2fnlJ4yBjHb15SLw/qM2h+G9Ru/EVyvirzpbh5DMssNuGO1IRklBJlidvqzZIIrO0vwXb2MbxWUNzqOryyJceUfkkWFJWVvLmyQxZxjeoGBWtOlTUlKUtF087/gv6v31hBpcyLHgPQEu7qW8ubm/s/FrM32OaUokMDbgU3cgZ4wAwPT7tewzaToejeHB/bcUMdpbIPtE7Fxl2YMSSvzct/M9ia850SOw183NnL513Fbai8Z0qSDZA92o/1srx8rGQMLkksy4z2rqviTqejGa1S8u9UkudMuFmeHSUDs7v8vluOQpIDHnnCsOpqK8pVaqim/l+H9bK/XUJJXSRi6v4p1SLX9M8S2t091Yi3SEaFB8tvJE+QJRNjaOxxjcCMcdK9FF3B9tjtkkH2iRGkEY+baF65I474z3NeZ6Fr+kReILqyvjeaiTeqtnDbQIsNw7DAKQdUC4PI6Yz3r0p7Fz4hmvWBPkWwtcDnBL7z0/Dr61hWjFNJq1l/wAMvlf17k1kk7EzYLluMYxgjpz2pjfNn26VKYZGAXa25unHXHpVW7uoLK2kmvLiKKJF3FnYDj29ScEAd65077GFmOHGfUn9KiZhk4AArKm8QWifZw9tqatOwQZtGwinPzuf4VGOSelXRfaeZBGNRsRKV3KjTqGIHfBPvWnJJdBND2A4+9z09653W7O51jxNY2cd1BJpNh5eoXcCyIdrEkIGA+YsSDxkYHNSXeviTxhp+gaZewLM8bzXUq7W2qBkJEehk4z3ABBrU0vSrDSLD7LpVpDa224uxHWRj1d3PLH3J49qafs9Xv8A1r/l/V7V4akhIG0IqoigKqqMBR6VGxBBHOCfypUdZYlkiYNHIN6OpyGB7g+lIVBJZf0GanYh6kTEjpz29c1DJ0Bxn2zUrc8c/wAqiYcdefamQ2RjJ/u5PIGeSPYen+NV725jt4WVlFxcMp8u1EqRyTn+6pbj8fauW8W6ZNqnifS5tFjabWdHdWcuwjtY1cghZWzndx91ecHPpXRQ2dw0kM+syWV1fQmTyWt4dsVuHxnYWyxPA+Y/hiplBJKTfy/L7/l5GiSRzNuvjT+07q41FdK+xsg+zael0B5XtvC/e9WOR1/ArprpMZcctjpRWinpsv6+YKSfQteHdfX/AIR6S98RXECPbeas1wmI4rrygS7W4J/eKAMBhgE9BWLot5ql7pOreIriF7y8liPl2e05Ma/NDbx4xhVJy/djxW1oGgKLW3m8RW2n3V/BJvtI0UyxafFgBIYQ4wNoGM85xmtue9htVe7vpY44FbLySEBQM9z/AFrk5oxb5VfX9dl/XodfNbY8Q1q507TZzY+JG1y4v7m3D6nJa7RN5jkN5Ks52xQrx8oGWOM8DFb3wl1HTvEGl6v4N1S1mvNPtT9rt98axts3jPKE4YMRyDjrWX4v8M3MXh+bVm8S6RdQxXktxkQPI95csOIyASNwUYwOMDJ4FcZbXsnh+7tryDWLyBoZkYNbxrG8QZRuCk8bQCR0wenFdM6knon+e67dv026HfRw1OvSbW6+493upfE3hmwa6kZfFGnQt5YtlhZL6OLk5DjKybR1LDJxWz4X17TvE+mm/wBIM5gWQxOJovLdHABKkeuCKbaeJtPbTrm7vpxaNawxTvvddzpIqlJEA5+ZmAAIHPtXBeB5Z/FvibUZL2dgi28UV5LasIZJ5UkdldtgAHyPsJ4ziinH2sJTatbqv8tv6R5sqUle6tY9B8U6Naa1o81tfF0jhIuI5UkZDDImSr5UEnHpjmqPg3QnsLQanqUEw8R6lCjapLMxDSODkBkB2qQDjApviCXUfEOsah4W08Q2FnaxwyajqLnfIVY5EEQHAYgcknI/n1lzJ507y7cFmLYHvUc8ow5b7/8AAt9+9vJGXQrso4xjHQgdqTZlx19hip1jJZflIycZxXAt4qur34kan4PvdIEVhbxlrq+iupklt41TcsuR8sfO3P161klzbFwi5HbYX5vUDOM1yWuTeMp9eNj4YykaSxhZGhQQSKRk7pGBwykAEDrnird/4u0Oxlcy6lC0cC75mZ/l29uRyfw57jNef23xpt7eRWTQ769t1nZJCp8vGMk4PIz0PPbPStqdGq7yUL+v/BNYRa1sdv4K1fXtQ1W9GqXNvfaPAsrXGoQW/kWySqyqscLkAuRg7ieB65pni7xmqtdaH4b02bXNXmf7JmNN1qjMuW3OrZO1SDxxnvXn+qavD4/ubq1n0KXTr2b5I9Q1S8lZbeEcrFEkSbQTk5JBzzmu88MXul+HfDNjolvFcQanBbFw9xbmBphvLH58bSpJO1Ax6AHkGun2Ki+Zx17bL1uv+AKcHe5X8G+HdE8LXNnY6fYf2pPBbpeXl/Id+11Y7yuThCpbAwMnnk1jX1lq3jbx1qd3MEtNYTSGQQXFsxhtGRiYSrkjcWBYqwHDK2RjFddZ6r9jvLuCytJ3FzO8VzMoQx/cBjR2YgtIegXH8Vc78NtdtNU8RXdlcWsNyl0ggju7gxpIm4kvalQcsCyErgkjnsTWjlP3qr1dt+v9eX3dhpWTkuhW8Fx3OtaRo8msBL6wsrPdJZxqPsj7yWMkhAOZGJyenOc13Gsa7Cvh+wt5bJp5mlS1gtYCYozledpOcJtG3PPWtDxVPDpXh2PSNISG1vb/AP0HTbeFAibj1OMYCqMkmuK1i5eC2tbjVdYurqys0SdPIVII7fyj89xkn99I+1iiDpuBxwKiLVZqTWl9P6Xf5Xs1e4r8zvYPE6QfZ5E1u5F5o00olTTorh2gDqyrvuZBz5aHGIo/qea848e+KH1TWprO2la7kurlo0uo5PJjtpUIRDDjBCKCfQHPU9aj1vxzrfjS+TS9D+03VpGmNPjljKTK+RtkbZkPIx4yeOT0rtPhx8OL7TLi21PWI4LPU7SaSUzSYn8xnXAV488FCc4B5713QjGhHmqvXov6+V/+AS5WWh29t4Z0O38G6PqOt6PNc6s1rDLJbWUWyeeVeMeUMbm5yxPXua39SguruBj4hkla2aXcllYAhpiQcKzDDOwz91cLxnnGana4EbyTt9pa5kUK0kgAmcDsoHRc9hgc1kX9rtubOy87dqN5ul2eaQ5QnLuxDZWJQNue/TvivL5pTfvP/gena39WMXqY3iiwuvElpPoX2Z00aOSJHjjfapZuFhDAZkZc735AHAHIJrA1TwH4V8MmO9tlmmltD5VuJpmnjmn2/LFGCcALj5z0wQvB5rvbNZGE1hbxyf2RZ8y3COVQhQWeNWbucjLDgLnvXk3ivxDc3viBbKW+TS5PK8uSMwkW1ra5LMUGMrI2QM45AB4zXTQ55Pljolr5/rr/AF2HGPM7GLqf2vUDdG31i523Vw0U2vFWjjuHZmDhMHDJyV4ABIGOMVdg02x8N6fBJo1hdXtuSETUTBmzhlztDSSD72M/MBxzjtW0sAvTFbQC10GGNYgltcTiJNPQghQSxy8jDD47bvc11tzren2U1leaRe2NvoWm23l6lpEKeXEiksfNjI4fOACRu4Oe5roqVZWSS/rpt32XT5Wv1X5NEcxovh60ntoBFqBvr+9kkP2TSfuGVVwzuzDbbKAeAR+taZ+F+pKUhj1TSrFLWMpamK2Msw353mWTgyNz649MdK62w8d+FW0yJjrVhp8ErH91JmJA3B2lioUtgjnvXQxSRzwxTwvHJDMokjlVgVdTyGUjqCK4amJrJ6q3qv8AgfIydacXoczF4G0vybdbu71OVoli3iGUWyTOnRn2Dc5zz8zGtzSLOy0xJotJsILRJX8yURJjzX/vHuT1q63JyucZwarXVvHdQPBcJ5kUgwy5IzznqOe1c3PKStJ6f10MZTk3dsq65pmn63p32LU7SGaEEGMhAHiYHIZT2INcSPDHiO11CXyzaXWnXEgknkjvTDPdyABY5WH3U2KBuAGDjjk5r0Bjhuo+lRk8DpVQqSgrReg41Gjz+58FSzW+oz+KfE+parqV0CIY7d/LjZ8grtiPPUAHGBjk11cGh6dDcTXU1lbyX1ysZuJGG8MycgKDkAA5IxTL1dVg1k6hGkF3pkNsVS1jfbcCQ53uPlIYYx8oOcA4qxpmoWWq2MV3pt1DdWsufLnibKtjqB0OR3BHFU5y5d9P60/D+rBKbZblkJclmJPcnuKgk2ZmZo4mMgVXLIDuAzgH6ZOKVmJHBzz27UxhhM44zk80kZXZUv7Gx1C1jt7yxtZoI1KRo8YwgPXb6Z74qg+kTQXds2lajNYWbOn22zI82O4jXoqBv9WSMgkcEHkVe1LUbDSYFm1S/tLGIkANczLHuJGenX9KbZX1pqdt9o068tr2AMUMtvIJFz6ZHQ005W8vw/yKuxsMCWmnW9paoNlvEIohwMgdM44FY2oWOtXcwJ1mS1gimM8K2iqg6jEcpPLoBu6Hkt7Ct5tu5QxAyduCcc+lZ9reC4uI4ZIJ7V5QxjS4hKeaV67c9eOcdcAnFNNp3QJsc93Gb2e3OEZQGDNkI2fQ+2a5p/F+3WbjT4dHulltzjzbqaO2Dvzjyg/EnTIGRniuoYbuqnapwoI7+oqKYeagSVVdAcgOARn1Ge/NF49V+Ik4p3aOY+Gsl2fCECaklyl6ZpZZluIvLfc75yf72Qev4dq6OQLk49Mc96UAoAB0Xjr0pkqkqRn8V4xUTlzScu4m76lGdtxIJOB16jqKKbKu3ABJkYYywzg+uO/0oq4zcVo7BZHYvFJED50TqegyKzdVkuGtpra0sbe9lljICXThYTyAdy4+YDOcd6pXGiCw0i4j8IxwaXenBU7iY5W4/wBaGzu+vX3rQsiwtIBNGI59g8xASQHx82CeozXFFJe8nf8Ar+up0s8e8f6aPDdroOnaNFLJL5s2pXEpuDELqRSEYbR0JDYAX+FvqawW1jwXpF/axQvqOoLIhinhuIRG1nGxyYlYnl1YEZI24PHNe8alpWm6mY/7T0+2vPLDCMzRhim4fNtPVScDkelR6Z4f0PTpreWz0awint4zDFN5AZwpzkZPXOTyeea6/axnFKabfrubUsVKkvdZ5Do/h22+IniMahpcdxpekJELe4ManzJWHJOeg+YDGf7vsK9pvLyx8G+GUhsrQwabbW0oWWA/LA6plGdfvNuYnJHQ9etT6PYWWj2b2ukWyWls7+a6J/E2MZOfYDis/wAcraXPhS+s9TvDYWV2gikuApJXPIwPcjHPGKc6kakoxt7q6fr6/eZSqOpIb8N5dJTwxaWWj6pb6jcCMXl8UmEsnnS8s0pHfPHPpRfeJNdj8aPpWi+HIb+ysGiTUJJpjFIfNGQUJwvAz0yfWua+GOgazHH/AGlqKN4ftmg+zQwWcvl3M0eAVJcA/uurAghiSecYrvNJ0yx0a0aDT45AZZTNPLLIZZZ5CMeY7tyxqJNc0m9W/wCun6d/IdVRhLR3PPdG8SavrHirxbp+p6hJ4blTEOmiR9+xjITuXPy5VFILgYGcnkitTVvC7z+HLbSU1eHRLq73ma7Zw0N5IwHJZyHlyPr16YxXUeKNMtNV0S9S72wyx2svlXiriW3O3duVuo5UZA69K8c0bw5rnifQ9E1fxf4gvJrSK9Dixm3ygwA4aUA/db/Z79MDpXTS5Ze8ny2fa+ttLf8AB2Dm5lob2v8AwmtxpsbxXfn3zIq3dzcRlocIMFguc5wOp4rY0/RRpFkNPg0eO3tZpU3200hnE8rr96T7y4O0dOa6x7y4068+zRfZmtomQSQvvM4jJC/Iehweu7k84qj4l8cw6ZEBoNsmrXscp+0Wrl4dkYyMh8YDZ28HnGeM1KnVqJRtzf116feWpz2K3hnRd+hXH2hpEmyVlnndNuc/cBBA+8pAzjjFZKanaR2TWZ1m1EFtcea8iQs64YHEajvtbO50BAwc1yfiPXL3xDcW17eW9tvgxElkrKls7sTy/O4uOAM8cCsGzuJpoZZbrU7qMWmUurBgqSWrE7Rw2G25IBK5xnniu2NDW9SSV+n9X/Q0jTlbU9bSxB0NNUtJLC9hntpnhlafbE0yHEYLnjdksQe5ABpui6RpKXmnW2qadbqZZQ8M4gKEXZw+crjy3Ygexxgd647wtcRaVaae9uN+mSXoWeGT5kt2kIBkQfwnIHt616rrnhRp7ozvPK80EiusKHY6rnkBjwTjPB65rGrek+Vy3vr/AF2Mp6PlkzlfEusandeNPFE7W07ppcFtp+nkfKIWuf8AXTpnq3BGRzjiuF163/4SOHTfC+lXOlCJ1EjQi/DzoWUHPzcFcNwiEnHOAa2rjUdZ8LeNdRuxDcNb20cbW9u6hVubFJCPl5/hA4yNwIyK5fXdck0XxfpvibRZ7O6sLxpZJYtkUXko8hkEcjj5gCOFJwccL0IroowcLcttlb1t/nr6thKNo3T0Pbvh74U0jwRpVpbCG2fWyjSTXEasZHxgER55AA2jt+tU49V1keMJoPscltpOyQrPMIz9qu85HlDO5l24HA69eK39L1MeIfBlrrNqEWSW2aZChYCORQQQpYZwCCMnrXPtcXV38QvDkEdwDJBby3EwmBxMjKuTHgfLt3cZxlvXFedHmnObqavW9/L+rf8AAOdvubOr3i6Nbahf6tZXV/L5TOEs0BMYxjy07knJJIHSsjTNKkvJ7zULto/t5txZ3uEZWhyFkaJWHKqq7VGOGJYmug1Se+iku2s7FLy5WCSKCAn5JAVyGIJGT7elYWg3enOsHhi0mnvL5ovNmEsDxSuuVP7zcARk8c9vwpU2+Rtb/p+n6/ITsYvjDUbnQL5Jr+dH0G2iIKQk/KxQ+UpGcttXOR0bAJ7VwHhKGfxFfaZp2u2zNJJcNeXksiks9mApVpRnCggDknHIz0q18Q9WbWfGVtoF1NcArcD99Ywq8RLAZUg8uquIV2N2BzXc/DfSbifTNZvL/wCzz3FxItteQsfME8ka5ZAw42MWAPYbcY4rvv7GhzS3a/4b87/cbwfKrl7wboUWpRLrOtTPfI8rzaZYTIRFZRFmCMQf9Y5THzNnjGDiusutM06c25nsLJzA2+EvbqfLYdCuRxiua0bxBLpdjrUGv2032rTbqCEmOVZXuJZ0VlT0UjcBnhfStPUNZfR/KvNasGstJeQx3VwZhK1px8ruq5GwnKnB4JHrXnVFUc9Plr5X0+T+d+5nK7ZsXYhv4xFqcEF7bZDGK5iWRcjvgjFefaFrreFL6TwreWxuLK2umaK+ecCSK2lzIhMQGXVScFlyF/CrvhLxJL44m1q60LUrax0/T5zawA2BlFxuGVlkZmBHTOxcY75rSk8F6NeTNca7aWmsXbEu01xAc7zwQvzfLEBhVj5wB1J5qYJU24VNu2uj/BdStIppsueHvEWkeIYi2kX8E7q7RGEuFkBBxkLnkHsRWlKrhv4gfcVUu9I0m7ZDc6bYOyLsQvAD5YxgYAx046Vk+E7uaOafRNWubm61uAkC4nt2jN3CnCuGxtY/NjgknHNDUXdw6dP+D/wxm0mro22HJ/OsfWNettMv7HTza3l7qV8jPa21rEWDheCWfoijuT0GTWy5O7DADPPNcHqV7rmn/EXVLrSPC1xqDyadDbW1y0wijbawY4kJwg5OVHJKg0U4qT17egoK71OhFlrU+pW9xqN9YWtvETIlrpqMzBuMZmfBOOegwc1mJ4f1LT0uodC1Gwt7UyPNaCSErLAzgGTewBDhjjsMYFZ1p/wkfhLT4oo9LXVbF3EtzdXNwltHal8s/wA7NlzuyNz4zx2Iq94X8daR4lilNhDfGVOEiSBpN785Xco2rjj5mIXnrWvLLVws4rtb8Vv/AFvYq8o6lW3XxEmtWukat4msP39s84exs1ErOuNy/N90YOQcZPcCteW1aZpo7DWbqC4RtzMUWYZK4GQwx74Hce9Z+n6Pq8ut6vrrxaPbajM6R6fFfB5Ps8IXa7OYyRvcAcDPviuhVZUjC3EsMs//AC0eFCiM3cqp5A+tNy16fJL/AC17evkTJrdGdbeHNPfE95YW+q36w+XPeXdusskqkYbdwQoOSMADjiq2kaDpXhwtHoVg1vHcDbK3mluhyBg9hnAxS+JNAbXzZMmtanpbWjmWP7G4VWfszDqSO38q0VjYv5k7Ey5Krlywx+Pc9TScnb4t+mv9f5E3BwG3A4INcdr2g6teeJrDVxqssiaa+baxViiSZGN+c4WQbmDEjkBcdTXYufmOBUM2TjDBORliM8dxilGXK7oIy5XoVVuc/u33NKp2nHOffNJNIqlB3J6D09ajijY3UuTIrHLheCGUd/wpl8+yNdqgszBAx/hzxn3oa1SIZl65banLdaZqHh42LSwM4njuiVFwrbQBntj5uetXWn1dkbfpmjI4bAZbyYqB6425/CrvA4TGBUcjfe6nBwazcrpJopS02Odv7TXbhSh1awsoWTbutLYvICT/AAs5wOKK0ZSm75cs2euODRWqlb/hl/kPnaNXXdfttGws1vf3UxAfyLGAyylc4JA4H5kVMmqaVeSRi21KBhNGHj3ExttJx0bGDnsefauaOkeKJPEXh24dXig0sukl49yN0sOeFXactuHLZHXpXY3dvaXqul3awXKMeRJGGJ5yOeuQeetcbUYpfozrlGMSs19aRGVZp1gWGYWzNOfLBkI+UKWxnODgjgkHB4q2pJ2MqsyMoZXGNpB5H1znjtXNzeGrKx8UQa5ZaVvg+zPbXVtAgl81iylH2OeoweRznGBVzwz4h0PVlt49Lmmt45lYwC+i8hXRDtbYSSPlxyM5ArZRTXNG7/r+vkYyXY3jFM1vKIJRCyoW85lDeWO7HJA4Hc8euelcvYfbNQhj0rSbq91HRLiZm1DxBdSoxmGf3luikfOCNq71wByB0NalhFHrcH27Uonks5JPMsrGXiIxrkLLKvVmY7jtPAGODW2pwsYO0BQAFUYVR6AdAPYU78mm7/r7/wAvUnYflQEWNEjjRQiRoMBFAwqgdgBgfhSEYfqQBxRkgH0Pr1pV4QAAbQPX0rMncpeJFabw5qSpaW95mAlre5crHKoILAkEEfKCRyOR1rn5dZ0qO2uLePVptahe3E6QpbiOOxh2AoquBjeB82SSePxJ4r8VWMcs+gxWI1G6uGgtZorhGFsn2jOwyMPmI4HAweeoxTPBHhtfCXh69ufEEW6e2aaR4kfMAiCYPlqR0Kjb83pXTCChC9S990u9/wCuljaKtG5j6jf3dnpU4jYW+t3AitxLdo29VJyZlY8OABkEZ564rh7rWZbC4u7JL23jRMIr7WwshzkO55LdSTggepNXvF/iO41yc3twV2WpS1WCCXciOT/CDwGxtB5xxUXhzT5PFPie1srWbT7i8iw8FtNZPcW0qDOTM6su0KeQDnJAz7+jpQpOpUXr1OyELLzNPwV4F0vxDov9oPd6nZm2druaWKRPs52kYdZF3cgZOGwevFdH410bwx4SaLX5/t1w95O86bY/ORg6knduG3ac7ySc4GAKveC7rS10lGtJrG40nQ7+e61J2Xy5JG2utu6qMKcgnAzgYAPIrkfhL47u9e8Q6lpetW1le6fqyyX1pZlY8LiQqykHowUFhnnCZHWvKqe0xKdWT2/r/g69GVOq6FXljt16GZ4djgszd6TLqNpcpd2+C1sD5bo/KMpwNoBGMY42kGvbfA2rzaloMFtqU4fW7CNYrxNx3YyQkhJAyGUZyPevK/HPg+Hwdb2t7odtJeRQbklngbc4jbGFkjC/IPl++D65AzzmL4p1PSZ7fXbG68qcbY3gHzQ30QywU9wR8446jbjHOe6C+u07J+8vz/4K/ToicVTUlzw2PZtf0X7RDK8EIWVwEd4RmZ0OQyITwpwTz0rxj4i+HL/wZ4PEMMVpMhungS8ZAft1oo8xRIvIBQ/J0HU8969z1fVPI0iw1KBBLYXnlOJo24RJFBDjI5AyD/hXmHxTunm8K6vYSr5/+hG+89oSUIVwnyZPysC4JPP0NZYSc00ntf8Ar7v67rlg5NWOu+AlzdXHw3tlvoZBFHKUhd4wnmKw3MQMnjcxAzjPWrl5DHblPEdi2ZdOQRXNvCgBmUEhlV2O0kLgbeASOtcr+zX9tPw7v7O5CTxC4Y2p80sNuNrKccjkAgY6ZNeixaAscIt5NQu0mO4r+8WNMk5wFx2PQnmssRJU6879/wAOv9dzFq5j6RqUurXt5NeyRfZHH/EvkijPzxfeyV6g9c5wajNxo3/CXxeR5jXbQCS41EthmgPLYc/eQFRk47gCr/iOfRfDKqNYv7a1kJEqLcfNM3J9OSpwcmuQ8QfEfQLz+0dJ8PF7q6htbhTJaRKsaqi8qgPVevIwMjgGnTg6mtOLs18vX+uoON2eZ6Xq8Fz4z1zxBptvK32O7kSRDECmJGIh8s5yHdvlII4ABznp654Pxp2lQ6FPd/ZfEdlbtdywTRHYJZV+VCBjftwMnJxn3rz3w3Dpmk+F0t9XiFnrlzq1jdG3hhYRpEQGiIPPJLZJOeh6V6OYNO8V6vIllqN1bmxuzqmotDIAkkYJRY3c/dUNHJleR94967MXJWs72XX8vlq/XQ2k3axZ1HwtfeIVjutZ1iO0LeRP9is7YPHFPGciRZMqzcZGGBAz3wK6LXdRh0/SdT1C4jD28MLu0XlmQP6IVHUEkD+orAl8eaZLNpsv2LVDpmoMfL1MWxS2UbsBjnkIT0JA456Vb8Y3Ev2nSvDcMSmbXTLFNK3KwWyAGYjplyDhRnvnnofLmpvlU1Zf5b/dbrqZxTclcqfC828vguGO0/s9Z1mllurawKslrI7lhGSCdxUHGST0xniumYbc9evPNYd94S0NtKuLPT7CDT3eMJDcwptkgZU2pIMEZI6+5zUAlvfDkGk291fvq8V3drbPNdfLMhZM5TaDvGVOFPI9TVStUk5Re/f7/wCr/iKSUndG8QCTjgfnXO+KtP02/vdLuNU1CS3ntgy2sTSlYXbOcun8QGDxkdTXSXTRwJJNczRQW8QzJJMwREX1YngVy8Pi+z1Ce8g0bRda1K5t1DIRZCOOVc4JWSQgBQT35PYYyaVPmvzR/r5kxTTuiOOTxbd+I40lbSbPRDbea1zFaicSyZOFTMit8wIbkADGMmptX07xENPuzpviOSe8PzxQ/ZYoY2ORuRPvFCRkKSTgnJ9r8N/crfxWN9pV1ZSzpI0Em9JoX2dVLr91sYIXHIzzxVp3WGMyyukUaY3SO2FUkgDJ7ckD8abk01ovuTv+f4MTlYxobHSPEFtItxG2rpCf3qXlw1ysTn7yEZAO0jHIwDV6NbexhS3s4I7W3kY/JbxBELH1Cjv6niuP1CDQF+JlzPMjWK6bHG81zp58mCa8ZjujuH+6cAIcZ6k9zXRR63pcMd2Dq1pNHZ/NNIJd2wHnLY7dcEcHFW4Oytdrf7xyT6F9vvMF/I9qilVpV8pGdWbo8Zww+hqnoeuaZrpm/se9ivWj2F0jzu+YAjg47H8O9VfE11dJbrpmmtAdcvMxrFxItuuCC8uGBUeh9ccU1B35Ho/MzSbZoxypMhaJlba5jOGzhgcEHFNl3hhsw3ODk9B7VW0jTn03Tba1MqSmGNUDIu0E4+YnPUlsnNWnzxu4Hr3pu19BMhWVZN5ikSTa2w7WDYPcHHQ+1NcnBHY/pUkVsA5FrDCjSMWYRqqeY56k46seOetYN14r0GLUbiy/tFLi6g4ljtUMu3kDluF4JA60oxc3aKuO3Y0biBJjH5y7/LO5BnAU+vH/AOqquqxSTabeJFn7QIWeFtoYiRRlTg9eRirw34PmReU2eULAkfiKZgk4HeltqTc4zwdqGvtezL4rkt447iCOWyIiEQZs/MgIOC3PKnngYrrZF4HGDXFaro9t461G5cD7A2lyLDFejMrTuMsCmGACr6453Y7V0TTeJnWR7jSdMlkbBAttQIM3qBuUbG7806qTldWT7ben4G84p7bj5so+QOCeBjv64orGl8Y6EryW1/dtYahEwSW0njbzI39OAc57EZ6iiqjSqPaL+4xafVHQ61N4svNMaLw5pdvpM0qFWutWnUPDnjKRpuyfc5x6VkW/gq6UyRN4w8TEtAI5LgXjBjNnLMFPGzoAM59+1dwp4B7N1oIz2yOoz2rkhUlH4dPT/g3Oly6HN6f4QsbZUGoX+sa0QDuXULxnjZj/ABeWOARzjB4ya2NT0a11fR5tKa2WK1eExxm3hUfZf9qPj5T7jrz61Y6kgH8KxvFmixeI7KLTZ7i6t18wPJJbylGVR94N2IYcY9TntWinLmUnLbr2ITvoWdL1e7l1t9I1FtImmjj3CXTp2LIFUf62JhlPTIJGcDvW+ATxjFcd4ZWPRPE9x4X0e3SWxtoVvLq8kUCUBgAkTMoAZ/unn+EE9as+M77XdP1HwxFol5ZwRXl0yXFvKgea5jG3IQEHgDOSMYyOaco3kox0uv0/AbV3odQ5EaSSyMFjjBkcnsAMn9KkjxJbRXKgtBIodJB0YEZByPY1l/Zb++N2Nelgt7CQNGLDTndi6nj95OQCQQeVUAe5rh5NF1jwTcXmt2GrwT+H7W1xi+ld3jhUZCIgGwHI2L/vetEKalpza/1pfuCin1PQLy4tI9UsrCW2hlbUYJ5GlRFL/uQpCvgbujHGemOOtc34q1S0TQtdthfzNb3Vl/oxfkJIDyik8kcdD34q5pHie0vvCR8WyaVPpXm2plMshV0aJZNowyktnOOqg49RXJ+PoimhWsrfuwvmyyxyNtJleTIeMDIZTg5HGMZrXD07zSl3t81r6dkbU4XkkzzaO8tEm+0kyx2USllBwELg/NIQB64x611nhfVLaw8Dz6jYy3q2d1qccd26WyqkbFSV+RW3MGGeRtBIAPHB5R7wmxcWiSyW8sypNB5zQg7G+8SDjI7ZyATnFeqjw5HrejwLDNpkMkZiW5gtEJg+1YfH+rK7QUHzHOcqM1rm9VpKm1o/0PWoqMXzS2Of8KRaVeaF4g07U7rWlt5v3jRaZGoMvmYCp0KhmIOAchcP0zTxb+FPDVhpF3qdhJpOvaI8qWg09F3ai8YCt5z7B8pOUJPXDkHBqHw9bG98Waho17pz6haQl2RYm+ytZyDbudfLIXZuI6k8YYclszXMcU/hy81p7Kd9Ou2ZrS5upC0lldgrmPeMlg2cBm468A9fJjXlBKF3b/M6K+Gp1qrlLrb+l/wxsfE+PUJb/Rtci1S30bS7yNJAdrkxz+SSwJAIyR8ucDOMYNcyiDW7L+0tM01f7HMZbUREpFvbzLne8atyAqhCcHALnb3qLTdYi1PwxJ4a1nUJY0u7gXlvOshligkU7QJNxz5ZIO4AnhgfWur8O6BHp51Gz8b3EXnTm3gtYI7wWbsFLf6QBwCoBAUkZOGB4rTD4h0JXW/6f156W8yatDkp8kum3mv63D4bX8b6wLGa5uIbe+jAjs5Jy8CshLfIv3fnz1GAfxrQ8QWduddSGJrq6028u5Ir37UC8f8ApMRjCI3Gxc/NgfxAHOcV5xf6b9g1Py9ZE0On20s9uZRHthMYfZui77lYc9R0I45r0zTr3ZYLptjvuJ7SUpqc07Eq435j+QZB3rgADBHPpXt1Um1Wp6pr+nf7vO9jyKkFGRw7/DzX/Dd2sXhLXbldL3RvKqyiKdnJxsVOjPjO35lBHFMTwnrniHSwms+PX+zR3TrGdjSqSzHcQwwSw24I6A8D1r0q70n+zdJ1Kee9uhYriaEwKGms1DZEZGGMpB+7uGcHB6ZrJ1x9S0/RpdUawRLa3mWK5SKBQYYX/wBbIIhkFnIRdpBCNknjNTHFTkt1fa9kn/w/9djFJPY8s17wjp+m3lvZ+KfFTta2ySnT4Q6LNKrdnc5ER3kZVs4UHr0qj4d13QPDenzyaJb3l7rkO1P7T8j9wkZkAfbwW3FTt3EY9B3rsNV8d6TbWzWegR6XmRJDcRXOmxzyCViFMmcYOEU7jjrj73OPTPh1calqOi+YrJatHIIpRZW8YS0g2qVhTcMeYMq2CDgMec1EsROzk9vPT9P+HN503ShzOxwUes6ffXuowXWumxlW4S8ieyhYrJM9s2yMSP8AcjULyCpGSenStT4O+GLO+8IIpnu7uwublL6+v3Dx/bXT7lrh+WjU7ixIwcgc547238EeG7RLSGHSbSa2gMjgXa+ezu5yXJbqSfX0GMYrornzXtZltpRDOIXELhRiJsHaduMYB7Yrnq4qPLaF1tv5f1fyOaVS+h55428URyeNB4b1I3FnplrHBfXUotnl+3R53GMbSAsQ4yTnJBGK3DKfGOsaHfpbXFpaaNdy3TSzgBp5ChQLGRwUwQxP0GK81+Ger23iLxYYfEAbXdRvgJTeWcp2SNG23DIwQCNcBsDHB6HNe5NdQyy3KJcwSvaEiaOOQMYyBnbgd8c4FZ14xpNQtqlv+Dfz8/L0KneKSW4yRvMyQv4DvWLqer2i6i2jx2VzquqxxrdLbRRYiVuqB5j8sXY56gcj0qXVfE+k6Jb6dc6hJM51GXyrKCNP3lw/cANgKBxktgCqfhTUdUtvAdlqx06TULwzTPNEhWPzP3jBWLchhgAbz2GemKzUWo8zXkumuv5W8vUyjB7lXRfCN5ZW1lD4h8R6nrAgcXE1nchWgklweuRuZFJyAeMqDgV1E0srj53Y+26uH+HEfiHTtHWLX7gSQwK6eXKxklExbcSsuTujA4GSfauvFzFKcRvlumDxVVdJu7T9CanNexQ8Q20t3ozm0uDbXNk32+CTzDGgdATiQgf6sjIYelc94durzxXfXc2uw2cNrbJA40mIs6v5sOVkkJGGRgxIHZlHpWX8X31GFbQ399JZeCZAsd9LbxeY/mlzlX2/OEK4wRkZ6g1hXXiS90bxTbXk+q2Igi00W8jSwNGtyRKNqMqjduWNsKR1YehNawpNwutW9t9P6/C6fU1pwbjoesR29vDZC0jtoFswNv2fy1MRHuhGD7kjmmlI1VgsMKrt27VjCjaOg4HQenSi1vrXUYWmsfPeAHaGmhaNumeQwB//AF0S48vGSKys76o5ndHNeOrfU5tIsbfRo42u5bgy+VHP5NxKqJkrEffOGzj5emSa0LS20vSIbULa2Gn3FyEgL7FE0shGfLL9W5B4zjiuM8bXlh/wkWraaJruzuksluo5rF9kk90FOEZjkqu3aPk2+/rVv4Wa9qGtaVLbayPPvdPEQkZ4irxqwbbuY8s3y/ewPxrb7Fl01+/+v6vY6ZUZqmpvY7Vs4JIPGc1BLy3/ANerDY27lO7I4I70xvlqEchSvbW1voTDe2sVzDuDhZBnaR3B6g1zniu803w1Lo2rxwwQpDMbeawsrYBp4pARuEaYBZWGQW46962NZ1uw0aIQySLeX5JiisY5186STHAb06qSfTNGjadLp/2i6vpln1m9KvezxcICPuxxjsi9Aep5Jq43VpPb8+//AA/9LRe6irZ69pd/I6QXJRlUswnQpt/2Wz0Yd161U1m+K67aeHYGlhvb9Gd55AUVIgvzeU3eX0HbrWnrhskspJ9SsTeptMe2ONWk+bqdzEBRxy2eOtcI2pf8I/fokNnrct4vlR2kV5cxyiC1kIPDYOC7sRkEsVUdBxVRipPRfl+f3FRhzXaO6s7O1sbZILG1htbeMcJEuPxPck+pqV8AnJPvUyBH3PbSpNCGZN8bZGQcEfUelRyZXjnGe1c71dzJ36lGdUMiy+XGZV6SmNTIo9A2MgewoqQQSSI3Ru2SQM/nRReOzFZs3YxweSQagnnjtgXcOVJ+bYpY03TtRsNQi8yyvYJkwrllPQP93dn7ue2etc7rPiGK5aLTtHuoPMl8xbt2VjJaIuB5hTg4yeD+PTNZU6cpStY6bXdi5BrslxdSmHQtVjtYm2rPIgD3S9/KjOCevBPHOaxdCtvHtjujZNHaxiika1tbmcvKWZ8qsrqMkgEjIOOma7SRMEFWLsoG0k43EDue2aSSaK0hhmu5oYFdxErO2A0h6ID3NaxqJaRitfVk3MCDS/EVz4gXVnuLXRkaxFvLZozTF5c8O+DtOBkAjnHGea2tA0ZdHku7x7qfUNTuhtkuZT85QdEUdFHXOMZ71fIeJmyh+VdxVeWxnrjr1qVmWJDJLIscS4LNIdqr7k9qUqkpKy2/r5i5mUtS1vTLPSLi+u763hhjjdgplAd2XIKKOpbIxgd6zb6KbxD4LgU6LLFZ6lAI7nTZ5tk8UZP3wcfeBAYDHTtUFjpOga54gn1pvJvLzS9QKQrFKTDFIET5mTAy2eeeM+tdbklyz8kncSTkk0StBqy18/y/4I7pbHGXfhm20TwKdI0z7YbSzha4jdnPmTbG8zZIBwST8oXGDmsfUtNU6EjSrdRmWaO5uIX25gS5i3NEoOPmD5wo6d66zUrDU2urz7JexQWUrwSsVTdMWVuVOeFU44I/Hiq+vomoaXqGuhLk3VsogKzfKGRGO6SJBwSckAnqBxXRSqONtb3f4u3/AATanPW54PPG32DUA00sU0IW4U42LhmyDxyT7DrXrvws0SI+G98Hihbe9up2nihsXVhv2FGEkUgyWAYcEEA4NedXsdwlwm+F47tvMCWkjbHnh39weM9TjtWj8OPEn/CPa1M8FoLm2l3faJopFF0jZ+VV8zhVxnKqMmu3H4Z14c0Fqj0HVlyOMXueseItKht9C/s69kkigleK0t9Sto3a5K7SW84oOCSo5xtIOD0zXO+KrvXLnS7TR92kWT3du1xNBbPEEYbuAAwLFiqAkjByT0HFbmm/EnQxbWss0N6sBd/MnnlQvBjcysUbDMCOmBx068V5z4/0nwnq90fE2malp0ejyqsjxxTvHcS3ZLHKx9QTnJJwAd3NeFPDSTs4v7rjwk5Ka9pp1V+50fw++H+ljUY4PE+nCTUjG8sUK3CNbjYw3B1Rixba4yD8pUDIzXTfEjS9O1LRzfXXh+yGqRt9i04zx75HjAJASOM9+QqnO0cnGa8qstZTRh9o8CWDx3Zm81by5mJfy9oAjfpvRirZyARx1xV3xZ4mn8XzR21wsdkn2WPz5ftUkab97ZSMZ2nPy8gZ9T0rqoYCvUSb0/rsViKj9upyldf15mXqV9Z6zBcNa3sq6lJBBBBp0p+2W20bdwjbbmLAAHzMScEE9q7jwlY3C6XrcNpp91bxrcKsV2ZBHDcbE2Oj7hxsAPzdOO1M8H+HNX+1Q6pa2thHpFuZEaSXIkG3KsscQ+6cjljzk1sWjxx6jNo1nHaXL3llgQTS4aU5+b5ycEBSRtHOea9KUowp+xhrb/gX7duvf0tw1Z80nY0NQv7WW4mh07MUVq8Iu71G2xQyPF8ux85ZQnJPTnrk1wOv6ha2Whz3V1r0EOoi1MFte2JfMjAjdHFuz8mDkEZ5NdX4mbS/CmlGPxI4v7fU43dtPluMyT3TFcqrD7qKqr14GAB6Vx00eoeG9Dsta1LwxPcw/wBoLeaRLdXAkEIKkRJKS3yxgHgcA4B61nQirXXy21+/+reYoNJXMz4ReCLrxTqNnd65pbah4bjlng/tIXTRS5C71BCsDsyNp46t7V7/AKR4e0rRLiR9G0qGymljEbmFWzIAc/Nz8xz/ABHk+tc/4SuvDfiySPUNBW8tTZSbpY7FzFBLLIuX3j/loeTljyCBzW1b6KyaWdPn17XpkErOkq3QSUIT8qGULvIH1/SubEVZSk020u2v9fkYVJ8z1LNtq2m3l01vY6lYXFyhZWgjnVpBtOG+Uc8HrWf4u1uPR9PMapNLf3qvDbJBH5jbwM/dyCeo6Vy3xA8S6V4a1fQbewt5RqujxO8cFvGEgihmATMhIwF6ksDkdP4jTPCUOv3vxHOp6vY2DLCkkpulLAIjKqKI488SnZ8znORgCoVDTneis3r18vnp94Qgl7z2NXwdoEN74L0WHxPpEP2yyma5hjaLyPJdzuOAuOm7GDxx04rnPE19pi+ObbS7bw8fKs4ZIVhggMc0kxAZblSGB2L0D5yST2r1ORwskEe4ZmYog7sQM8DvXjvxnsZZtf8APiit44JreNGcxfvZLhCwVWI+by+VzjFaYd+0qtN73t6v+mOnLmlqb3gL4cWmmQyT6vL9uWXLxxTSCViSQxLuCeM/wqcE9cmun8TeGdN8SXGnT6hLeR/2cXEUNrMYomDAcMB6AcYx+VP8KX9xqfhWxmZIrbUlhSGZWT90koUAlQDyvcDNZOnTeLdP1H/io006+02a4cTXsDeU0I5ERVBwVxtByMgnkms5upOblKXvL+tCeaTZu2tvp+iaHBZWoistLsk2qJHOyJc8lmYk9T1Nc22salq+6Twboqvbx9dQ1hzb20xyQPJC5d14zuGBzV/xTf3F3p0ml+HrSbULm9/dzXMOPs9vCfvlpD8pZhlQBnr7VsQvK8cUVxbyRMkCoQW3AY4ADA81ly2XNJXb7/m1uK9lcxZdEvtUs5LTxLqaz25bcIrBTCjkEkB853KAQAD1xk1grog0fxzcX+o4k0ExC5slW1Mm26QDLOEB2lVBCrghiQeoFd43JPApod0fchKsMcg4q1Vkr9n8iI1GtCtZ30Wp2MN9Zz/aLaZcpKuefUYPII7ggEUHcGbcRt4wB1965Txbo9/YiLV/Ct4umSxTSTag0rK0McMgHnTqjgjzMKP5AcmtybVZLbQY9TvbURyzj/RIE+Y3ZOTEFC55dQCQPu55xS5VvH7uoOF9V1MPxbpum+JruLTGtme8gkC3E5gKoICAXjaQYO4gDaP6VA/he/028huNEvra5jjnknaHUFdWbeoBG9Dg424G4HA4rodCt7uLSYRqhzfys9zcYOdruc7c99oIX8OKuOoycYx9Oa1jUlH3Vsgc2vdTMO91PUtIs7rUNZtbKXTLbDyLp29po4+7bXIDEHsMcc1R8VeJ57DS0TRNH1uTV70qlo81p5cVuSQC8rZIGAc/r0rqXjSRWSSOORGBQo65V1IwQfbFcb4Nmkg8UeINO06e8udJskRDNdXMkkkJH3Yxu/hHOMDHuaFaWttvu/r8xwSab7GxYromgWQWK70qDaFSa+Z40kuX/vO/VmPPep7W9sb1S1hf2N0Op8m4R8frV5wrSCV4YJZVIId4lYg9iCRwfeqF/pem33mG60yweSVPLaUWyLIR0xuAzQnfV7mbsUPGMIfwtqqu8UaLDvJnbbGQGHDH0PT34rz3wlqNtrep6+L3URdPDYxNZ/bIljYSRbyGwv32G7CEckEAdBXU6vogn1nT9BvphN4Vmty1tYrcFZbWaL5gTghmjIB27iwB+lX5/C2gukQk0q28yN1kW4UMs+9TkMZFIYsDzkmtU4KDi3vtZbfj5ar8WawqKmrWMT4UmF9Mu/J852DL5kzyoQ78nJQHcrc8k9QB1Oa627D+ZCI2Ccl3yM7lBUbfbqefp71UsNIbTbUx6PqVzbZeWUieKO48ySTG52Zl3Z46A4qf7PebW+0azcvnBUxWsUew98HaSc+/SueTvJyv+f8AkKrOM5uS6mZrOhaXqkiyanYQ3TqAFaQsMAfQgUVHew64kgNrqltcxRKcQ3NttaY5yA8i8LxxkD65orppKo4+7Ut/29b8zN3WiZqaBbvdvqeszX0jx6rKyLBE4aNYo2KI27HLfLuDDjBxzWnp1pbabFMtlGIzMxeeVjuklYnOXY8n+lTp8kMalFXaAgWIfKox0A7AdKBkduCO1edzOTfb+rfcbSZC8fmJgTTRc/ejO0//AFxVO/0LTdTvrW8vYDJc2ausBLsFj3dSAOM+h7VoFtsgVmVC52ruIG4+g9TWVretm2mi0/Sof7Q1m5cLFbpnYgz8zu/3VAGeD7VrT5nL3N/6v8iNTF8SeFdN0ez1HxFpkSLq9rF9pL3rvNFMyggblz154xxnHFaWkya14rtkn1mybSNGkRHFu+PtE7cZDf3VP3hgdDjntcPiGGxkmfV7K80tTMkKyTYkjkJ4XYVz15z6V0EgkDNvGD3yc1pKrOyUlr0b1+7p8x/CULGzvYNRvZ7rU2u0upfN8h7dUWEABVEZByAFABz169c1prj8/WoSpzxkc9jUi98ZOP1rB6/1/kTe427jVreSQMykLztGd2O2K5a683S9M1XVJwkumzEPJFPhXQEchAmWYDHA4I6eprqL5bdtPuhfQyXFoYm86BSQZUx8yjHPIzXh+naFqmozNdxwjT9FRpJNC0bUCWEoDlsPj5gVzlc84wORXThoKSbbsv628/yNqeu51HifSNN15tOxqmm3Mt3ZxXUj3MyQ5ZfkGI2OU64wOtcvceAri61e2tdIurTUraSAxyzyu6RwyJyqhzj5+208j1rvW0PW9b8P6xY2ei6Pol/PGttdX08yzxXQGWKxhVyqk4LFugPHNXLPwJpWoaLotxA09nI1ojXMQH7q9LoCzSxk4zu5BHoK6qeLdJW5vyfTrb8LdtdDX2iXoecT+G9Rsba2l1SwkhYo2992UTacDcWAOSfrVbSfD2sRTiO4tYoXmLxobi3a3Kgg7iSQS64PReuR616jqvgcTbJ31jUpjasksS5G6TywNkZJ4C7uR6VzV23iHRvEOhaRNqGvXdvqUjXFzNZRFOXBR974IXH+z2wfStljVKOjV/RmirSloipb6XLEVjaZtSdogbm6gVLeKAdGBLMSx7bR161p2z6bot4/maReW115ZcXSFrR8g/cLuhJyCD8mRjFdtN4V0C+ljsbvSobmzsNoiimQmMYGFI7E9c+tS3HhDRZbhDHZyRRRR7Y4Y7h/KU7ichCSA3PB7VzvFxlpK9vu/X9DH2yejOKPj7XW/s+0tkuIPtO8xFnVVK9QA7AtKWJAyep6CtDwt4a1W6n07UJbe0NrbyC6+yXUg2iTOcCMAtHIuSQT3GDip57OztPFfh+2spEa3/tBrQWt6DKTuQedLb4GYyuxgW+7k9jXoR2LI2xAu45OB1+tZ1K0Yr93FK/+bFOoorlitzzv4vtLqX9gWkFnZiC4uRLqH2lD50MMUgbIYD5Y8g7mHJHQVU8UeNruxbSota8Lafe2rYazt7ZWuUuCCUxCzYXOz7oGSc9s16hHNImPJZl5z071gzaJO195+n67fWFqCJI7SKKN0ilG7LLuHfcSR9K5lNOKi9Lev6DpVoRSUo3OD0rU/wCx/GEcq6IumvqKyXMFjC4t5o5Dn9xLuGAzAls9DgDtV7UPjT4cstUl04WOq30sI2TXFkiNEJP4lUluRnvW7418F22u+FrhJ7u4Ot29uTBrMnM6becZGMKeRtHrxTPBPhrQdP0PTbzStL+ySSwoQ1xLuYkKAzqm4qNx5Pv6Guh1aM1zzTbWn9P+n3Jlyy1OSu9Y12a/vfGR0Ca0jt4xpcEM8bGcxZDsCVHKnOQxG3JOegrbtLaeHSH1C51j+wtQv449S1e8t4vLkniPypbQ5JKNhFGRyScgc12WoapolvaXK6trFmbaSNoZo1uhvwRgqNpyGOcDockVyHhLTL/Xfh841uK9ttXS+d7GbVIPMlUIT9naRG6qoYj65NP2qlC9rJWXy+e9rX9bMm6sblnpp13TtP1DVpb+DVFiCuLecxGAk5eP5RwW+USdCdoHGKfF4N8O29xb3EWkW/2mBXVZ3LM7b+GLEn5icdT0rj/hG/iW31/VNG8RG+ijtwbjZNbZiaQnLv8AaD97cx4AyD1r1AgAZ5rOs50puClp5bWZnO8Xa5GqgLGgAVUUKoHYVHcWsF9bTWl1Ck9tOpjkikXKyKf4SKkX77/OCMcL6H/CpoVLSBBIY2Ybd69UJH3h9OtcsnbUlbnnPiHxHB4Z1DRdH8NtBqlsN3m2UEoka12nOwPn5MjOAxPI+td0uXtIZZIjDLIiySQsQzRsR90kcEj2rzv4M6jpvh/w0mkTSx2Nw1zP5t3IBBFcOGIA8xyN77VyMZGD1r0hVMqK8BWWM8b4mDj/AL6GRWtZcknF9Hv3/r7zWr00/wCCQ4PUZ/KmOOB1pzsPNSIBtxPJxxjHXPb0qpFKkWpvZhmJdPOUbCQozz839KhK5jYnJxk8EEYYOMhgeoI9PauYi8CeGUkkaHTPJkcoySpM4a1ZSSrQ5OIyCc4HBxXUsTuOVI9iKaVyT6VcZyjfldgUmji9M8U3K6zZaVrbWhu7nzhJudYprXyjtDzKDtPm5DLjbwe+aueKJdRv3uNH8Kaktlr1oUmlmkj+SJD0BLAg5yPu8j8a17/SdMv7sXN5YWs115Rh85kHmGM/wlu44GM9O1OhMUaCG3iKRAH+Hvnpz1q1KKtKK2+7+vL+nTlF6pFQWmsCSJv7cSVvK2zJNZIsc0mPv/Lhl59O1YenaP4nk8Qanres3WlWU9zax2cEVrI9x5KLn5tnEZJOD82ee1dYWOM7ajYHA68n8BRGbT6fciebSwxuQB6dc9SajUec4jwRnuR6VI3AJ6+3em5KOpC5AIOD3o9CTmfD5vL67uNdK2tpY6jbosdqshmlcoSokZvupwMbVznv0FazqCeevsax9OvodI1A6Ffo9udzSWt+8YjtrgOSwj35wJRlht77c9TitiVSrKCpUn1FaT38unp0CV7ixLgdeajlc4wamXGOtRy7cH1rB7iKVwuUJJ+929KKJe6/lRVoXM0a8VzbyX01kkyfaoYlkdB1VW6fn1x6c1zlx/wkGoeJ7p9LuTpmnWkAgdLy2LCeVs5eMg4O0YIPTsauyWNjpErapHp73V1JNma7ZwZIlfAd8seg9B9BW3LuBAGSV4x2/wDrVzRahrHXTrb56anW3bYzJtE0+9s4otYgGpsoG57n+JsfewD8p+nTpWjbbLSBobdFhhY5ZIwFBPTJx1PSoLnzZbaaOCYwSshVJQoYxsRw2Dwceho06Ce20+GG8vJL6dR+8uZI1jMh/wB1eAPpVttx1fy/rQyuy4VWWNo5UV4mGGQjII6Vg6XHf2HiC9sy93qNksFsschmBe2UtJksh6gkcsDnCgY4roEBI68isnVoNRm1LTG0m9NnMjM1w5txKtxDx+7YHpzznqM8dacHa8X1Gmbe7HBwcnHXApZFZo2CHy5GGA+OnvVa3luTO0N5AGCqGWeJT5bHOCOeh6HFXUVmYYye3T8ql+6SOhiPyKh3EYAz6+tchJ8QdBn8YyaFOqC4snZXur9zDEsgOAiYBOSc/McfjWzp3iLTbvU7myi1GyS6t2b5DdRneq43PwflUHj5sHiuPg8E6Zr/AIti8YaLOWhnuvtEsV2HjjkZcpI0Tx5zkqeTwOSM1cYrX2mn9fr0NqaSfv7HW2ei67HHO0/iVUkkmDRW9tZqbaGDBBh2nBYkHO/IOR+FdGNoWNEBCRoEUegHAqnp+oG+Mqy2b2N5AT5tqzh/LGcIwYcFWAyO/tVskEEnt2Hepk23Z/p+hlJt7i8jkc+tZEejNaa8+sWJtDcSZFwblGMhi2AeVEwOEX5QcY659a1l+8CeOOnenF2Vd3fIxj1pJtbCUiDR9Ti1bSrPUbaOVbO7gS4iaTgkNnjHqMVbDgDKvg+xrk4Yf+EP1iFonuf+EavWeH7KgLxWMrfMJSScouQw44OQMDHPWqAVVhhgwyrAdR7VdSKT93Z7f13E11RyuraffaRqtzrcAjvrCOFlitYv3N3bmRv3nlygHepLFiGwAOecUWFt4lsJ9QlOsnVtEuVSayWcgT2kZ5bLbcucHj6DpWx4kubSy8OapdamJmsIbdjKsJxI46BEP94kgD3NefaTqnjePUFsYblTfuitb6I0DTvp0UrAI95cMMrsBzgZJ9MVpHmqRsrad/6/Hz1N4XauzvvDGsLqOiwy3U9sWad7aGXzADcAH5WI7MR2/HvU/wDbeltcXNvaXiX13aY863sVM8kZzgKQowD16kdKwvD3giPTvt/9v36axHdsZ5rRYBFbGcn5pMA5fACqobptz1rrrWKO0iMVnFFbRvyRCgTJ9Tjr1rOpyJvl1/Bfj/kiJNX0OXuLXWfEt9dWusxX2gaHbIo8q2nAk1Fyxy3mL92PaPudckGquu+HdN8P6ddajp2nae2lxtGzWN1KyJuLgFY5GJCZJB29CRXZKPmGDnPUdea4j4hajL4d12xu/Lg1O/a3K6foksUhlaUPzLGBlTlcg7hkYyD1FaUpSnJRjp5K+v8AXdvQcJO50ujagjtFbWWjx2dgxfDpE0aqy42jayKCTk9PSs2/8XtDr/2C20W+1G0VUa41OCZPKhUnBcjOSqnIJ45VuOOZ5P8AhLtcmguLme38MwKu8WkRF7cu/be7DYq+qrk+9cUPAHinw742OqeDdYtH0y8nMt5a3vybv4iGAGGBYuFAHy5rNckXd2b7Xf57foaQhCd1J2PVSCyBC5KZ3AEkj9ahuporW1luLuaOC2hUyySOcKiKMkk+mKlt5vtNulwYHtmYZaGRldoz/dJUkEj2NZutalo0CPY61cW4WdAr21xHvEiEgcjBG3JAyeKiKbdkv1Oe2pesmjv7WHUNPnjuLCeLdHLEQyPz94MPyxUm3BJ7+tYuleFNE0vUpbyw0p9PmGAkCTMsSHu6xZ2rnntzW4FOT64yKTSvoD8iK5iS5WOOeOKaOJt6LKiuqtzyAQcGsqHw9otuhS1smsVZi+NPuHtgGPVtqHbuOOuO1bRQnJAGfUCoXXt396abSsmLmdzFutDma1aOy8Sa9DdGRX8+5uFuVwOqNGQAQRn371m2F9r2sx6jZwQ2+nX9tcvA80rhmjhDYEqwgE7mXlcnaM55xXVMpHse9YnifRmvdPu59KhVPEBVfstykxt2DgjBLjrgZ4IPpWkZJ+7L+vy09fuKUr7l2ytUsYfsyXF3cLlnD3kpllIJ7seuOgqVgQMZBPqap6HrcOvae91HbS2U8U721xazgB4ZkxuU4JBHIOQf4hV11YE4GAKTTT97ch3T1IHAxwQOnX9ajZBkOQcjpk1PJhRyMfhTHUnAFBOpEfY89eKZJkthfxqXB4GfxNRsuScN8tMZAqOu4O4JySCBjHoP/r0sRRZFMn3R+n+TTpFO0gEAscDjNR9znnv04p9AONGg6zqug2+m+IdStlswzG4gis0LSEMSu0kkDsdwGTntV9ok0K709bC2vptKmVoLiDzGmW0bAKTIDkheoZRx0IrecEAYb61Dgqcg4weCK3dRvfZ9Nt/60Bzb0Zl3Wv6JZTW8F9q1razXH+qWbcm7HqSMDqOpFXTtkyYZEkx1Mbhh+lTTxx3MEttdQQz20gKvHKiurAjBHP8AOuMtvAkOmJKPD+o3WmSSMoUxRo5AHBBJ5ORjkYORnmsUoPd2f3/ktPxKSTWp0U2dmB9MkUVlTapJBqK2GqwS2lwJVhjl8siG5ZlJXDeuB931opP3bXIcGdBr2nS6xot3pscvkrcFEllDbSsO4GTaegbbkDPGansL1bvR4dQMDW1sUZgJCcpGvRjxnoKqeIdOi1HS5BdzGOzgDSTo4JhdCpB8wDBKrnd1HSvMpTq9hrS+F/tK3cWryymCeS9beU2LjaDgKmBlVyc1nSpqrBpS21+XX9H5HbCHNoepJq1hLBJcwxajLaJgC4is3cSHGW2KMsQOASQOTVma/wBMt9KOrT3cY0opuWcHHmdgoBGck8AY61yzeK9Q8OaBqlmvh5YtW0qWK1s7e3JaK43sArk4HfljnkkdK6LSfCVhpl/qdw8dtL9ukEksQhYIsgOSRuYkZYbsZ6jIpSgofHddtndafdo732IaW/QzfC+sa3rCSQy2uk6bqMTMZdOvVlW5SIEbZDg4CncOo5xx1wOntrKSK6e4uJvNnZfLXy12RxocZULk55Gckk0lzpsE+p2upZlhvoPkM8TYM0XP7qTj5kyc47Eda0ByBgj0yKidRP4VYl2I/J2sc5pktubmGe3inEErxMiyFd3lllIDEd8dcVZIIccZXHr1qQEMAAM8c+1Z8z6EpHF+CdG0648NyaJrGj2U9/pji0vibddkrH5gwfALgrhjn2rs4LSO1to7a0hiht4V2wxRKFRVH8IA4AqdFJUKO54461VutU02zuGt7zUbOC4ABMUkoDDnHIGTnPbrVTqSqNv5lN8zuYNqt1od7rVzfWWp3EVzcM8C6bH9oSVSMqzr95HHKnqvcVtXl9aWFq9zqC3ltAg3SObV3EY7l9gOAPXpTn1S0Nm91am6viFzHHa27s0pIyAoIHX1PFRS3GtXi3Frb6XJpizxBBdz3SB03KQxVQDhlzxnvVXc3eSt31t+f/BB66s0URXijljkV4pFDxuDkOpGQwPcEc5p6QZ6ZI9u1ctpd7rujTppV14bX+wrHZHHf2y7/MtwgGAgORIGyxzxgniujn1nT7eK5u7k3dvp9tEJZL24t2jgAJxjJ5JHGeO9DhJPTX01/Lr5EuNthuqRXLaRqkOmzImoS2rx24kGV8wg7c/X34z9K57StcuJdHt00nQdX1W8jkEF3L+6to0lX5ZAWdzllxztyD69cal7dw31zptvpWpbheymOWSylQsyhcgBiCAuGJyOfTvUOk+IfBOlQ22iaZrOlW0dvIbeO1SYnDljkZPVi27nuc81aTUb8rb36/jb00+Y0/d5TH13Q9b8d+HNY0vVbR/DcBuo2syJllluI0Of3u0kLk4PHTjrjJ5+HSvGHhC8GpXl9arocaxWmoTSOrlot3Excnf8nA5JPPAr0qHUb651C6ji8P3qW8Z2RXU8saJP1yQMkgAisnUrLxPqVtdm603SktrRvtFpZG4859QlQZjEjEAIgYAkYycAZHfSnUktJcvL2uuvbXf128jSM38Oxzlz43vxfrdf6Ha6QhWRIxbm6lu4mICszI37oMTwCAScDk8V6FFPCNGS/vkawiSH7RcC7IU2wxk+Yegx39K8XdLvw/8AEFb+48OPLqomEslwbKSKGYsMy3OASDtwSAWAXGRya3PAM/iHx741vtS1pluPCNm8iIJIwbW7+YeWI0z/AMCLNu7DArSeH5o8+iilf/JebfmVUjDSx3ttf2+t3b2+iXtvPYJEDc3ltIsmxyeIhjoxXn2Hoay7/wAO+G28YafENQntPEJsmjiTzHndoCT8x35weuCCCRnriu0hs4LSMx2dvBbRlywjgjWNcnqQFHX1NOaCKWVZWgieVQVWUqN4U9QG6jqeK5FVs/dbS/rcwUknoc14La/ufDvmXtzDeATyLZ3KKE+0WwICOyjO1vvDHsM4JIGnfStZWV7dNb3NwLaMyCOLDyS4GSEFasMMcESwW8UcUMa4jjjXaqD0GOlVNV0+PUtPntZTLGsylPMgfZJGD1KsPunipdROV3tcltNjbdTLbQSGGWHzEEhimTa65GcMOxFcJ4h8G61rUHi5TLbTR3t1EdNs7tiqpGiBXPmL8y7s5xyPl6c132mWv2DT7ayV5Jo7eJYxJPJvkYAdWbuferSg5Y9yOB6U4V5U3eH9a3/Qalyu6PKPA+valaXQ07VIr+3uYYvKj0O5ZJpXjjUfvbacAGRsA5RzzngjFeiaVfadq1vHPpV9BcxSZKAMAxx94FPvAg5yCMjvXmHiGxtV+Pds1zcxlL1rKVVjOHjlXgKT6Pszx1Ga9I8VeEdM120vNtnZWerShni1SKIR3EM38MgdcNkHHfnvW1dx92T05lfb+r+u/rc3nCGnmjRaDByABUTRHHPI+lVPC2pjVtOhtp/O/tuxhjj1GCVCsqSYwW6AMGIJ3LkGtWMN3BHzYxjP51zycou0tznlGzKbW5PBxnvRHCGlRQDyQOPrVwjIwQcdh1qvcw/aILi1V2iaaJ4944KFgRuBHOQTng5qeZiVrnJeB53vl8QvJZrC39rTkzom0XGMKCB2KhAp9SCeua6I2+4Agc9evYdTXn2n+II7LxlpukeH/CVrc30cJs9Xks7hlOnKshGdjDAU7i+7OWyecjnvb2xt7bWoteu70w29hZzQsJSPKRXKkyA9QTtwc5z8uMY53qXjK/R7f0n16G1SCctdBGhypIHIHUnGaqalJHY2L3M0kEQXBzPIET6bjgetSya/oiXcdpNqtvBdyP5ccM4eKRn/ALoDAc9KyL2HTfEmv28d1Z3d9pQs3EfnW0kdrJIxG7fuxlgv3fqelJcyack0vQiNO++yKcPi7w08jJc69pkUqjJjWXeffBXIbp0BzTY/F/hKeRI4PEmls8pAQGXbuz06gfrW/Z+HtDs7QW9jothb26j/AFcUZUEA555559c1Dq2haPqWly6de6XYvaSIV2CIKAPYrgg+lX7Sjf7X4f18r/MbUBtnNaX8ckmnXVtdIjbXNvKsgVvQ4PH40eRuzkcg88/p/KuKufBF/wCGYLb/AIV0kMU8t27Xkl3J+9MTrtVA3AManDYIzkA885v+BvFjanqup+HtUe3j1jT2IAQEPcbTh3PYsPlz6gg84omra03dfj9xfsbwc4vY6KSA8DbgGoGgKjNaDR7d3LMXfd8xzgkAYHt7Vzmqale3WtQ6PoBjSVNz6hfTws0dooxtRQcBpGPoTilFylojBRuVvFOq3ejw2JsdLn1GW7laNYogdyqBlnwBkgf1FU411/UbmRryK10rSg5RbbJa7lTszMDhD04GevtWvbaQLbV7zUmvLi4vbgkFpW+WJCMFI1H3VOASOeQKmlyM7RkY79atSSSste+v9ad7DbSVkYcmj2IuUuDHJJLAS0JmmaQQsRgsoJ4J9fyxRWhKcBjzx1zRTbct3czuz//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power photomicrograph of normal lung tissue shows open alveoli with thin, capillary- containing interstitial spaces. An artery (A) is identifiable by its thick, muscular wall; the accompanying bronchus (B) contains mucoid material and is lined by columnar respiratory epithelial cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven E Weinberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_45_23256=[""].join("\n");
var outline_f22_45_23256=null;
var title_f22_45_23257="Lumbosacral plexus syndromes";
var content_f22_45_23257=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Lumbosacral plexus syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/45/23257/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/45/23257/contributors\">",
"     Paul T Twydell, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/45/23257/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/45/23257/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/45/23257/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/45/23257/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/45/23257/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lumbosacral plexopathies (LSP) represent a distinct group of disorders of the peripheral nervous system due in part to their relative rarity in comparison to other peripheral nerve disorders and also due to their wide array of etiologies. A thorough understanding of the anatomy of the lumbosacral plexus, the most common causes of LSP, and the most currently accepted diagnostic approaches is needed to manage these conditions effectively.",
"   </p>",
"   <p>",
"    Other neuropathies affecting the lower limbs are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42233?source=see_link\">",
"     \"Overview of lower extremity peripheral nerve syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/20/20810?source=see_link\">",
"     \"Lumbosacral radiculopathy: Pathophysiology, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5655?source=see_link\">",
"     \"Acute lumbosacral radiculopathy: Prognosis and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lumbar and sacral plexuses make up the collective lumbosacral plexus which is formed from the anterior (ventral) rami of the L1 through S4 nerve roots (",
"    <a class=\"graphic graphic_figure graphicRef75983 \" href=\"UTD.htm?6/50/6952\">",
"     figure 1",
"    </a>",
"    ). The anterior rami divide within the plexus into anterior and posterior divisions that in turn yield individual peripheral nerves.",
"   </p>",
"   <p>",
"    The lumbar plexus is derived from the anterior rami of the L1 through L4 nerve roots. These rami pass downward and laterally along the psoas major muscle where they eventually form the plexus. While within the psoas, they divide into anterior and posterior branches. The posterior branches of anterior rami, L2-L4, become the femoral nerve, which exits from the lateral aspect of the psoas, traveling through the iliacus and under the inguinal ligament to the anterior thigh. The anterior branches become the obturator nerve, which exits from the medial aspect of the psoas, and courses over the sacral ala through the obturator foramen to the medial thigh. The lumbar plexus also gives off the lateral femoral cutaneous nerve of the thigh, iliohypogastric, ilioinguinal, and genitofemoral nerves [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lumbar plexus and sacral plexus are united via the lumbosacral trunk, which is comprised of a portion of L4 nerve root anterior rami, and all L5 anterior rami. The lumbosacral trunk passes over the sacral ala and joins the anterior rami of the S1-4 nerve roots to complete the sacral plexus [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sacral plexus drapes the posterolateral wall of the pelvis and converges upon the sciatic notch. These anterior rami also divide into anterior and posterior branches. The posterior branches of the lumbosacral trunk and S1 and S2 anterior rami form the lateral or peroneal division of the sciatic nerve. The anterior branches form the medial or tibial division of the sciatic nerve. The sacral plexus also gives off the inferior and superior gluteal nerves, posterior cutaneous nerve of the thigh, and pudendal nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lumbosacral plexus has a rich vascular supply. It is fed by the five lumbar arteries that originate from the abdominal aorta, the deep circumflex iliac artery that branches from the external iliac artery, and the iliolumbar and gluteal branches of the internal iliac artery [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lumbosacral plexopathies have a multitude of clinical features. They most often present with asymmetric, focal weakness, numbness, dysesthesia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    paresthesia in multiple contiguous lumbosacral nerve root distributions.",
"   </p>",
"   <p>",
"    Patterns of weakness usually help localize the \"lesion\" to a more specific area within the plexus.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lumbar plexus lesions tend to cause weakness of hip flexion and adduction",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      knee extension.",
"     </li>",
"     <li>",
"      Lumbosacral trunk and upper sacral plexus lesions result in foot drop or flail foot depending on the extent of involvement, and weakness of knee flexion or hip abduction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patterns of sensory disturbance are less reliable given the difficult clinical delineation between dermatomal and named nerve sensory loss. However, in general, sensory disturbance involving the anterior and medial thigh typically represents lumbar plexus involvement, while sensory disturbance involving the foreleg, dorsum of the foot, and posterior thigh suggests a lumbosacral trunk",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sacral plexus lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the wide array of etiologies for patients presenting with signs and symptoms suspicious for LSP (",
"    <a class=\"graphic graphic_table graphicRef52765 \" href=\"UTD.htm?25/61/26587\">",
"     table 1",
"    </a>",
"    ), an organized, thorough approach to diagnosis is a necessity. The diagnostic evaluation includes electrodiagnostic studies, laboratory investigations, and oftentimes neuroimaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough general and neurologic examination can aid in the localization of lumbosacral plexus lesion.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Detailed assessment of functional strength, sensation, and deep tendon reflexes of both lower limbs is compulsory.",
"     </li>",
"     <li>",
"      Palpation of the greater trochanters may reveal tenderness indicating focal bursitis. Palpation of the inguinal region should be undertaken to look for mass or hematoma formation. Rectal examination is important to assess tone and to look for rectal mass.",
"     </li>",
"     <li>",
"      Maneuvers such as the Patrick test and straight leg raising may provide clues to the presence of lumbosacral radiculopathy, which can sometimes mimic LSP, or a musculoskeletal lesion of the hip (eg, sacroiliitis).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Patrick test is a maneuver where the hip is externally rotated with the ipsilateral knee flexed at 90 degrees and placed on the opposite knee. The test is positive if it elicits hip or buttock pain. A positive test raises suspicion for hip or sacroiliac disease. However, it is nonspecific for a radiculopathy or plexopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22088?source=see_link&amp;anchor=H25#H25\">",
"     \"Evaluation of the adult with hip pain\", section on 'Patrick (Fabere) test'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The straight leg raise test is done with the patient supine. The examiner raises the patient's extended leg on the symptomatic side with the foot dorsiflexed, being careful that the patient is not actively \"helping\" in lifting the leg. The straight leg raise test is useful for the diagnosis of radiculopathy due to disc herniation, particularly for the L5 and S1 levels.",
"   </p>",
"   <p>",
"    The reverse straight leg raise (femoral stretch) test is accomplished by placing the patient prone on the table and passively extending the hip and leg straight up off the plane of the table. This maneuver is most useful for evaluating the L2, L3, and L4 roots. However, the value of this test is limited by inadequate information on its sensitivity and specificity. A positive reverse straight leg raise test may be difficult to interpret due to supposed stretch of the femoral nerve, lumbar plexus, and lumbar spinal nerve root fibers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the advent of MRI, computed tomography (CT) was the most effective radiological method to investigate the lumbosacral plexus. MRI has superseded CT as the imaging method of choice for plexus evaluation given its versatility and improved anatomical detail. The superior anatomic resolution offered by MRI techniques compared with CT may increase the diagnostic accuracy and assist interventionalists or surgeons in preoperative planning. However, CT may be more readily available than MRI and remains the optimal choice for those with contraindications to MRI.",
"   </p>",
"   <p>",
"    Gadolinium-enhancement can be helpful in certain instances, such as suspected neoplasm, abscess, inflammation, or postoperative changes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Electrodiagnostic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrodiagnostic studies can help differentiate LSP from lumbosacral radicular and individual nerve syndromes, and may also provide clues to the intraplexus location and possible etiology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1769?source=see_link\">",
"     \"Overview of electromyography\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/31/2554?source=see_link\">",
"     \"Overview of nerve conduction studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nerve conduction studies (NCS) are most useful for differentiating LSP from isolated mononeuropathy or polyneuropathy. The suggested evaluation for LSP includes the following studies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tibial motor studies while recording from abductor hallucis brevis",
"     </li>",
"     <li>",
"      Peroneal motor studies while recording from extensor digitorum brevis; recording from the tibialis anterior may also be useful if the extensor digitorum brevis response is absent or quite small",
"     </li>",
"     <li>",
"      Tibial and peroneal F waves",
"     </li>",
"     <li>",
"      H reflex",
"     </li>",
"     <li>",
"      Sural, superficial peroneal, medial plantar, and saphenous sensory potentials",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prolonged F waves and H responses, though nonspecific, can suggest more proximal lesions. Bilateral studies should be performed in nearly all cases. Upper limb NCS should be performed to exclude polyneuropathy if symptoms are bilateral or diffuse.",
"   </p>",
"   <p>",
"    Needle electromyography (EMG) should be done primarily to distinguish LSP from radiculopathy and characterize the severity of involvement. The electrodiagnostic approach will depend upon the clinical evaluation, but may include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Peroneal innervated muscles (at least two)",
"     </li>",
"     <li>",
"      Tibial innervated muscles (at least two)",
"     </li>",
"     <li>",
"      Sciatic innervated muscles in the thigh (at least one)",
"     </li>",
"     <li>",
"      Superior gluteal innervated muscles (at least one)",
"     </li>",
"     <li>",
"      Inferior gluteal innervated muscles (at least one)",
"     </li>",
"     <li>",
"      Femoral innervated muscles (at least two)",
"     </li>",
"     <li>",
"      Obturator innervated muscles innervated muscles (at least one)",
"     </li>",
"     <li>",
"      Lumbosacral paraspinal muscles innervated by L2, L3, L4, L5, and S1",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bilateral studies may be necessary if symptoms are bilateral or if abnormalities are modest in the limb of interest [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/5\">",
"     5",
"    </a>",
"    ]. Upper limb EMG should be performed to exclude polyneuropathy if symptoms are bilateral or diffuse.",
"   </p>",
"   <p>",
"    EMG of deep or paraspinal muscles is relatively contraindicated in certain patient populations, particularly those with thrombocytopenia or a bleeding disorder, and those on anticoagulation therapy. In these subgroups, magnetic stimulation of nerve roots may be helpful in the diagnosis of LSP [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nerve conduction studies with abnormal motor and intact sensory responses of lower limb, along with EMG findings in a myotomal distribution with paraspinal muscle involvement, typically indicate a radicular process rather than LSP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/20/20810?source=see_link\">",
"     \"Lumbosacral radiculopathy: Pathophysiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are limited options for performing NCS in the proximal lower limb. Femoral nerve conductions while recording from rectus femoris can be attempted. However, these are often painful and difficult because of body habitus. When responses are obtained, they are best utilized with side-to-side comparisons of amplitude and may help determine prognosis.",
"   </p>",
"   <p>",
"    However, EMG abnormalities favoring acute denervation and chronic reinnervation of L2-, L3-, and L4-innervated thigh muscles but sparing thigh adductors, tibialis anterior, and corresponding paraspinal muscles can differentiate an isolated femoral neuropathy from LSP or lumbar radiculopathy.",
"   </p>",
"   <p>",
"    Slowed peroneal motor nerve conduction velocities across the fibular head, with or without corresponding diminished motor responses",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    superficial peroneal sensory involvement, can distinguish peroneal neuropathy from LSP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Laboratory investigations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suggested blood tests for LSP of unknown cause include a complete blood count, coagulation profile, glycated hemoglobin, sedimentation rate, c-reactive protein, antinuclear antigen, antineutrophilic cytoplasmic antibodies, angiotensin converting enzyme, serum protein electrophoresis with immunofixation, anti-Ro and La antibodies, and serologies for EBV, VZV, HIV, Lyme disease, and syphilis.",
"   </p>",
"   <p>",
"    In the setting of a negative blood evaluation, a lumbar puncture to assess for leukocytes, protein, and cytology can be helpful to look for an occult infectious process or malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pathologic investigation into patients with LSP will depend on the suspected etiology. Image-guided needle biopsies of intra-abdominal and intrapelvic organs and tissues are the gold standard for suspected neoplasm or infiltrative processes. However, for those in which the diagnosis remains elusive, there may be a role for fascicular biopsy of proximal nerves",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nerve roots.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SPECIFIC DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of LSP are vast and diverse (",
"    <a class=\"graphic graphic_table graphicRef52765 \" href=\"UTD.htm?25/61/26587\">",
"     table 1",
"    </a>",
"    ). The most common presentations are idiopathic lumbosacral radiculoplexus neuropathy and diabetic amyotrophy. These are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20631?source=see_link\">",
"     \"Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following sections will discuss of some of the more common causes of LSP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Diabetic amyotrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic amyotrophy is reviewed briefly here and discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20631?source=see_link\">",
"     \"Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diabetic amyotrophy typically occurs in patients with type 2 diabetes mellitus. It is not a pure LSP because it also affects the lumbosacral nerve roots and peripheral nerves. The traditional features include the acute, asymmetric, focal onset of pain followed by weakness involving the proximal leg, with associated autonomic failure and weight loss. However, onset in the distal leg is not uncommon. The condition becomes more widespread and symmetric with time. Progression occurs over months and is followed by partial recovery in most patients.",
"   </p>",
"   <p>",
"    Thoracic and upper limb involvement has also been observed as part of the syndrome of diabetic amyotrophy in a minority of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Idiopathic lumbosacral radiculoplexus neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic lumbosacral radiculoplexus neuropathy is similar to diabetic amyotrophy with respect to its pathophysiology, clinical features, prognosis, and management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20631?source=see_link\">",
"     \"Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Neoplastic invasion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lumbosacral plexus lies in close proximity to bone, multiple soft tissues, and organs and is susceptible to neoplastic invasion from nearby malignancy. The most frequent mechanism of LSP from neoplasm is direct extension of tumor. Other common mechanisms include meningeal dissemination, secondary extension of tumor to the sacrum, iliac wings or lumbar vertebrae, hematogenous or lymphatic spread of cells from primary tumor sites, and paraneoplastic phenomenon.",
"   </p>",
"   <p>",
"    Neoplastic invasion of the lumbosacral plexus can occur in multiple forms of cancer, including the following [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Carcinoma (colorectal, breast, lung, gastric, thyroid, renal, ureteral, bladder, testicular, penile, prostate, cervical, ovarian, uterine, vaginal, melanoma)",
"     </li>",
"     <li>",
"      Lymphoma",
"     </li>",
"     <li>",
"      Sacral chordoma",
"     </li>",
"     <li>",
"      Sarcoma (retroperitoneal and pelvic), malignant schwannoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lumbosacral plexopathies may also arise from benign tumors, such as benign uterine leiomyoma, neurofibromas, and plexiform lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neoplastic invasion typically presents with severe, lancinating pain with or without radicular symptoms. Patients can have positional or mechanical exacerbation of pain, and symptoms may be aggravated by lying supine, weight-bearing, or straining to have a bowel movement. Within weeks to months, pain is usually followed by the development of progressive numbness, paresthesia, and weakness. Weakness can proceed to focal paralysis such as foot drop (weakness of dorsiflexion), flail foot (weakness of both dorsiflexion and plantar flexion), loss of hip flexion, or loss of knee",
"    <span class=\"nowrap\">",
"     flexion/extension.",
"    </span>",
"   </p>",
"   <p>",
"    One of the largest reports was published in the late 1980s and studied 85 patients with pelvic tumors and LSP, including 34 who were prospectively examined [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/9\">",
"     9",
"    </a>",
"    ]. The following observations were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pain at presentation was reported in 91 percent, and pain eventually developed in 98 percent. The pain was typically aching and pressure-like and could be local, radicular, or referred; a combination of local and radicular pain was common.",
"     </li>",
"     <li>",
"      Clinical signs (from most to least frequent) included leg weakness (86 percent), sensory loss (73 percent), reflex asymmetry (64 percent), focal tenderness involving the sciatic notch, lumbar, or sacral spine (55 percent), positive direct (53 percent) and reverse (45 percent) straight leg raising test, leg edema (47 percent), rectal mass (39 percent), dysesthesia (15 percent), decreased sphincter tone (12 percent), and fasciculations (12 percent). Autonomic involvement was rare. Urinary incontinence tended to be associated with epidural extension of tumor.",
"     </li>",
"     <li>",
"      Bilateral plexopathy occurred in 27 percent and epidural extension was detected in 35 percent.",
"     </li>",
"     <li>",
"      The most common primary tumors were colorectal, cervical, and breast cancers, sarcoma, and lymphoma. Direct invasion from intra-abdominopelvic neoplasm was reported in 73 percent; the remainder had metastasis of extra-abdominopelvic tumor.",
"     </li>",
"     <li>",
"      Metastatic lesions tended to affect the lower plexus while direct intra-abdominal or intrapelvic mass extension was more likely to affect the upper plexus. Approximately 20 percent of affected patients had a panplexopathy secondary to massive tumors.",
"     </li>",
"     <li>",
"      Plexopathy developed within one year of primary tumor diagnosis in one-third of patients, and within three years in two-thirds. The symptoms of LSP preceded discovery of primary tumor in 15 percent of patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There have been occasional reports of prostate cancer causing LSP with the suggestion of perineural spread of tumor cells [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/7\">",
"     7",
"    </a>",
"    ]. The authors postulated that the metastatic foci arose within the nerve or via perineural spread because there was evidence of tumor cells in the endoneurium, which is protected by the blood-nerve barrier, has no lymphatics, and is devoid of meninges, and not the epineurium where lymphatics and meninges exist. The authors also suggested that prostatic neoplastic cells may express nerve growth factor receptors, neural cell adhesion molecules, and anti-apoptotic factors, increasing the likelihood of cellular proliferation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general approach to the diagnosis of LSP is discussed above. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Diagnostic evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In addition to other disorders discussed in this topic, the differential diagnosis of LSP in a patient with cancer includes lumbosacral radiculopathy, meningeal carcinomatosis, cauda equina syndrome, retroperitoneal hemorrhage or iliopsoas hematoma, and radiation plexopathy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Since many patients may present radicular symptoms, lumbosacral radiculopathies are often the first diagnostic consideration. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/20/20810?source=see_link\">",
"       \"Lumbosacral radiculopathy: Pathophysiology, clinical features, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Meningeal carcinomatosis is frequently associated with other clinical signs such as nuchal rigidity, cranial nerve palsies, mental status changes, or headache. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24329?source=see_link\">",
"       \"Clinical features and diagnosis of leptomeningeal metastases from solid tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cauda equina syndrome is likely to be accompanied by urinary incontinence but usually not by leg edema or obvious rectal mass. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6585?source=see_link\">",
"       \"Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Retroperitoneal hemorrhage typically presents acutely instead of insidiously and may also be associated with ecchymoses. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Retroperitoneal hematoma'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When there is suspicion for neoplasm as the cause of LSP, it is reasonable to evaluate the pelvic anatomy with contrast enhanced imaging using either MRI or CT. Limited retrospective data suggest that MRI is more sensitive than CT for detecting cancer as the cause of LSP [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/12\">",
"     12",
"    </a>",
"    ]. MRI can often differentiate among direct compression, metastatic disease, and primary infiltration of plexus structures. However, different stages of inflammation, hemorrhage, or necrosis can still make diagnosis challenging.",
"   </p>",
"   <p>",
"    Lymphomas affecting the plexus have variable appearances on neuroimaging, ranging from asymmetric muscle enlargement and altered signal density on CT to focal or diffuse low T1-weighted or high T2-weighted signal on MRI. Contrast enhancement is also variable and may be absent, ring-shaped, or uniform. High-resolution MR neurography has demonstrated significant utility in diagnostic dilemmas involving lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with LSP secondary to primary tumors in the abdominopelvic region tend to have a relatively focal disease process with lumbar plexus involvement due to direct extension. Thus, nerve conduction studies will most likely be normal or minimally involved. Electromyography will demonstrate abnormalities in the hip flexors, hip adductors, and knee extensors with sparing of lumbar paraspinal muscles.",
"   </p>",
"   <p>",
"    Metastatic lesions are more likely to cause lumbosacral or sacral plexus involvement, with nerve conduction studies demonstrating diminished sensory and motor responses, and electromyography displaying abnormalities in hip abductors, knee flexors, ankle dorsiflexors, and plantar flexors, evertors, and invertors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Prognosis and management",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the prognosis for patients with LSP due to tumor appears to be poor, although data are limited. In a series from the late 1980s of patients with tumor-related LSP, there were 59 patients who had follow-up examinations, and neurologic deterioration was noted in approximately 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/9\">",
"     9",
"    </a>",
"    ]. Among 67 patients not lost to follow-up at the end of the study, 40 had died. The median survival from time of diagnosis was approximately six months (range 1 to 34 months). Response to therapy often differs according to the type of tumor, and lymphoma was the most responsive tumor in this series [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prospective trials are needed to determine whether radiotherapy, chemotherapy, surgery, or some combination of treatments is beneficial for tumor-related LSP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Radiation plexopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with radiation-induced LSP typically present with leg weakness, sometimes accompanied by sensory loss. Pain is usually absent or mild. Radiation plexopathy tends to occur months, years, or even decades after pelvic irradiation, has a predilection for the upper plexus, and is often bilateral [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiation-induced LSP is uncommon with standard external beam radiation doses and conventional fractionation schedules. However, certain specialized radiation therapy techniques provide an increased dose of radiation to the pelvis and may increase the risk of LSP. These techniques include intracavitary radiation therapy and intraoperative radiation therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38437?source=see_link&amp;anchor=H10#H10\">",
"     \"Complications of peripheral nerve irradiation\", section on 'Incidence and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiation plexopathy is thought to be caused by tissue fibrosis with retraction of nerve trunks, direct toxicity to axons, and microinfarction of nerve axons due to radiation effects on the vasa nervorum [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Differentiating radiation plexopathy from a recurrent tumor can be difficult, as both may have variable signal characteristics on imaging. Positron emission tomography may show increased uptake of 2-fluorodeoxyglucose in a recurrent tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately one-half of patients with radiation plexopathy have myokymia by electromyography. This finding can help distinguish radiation plexopathy from recurrent tumor invasion in diagnostically challenging patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1769?source=see_link&amp;anchor=H21#H21\">",
"     \"Overview of electromyography\", section on 'Myokymia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Prognosis and management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of radiation plexopathy typically progress slowly for years after radiation therapy. Rarely, spontaneous resolution or stabilization for several years can occur.",
"   </p>",
"   <p>",
"    There are no effective therapies for radiation plexopathy. A small randomized trial found no benefit for hyperbaric oxygen therapy in patients with radiation-induced brachial plexopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with neuropathic pain or dysesthesia, symptomatic therapies such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    may be helpful. Physical therapy is a useful adjunct to help patients cope with gait difficulties and to evaluate for equipment needs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic trauma occasionally causes LSP. Injuries from high velocity flexion-abduction of the hip, posterior hip dislocation, and hyperextension of the thigh with external rotation of the fractured or dislocated portion of the pelvis may also disrupt the plexus [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a retrospective review of 2054 patients treated for pelvic fractures at a single center, the estimated incidence of LSP, based upon patients who had electrodiagnostic studies, was 0.7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/21\">",
"     21",
"    </a>",
"    ]. The estimated incidence of LSP was significantly higher with sacral fractures 77 (2 percent) than with pelvic and acetabular fractures (0.7 percent). These findings probably underestimate the true incidence of LSP associated with pelvic fractures, since not all trauma patients were referred for electrodiagnostic studies. The close proximity of the plexus to the sacrum makes it more susceptible to injury from sacral fractures and dislocations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Trauma-induced LSP may go unnoticed due to either patient expiration from multiorgan involvement, or from inability to adequately assess neurologic function or incomplete work-up due to the severity of trauma and pain [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. A postmortem study of 42 victims of lethal trauma who sustained concomitant pelvic fracture found evidence of lumbosacral plexus damage in 20 (48 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Electrodiagnostic study findings in LSP related to trauma are likely to be compatible with lower lumbosacral or sacral involvement given that most are caused by sacral fractures and sacroiliac dislocation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment options are limited in traumatic LSP. Although data are sparse, surgical nerve repair and nerve grafting techniques may lead to partial recovery of proximal leg muscle function [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/20,23\">",
"     20,23",
"    </a>",
"    ]. One retrospective study reported 10 patients, most with pelvic fractures and severe injuries to the lumbosacral plexus, who were treated with nerve grafting and nerve transfer procedures at a mean of seven months after the injury (range 4 days to 36 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/20\">",
"     20",
"    </a>",
"    ]. Over a mean follow-up of 38 months, slow recovery was observed in nine patients, with return of unsupported standing and walking in those previously unable to do so without assistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Peripartum plexopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lumbosacral plexopathy related to pregnancy can present in the antepartum, intrapartum, and postpartum periods.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antepartum LSP is rare. It usually involves the upper lumbar plexus from direct compression by the gravid uterus with symptoms most often occurring around 32 to 34 weeks of gestation. Typical manifestations are those of low back or groin pain, development of weakness involving hip flexion and adduction, and numbness and paresthesia confined to the anteromedial thigh.",
"     </li>",
"     <li>",
"      Intrapartum and postpartum LSP result from direct compression of the lumbosacral trunk during fetal descent. The lumbosacral trunk is most susceptible to injury at its terminal portion near the pelvic brim, where it is no longer cushioned by the psoas muscle and instead lies in close contact with the bony pelvis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/24\">",
"       24",
"      </a>",
"      ].",
"      <span class=\"nowrap\">",
"       Intrapartum/postpartum",
"      </span>",
"      LSP is more common than antepartum but still infrequent, with an estimated incidence between 1:2000 and 1:6400 deliveries [",
"      <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. However, there are no prospective epidemiologic data.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most women with",
"    <span class=\"nowrap\">",
"     intrapartum/postpartum",
"    </span>",
"    LSP initially present with numbness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    paresthesia of the lateral foreleg and dorsum of foot. Foot drop typically develops due to involvement of the lumbosacral trunk. Less often, there is mild weakness of hip flexion, hip abduction, knee flexion, and knee extension. Autonomic involvement is rare.",
"   </p>",
"   <p>",
"    Symptoms of",
"    <span class=\"nowrap\">",
"     intrapartum/postpartum",
"    </span>",
"    LSP may not be apparent during the time of delivery due to epidural anesthesia. In addition, complaints of numbness or pain may be dismissed as typical labor pains until more prominent symptoms of weakness develop hours later.",
"   </p>",
"   <p>",
"    Possible risk factors for developing",
"    <span class=\"nowrap\">",
"     intrapartum/postpartum",
"    </span>",
"    LSP include short maternal stature, large infant size, and prolonged or arrested labor [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/24,25,27-31\">",
"     24,25,27-31",
"    </a>",
"    ]. Some [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/31,32\">",
"     31,32",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/30\">",
"     30",
"    </a>",
"    ] investigators have speculated that the use of forceps or other instrumentation is a possible risk factor. The number of previous pregnancies does not appear to be an independent risk factor for developing LSP [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vaginal deliveries are not contraindicated in women who develop antepartum or intrapartum LSP [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/33\">",
"     33",
"    </a>",
"    ]. However, midforceps delivery is relatively contraindicated in intrapartum LSP.",
"   </p>",
"   <p>",
"    Some women with",
"    <span class=\"nowrap\">",
"     intrapartum/postpartum",
"    </span>",
"    LSP will be mistakenly diagnosed with L5 radiculopathy or peroneal palsy at the fibular head. Thus, it is important to differentiate LSP from peroneal or femoral neuropathy due to prolonged positioning. Electrodiagnostic findings in antepartum and",
"    <span class=\"nowrap\">",
"     intrapartum/postpartum",
"    </span>",
"    LSP will likely reflect lumbar plexus and lumbosacral plexus involvement, respectively. Cases of LSP with severe traction injury may have nerve root involvement with findings of paraspinal muscle denervation on EMG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Prognosis and management",
"    </span>",
"    &nbsp;&mdash;&nbsp;In modern series, nearly all women with",
"    <span class=\"nowrap\">",
"     intrapartum/postpartum",
"    </span>",
"    LSP have complete or near complete resolution of their symptoms within two to six months [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/24,27-30\">",
"     24,27-30",
"    </a>",
"    ]. In reports published before 1960, some women were left with persistent deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/25,31\">",
"     25,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathophysiologic correlate of",
"    <span class=\"nowrap\">",
"     intrapartum/postpartum",
"    </span>",
"    LSP is probably a demyelinating lesion of the lumbosacral trunk as evidenced by electrodiagnostic findings of decreased motor unit action potential recruitment with relatively preserved compound muscle action potential amplitudes in the majority of patients, and by the complete resolution of clinical symptoms over several months. Rare patients with more sustained or permanent deficits likely experienced axonal disruption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Postoperative plexopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are case reports of LSP due to gynecologic surgery and total knee arthroplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Iatrogenic, intraoperative causes are probably the result of positioning, leading to stretching, compression, transaction, or ligation of plexus components. Postoperatively, scar or undetected hematoma formation may lead to LSP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Vascular causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular etiologies of LSP include ischemia, hemorrhage, and direct compression by vascular structures. Retroperitoneal hematoma is an important vascular cause of LSP, and is discussed in detail below. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Retroperitoneal hematoma'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Arterial pseudoaneurysms, a postoperative complication usually due to infection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    defective vascular anastomosis in abdominal vascular surgeries, may cause LSP by direct compression of the lumbosacral plexus [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/35\">",
"     35",
"    </a>",
"    ]. Aneurysm and pseudoaneurysm formation (with or without rupture) of the abdominal aorta, common, external, and internal iliac arteries, inferior and superior gluteal arteries, and hypogastric arteries have all been described as causes of LSP (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56082 \" href=\"UTD.htm?21/30/21988\">",
"     image 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/35-39\">",
"     35-39",
"    </a>",
"    ]. Retroperitoneal hematoma predominantly affects the lumbar plexus while iliac artery aneurysm or pseudoaneurysm is more likely to compress the lumbosacral or sacral plexus.",
"   </p>",
"   <p>",
"    The rich vascular supply to the lumbosacral plexus makes ischemia of the plexus rather unusual. However, ischemic LSP has been reported in kidney transplantation, especially in those who have pre-existing atherosclerotic disease, due transient hypoperfusion during arterial transposition or bypass [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Ischemic LSP also been observed following surgical treatment of mesenteric artery thrombosis, possibly due to pre-existing atherosclerosis and concomitant aortic cross-clamping during the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/2\">",
"     2",
"    </a>",
"    ]. Lastly, aortic dissection may be a cause of ischemia to the lumbosacral plexus [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Retroperitoneal hematoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retroperitoneal hematoma is an important vascular cause of LSP (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51078 \" href=\"UTD.htm?0/9/145\">",
"     image 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/10,43,44\">",
"     10,43,44",
"    </a>",
"    ]. Retroperitoneal hematoma typically occurs within the psoas muscle.",
"   </p>",
"   <p>",
"    Smaller retroperitoneal hematomas predominantly compress the femoral nerve, while larger ones can affect the entire lumbar or upper plexus, leading to anteromedial thigh numbness and paresthesia as well as weakness of hip flexion, thigh adduction, and knee extension. Less often, a retroperitoneal hemorrhage will affect the entire lumbosacral plexus, causing a more confluent weakness and numbness of the ipsilateral leg.",
"   </p>",
"   <p>",
"    Lumbosacral plexopathy due to retroperitoneal hematoma may occur spontaneously, but is best described as a sequelae of femoral artery or vein catheterizations and concomitant anticoagulation. It has also been reported after lumbar plexus block for postoperative analgesia in hip surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/45,46\">",
"     45,46",
"    </a>",
"    ] and following femoral vein dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/43\">",
"     43",
"    </a>",
"    ]. There is typically a delay of 2 to 10 days in presentation, likely due to postoperative institution of anticoagulant therapy. In addition, anticoagulant therapy alone has been associated with spontaneous retroperitoneal hematoma and LSP [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a retrospective review of over 9200 femoral artery catheterizations, there were 45 cases of retroperitoneal hematoma, for an incidence of 0.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/48\">",
"     48",
"    </a>",
"    ]. Clinical manifestations of retroperitoneal hematoma included suprainguinal tenderness and fullness, severe back and lower quadrant pain, and femoral neuropathy in 100, 64, and 36 percent, respectively.",
"   </p>",
"   <p>",
"    Among the 45 patients with retroperitoneal hematoma, 20 developed neuropathy, which was confined to the groin and involved cutaneous branches of the femoral nerve in four patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/49\">",
"     49",
"    </a>",
"    ]. The remaining 16 patients had large retroperitoneal hematomas and sensory neuropathy in the femoral nerve distribution, while nine had motor deficits involving only the femoral nerve, and four had motor weakness involving femoral plus obturator nerve. Thus, among 45 patients with a retroperitoneal hematoma, a lumbar plexopathy involving femoral and obturator nerves developed in four patients (9 percent) while an isolated femoral neuropathy developed in 12 (27 percent).",
"   </p>",
"   <p>",
"    Hematomas are visualized well by both CT and MRI, with CT more likely to demonstrate active bleeding sites and MRI allowing more characterization of the age of collected blood products [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lumbosacral plexopathy due to retroperitoneal hematoma must be differentiated from isolated femoral nerve compression due to hematoma formation at the inguinal ligament or mild retroperitoneal hematoma with fascial tracking of blood to the femoral nerve sheath. Under the inguinal ligament, the femoral nerve is more susceptible to injury due to limited extraneural space for blood products to expand and a relative paucity of microvasculature and lack of collateral blood flow. Concomitant involvement of the obturator nerve, manifested as weakness of adduction, points to a lumbar plexus lesion and excludes an isolated femoral neuropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Prognosis and management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retrospective data suggest that patients with LSP from a retroperitoneal hematoma generally have good neurologic recovery. As an example, in one study that reported 16 patients with large retroperitoneal hematomas and lumbar plexopathy, the only persistent sequelae at long-term follow-up were a mild sensory neuropathy in five patients and a mild motor deficit in one [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of retroperitoneal hematoma primarily consists of addressing the acute manifestations such as hypovolemia and shock [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/43\">",
"     43",
"    </a>",
"    ]. Rapid reversal of anticoagulation should be undertaken in patients with serious bleeding at any degree of anticoagulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=see_link&amp;anchor=H15#H15\">",
"     \"Correcting excess anticoagulation after warfarin\", section on 'Significant or life-threatening bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Otherwise, management is usually conservative, consisting of bed rest and blood transfusion. Rarely, surgical evacuation has been performed for severe acute cases or in chronic, unresolved LSP [",
"    <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/43\">",
"     43",
"    </a>",
"    ]. There is no consensus regarding the utility of aggressive surgical intervention in patients with neurological symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Infectious, inflammatory, and infiltrative causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other etiologies of LSP include Infectious, inflammatory, and infiltrative disorders.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infectious or parainfectious causes of LSP include direct infection or remote inflammatory effects of infection by such organisms as Borrelia burgdorferi, mycobacterium tuberculosis, Treponema pallidum, varicella zoster virus, human immunodeficiency virus (HIV), Epstein-Barr virus, or cytomegalovirus [",
"      <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/50,51\">",
"       50,51",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Cytomegalovirus and HIV are typically associated with pure radicular syndromes. However, they can rarely cause a lumbosacral radiculoneuropathy that is similar to diabetic amyotrophy electrophysiologically [",
"      <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/51\">",
"       51",
"      </a>",
"      ]. In immunocompromised patients, a lumbosacral polyradiculoneuropathy has been observed with echovirus infection and Epstein-Barr virus reactivation.",
"      <br/>",
"      <br/>",
"      Local abscess formation in the psoas muscles or nearby structures may lead to direct compressive effects on the lumbosacral plexus and subsequent LSP. Such cases have been reported in untreated tuberculosis and salmonella infections, but other organisms should be considered [",
"      <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/52\">",
"       52",
"      </a>",
"      ]. Abscesses can be adequately visualized by MRI or CT. With CT, gas collections are more easily seen, while bony destruction is more noticeable with MRI. Image-guided percutaneous drainage with CT can be used for both the diagnosis and treatment of abscess.",
"     </li>",
"     <li>",
"      Inflammatory, infiltrative, or autoimmune causes of LSP are rare. However, atypical presentations of systemic and nonsystemic vasculitides, collagen-vascular disease, and sarcoid have been reported in association with LSP. Sj&ouml;gren syndrome, systemic lupus, and mixed connective tissue disorders do not typically cause LSP, but should be considered in the differential diagnosis. They likely exert their affects on the plexus by causing a microvasculitis of the vasa nervorum. Sarcoidosis typically affects the cranial nerves and less often causes a length-dependent, symmetric polyneuropathy, but rarely may present as LSP [",
"      <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/53\">",
"       53",
"      </a>",
"      ]. Amyloidosis has also been implicated in rare cases of LSP [",
"      <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/54\">",
"       54",
"      </a>",
"      ]. Heroin injection has also been reported to cause LSP, purportedly by immunologically-mediated mechanisms [",
"      <a class=\"abstract\" href=\"UTD.htm?22/45/23257/abstract/55\">",
"       55",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Initial electrodiagnostic findings in inflammatory or autoimmune causes of LSP may be normal or show only decreased motor unit recruitment on EMG.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The collective lumbosacral plexus is formed from the anterior (ventral) rami of the L1 through S4 nerve roots (",
"      <a class=\"graphic graphic_figure graphicRef75983 \" href=\"UTD.htm?6/50/6952\">",
"       figure 1",
"      </a>",
"      ). The anterior rami divide within the plexus into anterior and posterior divisions that in turn yield individual peripheral nerves. The lumbar plexus is derived from the anterior rami of the L1 through L4 nerve roots. The lumbar plexus and sacral plexus are united via the lumbosacral trunk, which is comprised of a portion of L4 nerve root anterior rami, and all L5 anterior rami. The lumbosacral trunk passes over the sacral ala and joins the anterior rami of the S1-4 nerve roots to complete the sacral plexus. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lumbosacral plexopathy (LSP) most often presents with asymmetric, focal weakness, numbness, dysesthesia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      paresthesia in multiple contiguous lumbosacral nerve root distributions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Lumbar plexus lesions tend to cause weakness of hip flexion and adduction",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      knee extension.",
"     </li>",
"     <li>",
"      Lumbosacral trunk and upper sacral plexus lesions result in foot drop or flail foot depending on the extent of involvement, and weakness of knee flexion or hip abduction. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Information from the clinical setting and the physical and neurologic examinations should be used to direct the diagnostic evaluation of LSP, which may include laboratory studies, neuroimaging, and electrodiagnostic studies. MRI is the imaging method of choice for plexus evaluation given its versatility and improved anatomical detail. However, CT may be more readily available than MRI and remains the optimal choice for those with contraindications to MRI. Electrodiagnostic studies can help differentiate LSP from lumbosacral radicular and individual nerve syndromes, and may also provide clues to the intraplexus location and possible etiology. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The causes of LSP are numerous and diverse (",
"      <a class=\"graphic graphic_table graphicRef52765 \" href=\"UTD.htm?25/61/26587\">",
"       table 1",
"      </a>",
"      ). Important considerations include the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20631?source=see_link\">",
"       \"Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Neoplastic invasion (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Neoplastic invasion'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Radiation therapy (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Radiation plexopathy'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Trauma (see",
"      <a class=\"local\" href=\"#H19\">",
"       'Trauma'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Pregnancy (see",
"      <a class=\"local\" href=\"#H21\">",
"       'Peripartum plexopathy'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Surgery (see",
"      <a class=\"local\" href=\"#H23\">",
"       'Postoperative plexopathy'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Vascular conditions, particularly retroperitoneal hematoma (see",
"      <a class=\"local\" href=\"#H24\">",
"       'Vascular causes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       'Retroperitoneal hematoma'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Parainfectious, inflammatory, and infiltrative disorders (see",
"      <a class=\"local\" href=\"#H27\">",
"       'Infectious, inflammatory, and infiltrative causes'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Stewart, JD. Focal peripheral neuropathies. Lippincott Williams &amp; Wilkins, Philadelphia 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/2\">",
"      Garc&iacute;a-Manzanares MD, Forner-Cordero I, Lavara-Perona MC, et al. Bilateral lumbosacral plexopathy after mesenteric thrombosis. Spinal Cord 1999; 37:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/3\">",
"      Maravilla KR, Bowen BC. Imaging of the peripheral nervous system: evaluation of peripheral neuropathy and plexopathy. AJNR Am J Neuroradiol 1998; 19:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/4\">",
"      Moore KR, Tsuruda JS, Dailey AT. The value of MR neurography for evaluating extraspinal neuropathic leg pain: a pictorial essay. AJNR Am J Neuroradiol 2001; 22:786.",
"     </a>",
"    </li>",
"    <li>",
"     Preston, DC, Shapiro, BE. Lumbosacral plexopathy. In: Electromyography and neuromuscular disorders: Clinical-electrophysiologic correlations. Butterworth-Heinemann, Boston 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/6\">",
"      Souayah N, Sander HW. Lumbosacral magnetic root stimulation in lumbar plexopathy. Am J Phys Med Rehabil 2006; 85:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/7\">",
"      Ladha SS, Spinner RJ, Suarez GA, et al. Neoplastic lumbosacral radiculoplexopathy in prostate cancer by direct perineural spread: an unusual entity. Muscle Nerve 2006; 34:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/8\">",
"      Rigor BM Sr. Pelvic cancer pain. J Surg Oncol 2000; 75:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/9\">",
"      Jaeckle KA, Young DF, Foley KM. The natural history of lumbosacral plexopathy in cancer. Neurology 1985; 35:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/10\">",
"      Planner AC, Donaghy M, Moore NR. Causes of lumbosacral plexopathy. Clin Radiol 2006; 61:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/11\">",
"      Felice KJ, Donaldson JO. Lumbosacral plexopathy due to benign uterine leiomyoma. Neurology 1995; 45:1943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/12\">",
"      Taylor BV, Kimmel DW, Krecke KN, Cascino TL. Magnetic resonance imaging in cancer-related lumbosacral plexopathy. Mayo Clin Proc 1997; 72:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/13\">",
"      Moore KR, Blumenthal DT, Smith AG, Ward JH. Neurolymphomatosis of the lumbar plexus: high-resolution MR neurography findings. Neurology 2001; 57:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/14\">",
"      Thomas JE, Cascino TL, Earle JD. Differential diagnosis between radiation and tumor plexopathy of the pelvis. Neurology 1985; 35:1.",
"     </a>",
"    </li>",
"    <li>",
"     Levin, VA. Cancer in the Nervous System. Oxford University Press, New York 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/16\">",
"      Ahmad A, Barrington S, Maisey M, Rubens RD. Use of positron emission tomography in evaluation of brachial plexopathy in breast cancer patients. Br J Cancer 1999; 79:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/17\">",
"      Aho K, Sainio K. Late irradiation-induced lesions of the lumbosacral plexus. Neurology 1983; 33:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/18\">",
"      Gutmann L. AAEM minimonograph #37: facial and limb myokymia. Muscle Nerve 1991; 14:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/19\">",
"      Yarnold J. Double-blind randomised phase II study of hyperbaric oxygen in patients with radiation-induced brachial plexopathy. Radiother Oncol 2005; 77:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/20\">",
"      Lang EM, Borges J, Carlstedt T. Surgical treatment of lumbosacral plexus injuries. J Neurosurg Spine 2004; 1:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/21\">",
"      Kutsy RL, Robinson LR, Routt ML Jr. Lumbosacral plexopathy in pelvic trauma. Muscle Nerve 2000; 23:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/22\">",
"      Huittinen VM. Lumbosacral nerve injury in fracture of the pelvis. A postmortem radiographic and patho-anatomical study. Acta Chir Scand Suppl 1972; 429:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/23\">",
"      Tung TH, Martin DZ, Novak CB, et al. Nerve reconstruction in lumbosacral plexopathy. Case report and review of the literature. J Neurosurg 2005; 102:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/24\">",
"      Katirji B, Wilbourn AJ, Scarberry SL, Preston DC. Intrapartum maternal lumbosacral plexopathy. Muscle Nerve 2002; 26:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/25\">",
"      COLE JT. Maternal obstetric paralysis. Am J Obstet Gynecol 1946; 52:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/26\">",
"      HILL EC. Maternal obstetric paralysis. Am J Obstet Gynecol 1962; 83:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/27\">",
"      Feasby TE, Burton SR, Hahn AF. Obstetrical lumbosacral plexus injury. Muscle Nerve 1992; 15:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/28\">",
"      Kunnert JE, Vautravers P, Lecocq J, et al. [Involvement of the lumbosacral trunk during delivery]. Presse Med 1987; 16:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/29\">",
"      Gonik B, Stringer CA, Cotton DB, Held B. Intrapartum maternal lumbosacral plexopathy. Obstet Gynecol 1984; 63:45S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/30\">",
"      Bademosi O, Osuntokun BO, Van de Werd HJ, et al. Obstetric neuropraxia in the Nigerian African. Int J Gynaecol Obstet 1980; 17:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/31\">",
"      BROWN JT, MCDOUGALL A. Traumatic maternal birth palsy. J Obstet Gynaecol Br Emp 1957; 64:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/32\">",
"      Kleinberg, S. Maternal obstetrical sciatic paralysis. Surg Gynecol Obstet 1927; 45:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/33\">",
"      Alsever JD. Lumbosacral plexopathy after gynecologic surgery: case report and review of the literature. Am J Obstet Gynecol 1996; 174:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/34\">",
"      Myers MA, Harmon RL. Sacral plexopathy and sciatic neuropathy after total knee arthroplasty. Electromyogr Clin Neurophysiol 1998; 38:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/35\">",
"      Luzzio CC, Waclawik AJ, Gallagher CL, Knechtle SJ. Iliac artery pseudoaneurysm following renal transplantation presenting as lumbosacral plexopathy. Transplantation 1999; 67:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/36\">",
"      Yurtseven T, Zileli M, G&ouml;ker EN, et al. Gluteal artery pseudoaneurysm, a rare cause of sciatic pain: case report and literature review. J Spinal Disord Tech 2002; 15:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/37\">",
"      Papadopoulos SM, McGillicuddy JE, Albers JW. Unusual cause of 'piriformis muscle syndrome'. Arch Neurol 1990; 47:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/38\">",
"      Wider C, Kuntzer T, Von Segesser LK, et al. Bilateral compressive lumbosacral plexopathy due to internal iliac artery aneurysms. J Neurol 2006; 253:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/39\">",
"      Brin BJ, Busuttil RW. Isolated hypogastric artery aneurysms. Arch Surg 1982; 117:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/40\">",
"      Dhillon SS, Sarac E. Lumbosacral plexopathy after dual kidney transplantation. Am J Kidney Dis 2000; 36:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/41\">",
"      Hefty TR, Nelson KA, Hatch TR, Barry JM. Acute lumbosacral plexopathy in diabetic women after renal transplantation. J Urol 1990; 143:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/42\">",
"      Lefebvre V, Leduc JJ, Choteau PH. Painless ischaemic lumbosacral plexopathy and aortic dissection. J Neurol Neurosurg Psychiatry 1995; 58:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/43\">",
"      Kaymak B, Oz&ccedil;akar L, Cetin A, et al. Bilateral lumbosacral plexopathy after femoral vein dialysis: synopsis of a case. Joint Bone Spine 2004; 71:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/44\">",
"      Oz&ccedil;akar L, Sivri A, Aydinli M, Tavil Y. Lumbosacral plexopathy as the harbinger of a silent retroperitoneal hematoma. South Med J 2003; 96:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/45\">",
"      Aveline C, Bonnet F. Delayed retroperitoneal haematoma after failed lumbar plexus block. Br J Anaesth 2004; 93:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/46\">",
"      Klein SM, D'Ercole F, Greengrass RA, Warner DS. Enoxaparin associated with psoas hematoma and lumbar plexopathy after lumbar plexus block. Anesthesiology 1997; 87:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/47\">",
"      Emery S, Ochoa J. Lumbar plexus neuropathy resulting from retroperitoneal hemorrhage. Muscle Nerve 1978; 1:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/48\">",
"      Kent KC, Moscucci M, Mansour KA, et al. Retroperitoneal hematoma after cardiac catheterization: prevalence, risk factors, and optimal management. J Vasc Surg 1994; 20:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/49\">",
"      Kent KC, Moscucci M, Gallagher SG, et al. Neuropathy after cardiac catheterization: incidence, clinical patterns, and long-term outcome. J Vasc Surg 1994; 19:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/50\">",
"      Logigian EL, Steere AC. Clinical and electrophysiologic findings in chronic neuropathy of Lyme disease. Neurology 1992; 42:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/51\">",
"      Steiner I, Cohen O, Leker RR, et al. Subacute painful lumbosacral polyradiculoneuropathy in immunocompromised patients. J Neurol Sci 1999; 162:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/52\">",
"      Stoeckli TC, Mackin GA, De Groote MA. Lumbosacral plexopathy in a patient with pulmonary tuberculosis. Clin Infect Dis 2000; 30:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/53\">",
"      Zuniga G, Ropper AH, Frank J. Sarcoid peripheral neuropathy. Neurology 1991; 41:1558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/54\">",
"      Ladha SS, Dyck PJ, Spinner RJ, et al. Isolated amyloidosis presenting with lumbosacral radiculoplexopathy: description of two cases and pathogenic review. J Peripher Nerv Syst 2006; 11:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/45/23257/abstract/55\">",
"      Stamboulis E, Psimaras A, Malliara-Loulakaki S. Brachial and lumbar plexitis as a reaction to heroin. Drug Alcohol Depend 1988; 22:205.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5267 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-655B890CD5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_45_23257=[""].join("\n");
var outline_f22_45_23257=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Electrodiagnostic studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Laboratory investigations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SPECIFIC DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Diabetic amyotrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Idiopathic lumbosacral radiculoplexus neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Neoplastic invasion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Prognosis and management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Radiation plexopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Prognosis and management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Trauma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Peripartum plexopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Prognosis and management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Postoperative plexopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Vascular causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Retroperitoneal hematoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Prognosis and management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Infectious, inflammatory, and infiltrative causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5267\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5267|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/30/21988\" title=\"diagnostic image 1\">",
"      Gluteal artery pseudoaneurysm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/9/145\" title=\"diagnostic image 2\">",
"      Retroperitoneal hematoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5267|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/50/6952\" title=\"figure 1\">",
"      Lumbosacral plexus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5267|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/61/26587\" title=\"table 1\">",
"      Causes of lumbosacral plexopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5655?source=related_link\">",
"      Acute lumbosacral radiculopathy: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24329?source=related_link\">",
"      Clinical features and diagnosis of leptomeningeal metastases from solid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6585?source=related_link\">",
"      Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38437?source=related_link\">",
"      Complications of peripheral nerve irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=related_link\">",
"      Correcting excess anticoagulation after warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20631?source=related_link\">",
"      Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22088?source=related_link\">",
"      Evaluation of the adult with hip pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/20/20810?source=related_link\">",
"      Lumbosacral radiculopathy: Pathophysiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1769?source=related_link\">",
"      Overview of electromyography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42233?source=related_link\">",
"      Overview of lower extremity peripheral nerve syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/31/2554?source=related_link\">",
"      Overview of nerve conduction studies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_45_23258="Fosphenytoin: Pediatric drug information";
var content_f22_45_23258=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fosphenytoin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?13/51/14138?source=see_link\">",
"    see \"Fosphenytoin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?15/11/15540?source=see_link\">",
"    see \"Fosphenytoin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F15795819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F174565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cerebyx&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1053056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticonvulsant, Hydantoin",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      The dose, concentration in solutions, and infusion rates for fosphenytoin are expressed as PHENYTOIN SODIUM EQUIVALENTS (PE)",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Fosphenytoin should ALWAYS be prescribed and dispensed in mg of PE",
"     </b>",
"     ; otherwise, significant medication errors may occur",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     A limited number of clinical studies have been conducted; based on pharmacokinetic studies, experts recommend the following (Fischer, 2003): Use the neonatal I.V. phenytoin dosing guidelines to dose fosphenytoin using doses in",
"     <b>",
"      PE",
"     </b>",
"     equal to the phenytoin doses (ie, phenytoin 1 mg = fosphenytoin 1 mg",
"     <b>",
"      PE",
"     </b>",
"     ). Dosage should be individualized based upon clinical response and serum concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Status epilepticus; neonatal seizures:",
"     </b>",
"     Limited data available: I.M., I.V.: 15-20 mg PE/kg; then begin maintenance therapy usually 12 hours after dose.",
"     <b>",
"      Note:",
"     </b>",
"     Phenobarbital is the preferred treatment for treatment of neonatal seizures (Hegenbarth, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Seizures; short-term maintenance therapy when oral route not available or appropriate:",
"     </b>",
"     Limited data available:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Not currently on phenytoin: I.M. or  I.V.: Initial: 5 mg PE/kg/day in 2 divided doses; usual range: 4-8 mg PE/kg/day in 2 divided doses; some patients may require dosing every 8 hours; dosing based on phenytoin recommendations for this patient population; in adult patients, treatment duration &gt;5 days has not been evaluated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Substitution for oral phenytoin therapy: I.M. or I.V.: May be substituted for oral phenytoin sodium at the same total daily dose; due to bioavailability differences of oral phenytoin dosage forms, serum phenytoin concentrations may increase when I.M. or I.V. fosphenytoin is substituted for oral phenytoin sodium therapy; monitor serum concentrations closely when converting dosage form.",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1053049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/51/14138?source=see_link\">",
"      see \"Fosphenytoin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      The dose, concentration in solutions, and infusion rates for fosphenytoin are expressed as PHENYTOIN SODIUM EQUIVALENTS (PE)",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Fosphenytoin should ALWAYS be prescribed and dispensed in mg of PE",
"     </b>",
"     ; otherwise significant medication errors may occur",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents: I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     A limited number of clinical studies have been conducted in pediatric patients; based on pharmacokinetic studies, experts recommend the following (Fischer, 2003): Use the pediatric I.V. phenytoin dosing guidelines to dose fosphenytoin using doses in",
"     <b>",
"      PE",
"     </b>",
"     equal to the phenytoin doses (ie, phenytoin 1 mg = fosphenytoin 1 mg",
"     <b>",
"      PE",
"     </b>",
"     ). Dosage should be individualized based upon clinical response and serum concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Status epilepticus:",
"     </b>",
"     Limited data available: Loading dose: I.M., I.V.: 15-20 mg PE/kg; maximum dose: 1000 mg PE; then begin maintenance therapy usually 12 hours after dose (Brophy, 2012; Hegenbarth, 2008). An additional load of 5 mg PE/kg may be given 10 minutes after initial loading infusion completed if status epilepticus is not resolved; however, some experts recommend trying another agent once a total loading dose of 20 mg PE/kg has been given (Brophy, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Seizures; short-term maintenance therapy when oral route not available or appropriate:",
"     </b>",
"     Limited data available; dosing presented based on phenytoin recommendations for this patient population:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Not currently receiving phenytoin:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     Loading dose: I.M., I.V.: 15-20 mg PE/kg; if currently on phenytoin, reloading dose should be  based upon serum concentrations and recent dosing history",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     Maintenance therapy: I.M., I.V.: Usual range: 4-8 mg PE/kg/day divided twice daily; maximum daily dose: 300 mg PE/",
"     <b>",
"      day",
"     </b>",
"     . Some experts suggest higher maintenance doses (8-10 mg PE/kg/day) may be necessary in infants and young children (Guerrini, 2006). Dosing should be based upon ideal body weight (IBW); in adult patients, treatment duration &gt;5 days has not been evaluated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Substitution for oral phenytoin therapy: I.M. or I.V.: May be substituted for oral phenytoin sodium at the same total daily dose; however, Dilantin&reg; capsules are ~90% bioavailable by the oral route; phenytoin, supplied as fosphenytoin, is 100% bioavailable by both the I.M. and I.V. routes; for this reason, plasma phenytoin concentrations may increase when I.M. or I.V. fosphenytoin is substituted for oral phenytoin sodium therapy; in adult clinical trials, I.M. fosphenytoin was administered as a single daily dose utilizing either 1 or 2 injection sites; some patients may require more frequent dosing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Seizure prophylaxis, traumatic brain injury:",
"     </b>",
"     Limited data available; efficacy results variable dosing based on experience with phenytoin: I.V.: Initial: 18 mg PE/kg  loading dose; followed by 6 mg PE/kg/day divided every 8 hours for 48 hours was used in a double-blind, placebo-controlled trial of 102 pediatric patients (n=46 treatment group) and showed no significant difference in seizure frequency between groups; however, the trial was stopped early due to a very low seizure frequency among both study groups (Young, 2004). In a retrospective trial, reduced seizure frequency with prophylactic phenytoin use was described (Lewis, 1993).",
"     <b>",
"      Note:",
"     </b>",
"     Current guidelines suggest that prophylactic phenytoin may be considered to reduce the incidence of early post-traumatic seizures in pediatric patients with severe traumatic brain injuries but it does not reduce the risk of long-term seizures or improve neurologic outcome (Kochanek, 2012). Further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"     <b>",
"      Note:",
"     </b>",
"     The dose, concentration in solutions, and infusion rates for fosphenytoin are expressed as phenytoin sodium equivalents (PE); fosphenytoin should always be prescribed and dispensed in phenytoin sodium equivalents (PE).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Status epilepticus:",
"     </b>",
"     I.V.: Loading dose: 15-20 mg PE/kg administered at 100-150 mg PE/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Nonemergent loading and maintenance dosing:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     Loading dose:  I.M., I.V.: 10-20 mg PE/kg; for I.V. administration, infuse more slowly (eg, over 30 minutes); maximum rate: 150 mg PE/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     Initial daily maintenance dose: I.M., I.V.: 4-6 mg PE/kg/day in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Substitution for oral phenytoin therapy:",
"     </b>",
"     I.M. or I.V.: May be substituted for oral phenytoin sodium at the same total daily dose; however, Dilantin&reg; capsules are ~90% bioavailable by the oral route; phenytoin, supplied as fosphenytoin, is 100% bioavailable by both the I.M. and I.V. routes; for this reason, plasma phenytoin concentrations may increase when I.M. or I.V. fosphenytoin is substituted for oral phenytoin sodium therapy; in clinical trials, I.M. fosphenytoin was administered as a single daily dose utilizing either 1 or 2 injection sites; some patients may require more frequent dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Adults: No initial dosage adjustment necessary. Free (unbound) phenytoin serum concentrations should be monitored closely in patients with renal disease or in those with hypoalbuminemia, serum concentrations may be increased; furthermore, fosphenytoin clearance to phenytoin may be increased without a similar increase in phenytoin clearance in these patients leading to increase frequency and severity of adverse events.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Adults: No initial dosage adjustment necessary. Phenytoin clearance may be substantially reduced in cirrhosis and serum concentration monitoring with dose adjustment advisable. Free (unbound) phenytoin concentrations should be monitored closely in patients with hepatic disease or in those with hypoalbuminemia; concentrations may be increased; furthermore, fosphenytoin clearance to phenytoin may be increased without a similar increase in phenytoin clearance in these patients leading to increased frequency and severity of adverse events.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F174535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sodium: 75 mg [50 mg PE]/mL (2 mL, 10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F174519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1053061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M.: May administer undiluted; the quadricep area has been recommended as an injection site; in adults, fosphenytoin has been administered as a single daily dose using 1-4 injection sites (up to 20 mL per site well tolerated in adults) (Meek, 1999; Pryor, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Further dilute solution for injection with D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS to final concentration of 1.5-25 mg PE/mL; administer as intermittent I.V. infusion; do not administer as a continuous infusion or I.V. push",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Maximum rates of infusion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Pediatric patients (0-18 years): Administer at",
"     <b>",
"      1-3 mg PE/kg/minute up to a maximum of 150 mg PE/minute",
"     </b>",
"     (Brophy, 2012; Hegenbarth, 2008); slower administration reduces incidence of cardiovascular events (eg, hypotension, arrhythmia) as well as severity of paresthesias and pruritus. For nonemergent situations, may administer loading dose more slowly (eg, over 30 minutes) (Fischer, 2003)]. Highly sensitive patients (eg, patients with pre-existing cardiovascular conditions) should receive fosphenytoin more slowly (Meek, 1999).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adults: D",
"     <b>",
"      o not exceed 150 mg PE/minute.",
"     </b>",
"     Slower administration reduces incidence of cardiovascular events (eg, hypotension, arrhythmia) as well as severity of paresthesias and pruritus. For nonemergent situations, may administer loading dose more slowly [eg, over 30 minutes (~33 mg PE/minute for 1000 mg PE)",
"     <b>",
"      or",
"     </b>",
"     50-100 mg PE/minute (Fischer, 2003). Highly sensitive patients (eg, elderly, patients with pre-existing cardiovascular conditions) should receive fosphenytoin more slowly (eg, 25-50 mg PE/minute) (Meek, 1999).",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F174599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, hetastarch 6% in NS, mannitol 20%, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Lorazepam, phenobarbital.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Fenoldopam, midazolam.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1053053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store intact vials at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not store at room temperature for &gt;48 hours; do not use vials containing particulate matter. Fosphenytoin at concentrations of 1, 8, and 20 mg phenytoin sodium equivalents",
"     <b>",
"      (PE)",
"     </b>",
"     /mL in D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS is stable for 30 days when stored at 25&deg;C or 4&deg;C in glass bottles or polyvinyl chloride infusion bags, and when frozen at -20&deg;C in polyvinyl chloride infusion bags. After removal from the freezer, these solutions are stable for 7 days at 25&deg;C or 4&deg;C (Fischer, 1997).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Undiluted fosphenytoin injection (50 mg",
"     <b>",
"      PE",
"     </b>",
"     /mL) is stable in polypropylene syringes for 30 days at 25&deg;C, 4&deg;C, or frozen at -20&deg;C (Fischer, 1997).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Fosphenytoin at concentrations of 1, 8, and 20 mg",
"     <b>",
"      PE",
"     </b>",
"     /mL prepared in D",
"     <sub>",
"      5",
"     </sub>",
"     /",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     /",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS with KCl 20 mEq/L, D",
"     <sub>",
"      5",
"     </sub>",
"     /",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS with 40 mEq/L, LR, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      10",
"     </sub>",
"     W, amino acid 10%, mannitol 20%, hetastarch 6% in NS or Plasma-Lyte&reg; A injection is stable in polyvinyl chloride bags for 7 days when stored at 25&deg;C (room temperature) (Fischer, 1997).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1053060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of generalized convulsive status epilepticus; short-term (&le;5 days) parenteral administration of phenytoin when other means are unavailable, inappropriate, or deemed less advantageous; prevention and treatment of seizures occurring during neurosurgery (All indications: FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F174602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cerebyx may be confused with CeleBREX&reg;, CeleXA&reg;, Cerezyme&reg;, Cervarix&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Fosphenytoin may be confused with fospropofol",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Overdoses have occurred due to confusion between the",
"       <b>",
"        mg per mL concentration",
"       </b>",
"       of fosphenytoin (50 mg phenytoin equivalent (PE)/mL) and",
"       <b>",
"        total drug content per vial",
"       </b>",
"       (either 100 mg PE/2 mL vial or 500 mg PE/10 mL vial). ISMP recommends that the total drug content per container is identified instead of the concentration in mg per mL to avoid confusion and potential overdoses. Additionally, since most errors have occurred with overdoses in children, ISMP recommends that pediatric hospitals consider stocking only the 2 mL vial.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F174598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The more important adverse clinical events caused by the I.V. use of fosphenytoin or phenytoin are cardiovascular collapse and/or central nervous system depression. Hypotension can occur when either drug is administered rapidly by the I.V. route.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     The adverse clinical events most commonly observed with the use of fosphenytoin in clinical trials were nystagmus, dizziness, pruritus, paresthesia, headache, somnolence, and ataxia. Paresthesia and pruritus were seen more often following fosphenytoin (versus phenytoin) administration and occurred more often with I.V. fosphenytoin than with I.M. administration. These events were dose and rate related (adult doses &ge;15 mg/kg at a rate of 150 mg PE/minute). These sensations, generally described as itching, burning, or tingling are usually not at the infusion site. The location of the discomfort varied with the groin mentioned most frequently. The paresthesia and pruritus were transient events that occurred within several minutes of the start of infusion and generally resolved within 10 minutes after completion of infusion.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Transient pruritus, tinnitus, nystagmus, somnolence, and ataxia occurred 2-3 times more often at adult doses &ge;15 mg/kg and rates &ge;150 mg PE/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      I.V. and I.M. administration (as reported in clinical trials):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Facial edema, hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Chills, fever, intracranial hypertension, nervousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Hyperreflexia, myasthenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      I.V. administration",
"     </b>",
"     (maximum dose/rate):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Ataxia, dizziness, nystagmus, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension, tachycardia, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Agitation, brain edema, dysarthria, extrapyramidal syndrome, headache, hypoesthesia, incoordination, paresthesia, stupor, tremor, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dry mouth, nausea, tongue disorder, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, muscle weakness, pelvic pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Amblyopia, diplopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Deafness, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Taste perversion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      I.M. administration",
"     </b>",
"     (substitute for oral phenytoin):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Ataxia, dizziness, headache, incoordination, nystagmus, paresthesia, reflexes decreased, somnolence, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic/lymphatic: Ecchymosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      I.V. and I.M. administration:",
"     </b>",
"     Rare but important or life-threatening: Acidosis, acute hepatic failure, acute hepatotoxicity, alkalosis, akathisia, amnesia, anemia, anorexia, aphasia, apnea, arthralgia, asthma, atrial flutter, Babinski sign positive, bundle branch block, cachexia, cardiac arrest, cardiomegaly, cerebral hemorrhage, cerebral infarct, CHF, circumoral paresthesia, CNS depression, cyanosis,  dehydration, diabetes insipidus, dyskinesia, dysphagia, dyspnea, edema, emotional lability, encephalopathy, epistaxis, extrapyramidal symptoms, GI hemorrhage, hemiplegia, hemoptysis, hostility, hyperacusis, hyperesthesia, hyper-/hypokinesia, hyperkalemia, hyperventilation, hypochromic anemia, hypophosphatemia, hypotonia, hypoxia, ileus, injection site (edema, hemorrhage, inflammation), ketosis, leg cramps, leukocytosis, leukopenia, LFTs abnormal, malaise, migraine, myalgia, mydriasis, myopathy, neurosis, orthostatic hypotension, palpitation, paralysis, parosmia, petechia, photophobia, photosensitivity reaction, psychosis, pulmonary embolus, QT interval prolongation, rash (maculopapular or pustular), renal failure, sinus bradycardia, shock, subdural hematoma, syncope, Stevens-Johnson syndrome, tenesmus, thrombocytopenia, thrombophlebitis, tongue edema, toxic epidermal necrolysis, urticaria, ventricular extrasystoles, visual field defect",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1053064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fosphenytoin, phenytoin, other hydantoins, or any component; second- and third-degree AV block, sinoatrial block, sinus bradycardia, Adams-Stokes syndrome; concurrent use of delavirdine [due to loss of virologic response and possible resistance to delavirdine or other non-nucleoside reverse transcriptase inhibitors (NNRTIs)]",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1053048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with any condition associated with low serum albumin levels, which will increase the free fraction of phenytoin in the serum and, therefore, the pharmacologic response. Use with caution in renal impairment; serum concentrations may be difficult to interpret; consider monitoring free (unbound) concentrations; also consider the phosphate load delivered with fosphenytoin (0.0037 mmol phosphate/mg PE fosphenytoin). Use with caution in hepatic impairment; clearance may be substantially reduced in cirrhosis; frequent monitoring of free (unbound) serum concentrations should be considered. Use with caution in patients with underlying cardiac disease; use is contraindicated in bradycardia, sinoatrial block, second- and third-degree heart block, or Adam-Stokes syndrome. Use with caution in patients with porphyria; may cause exacerbations. Should not be used to treat absence seizures; phenytoin has been shown to increase frequency. May cause sedation, confusional states, or cerebellar dysfunction (loss of motor coordination) at higher total serum phenytoin concentrations, or at lower total serum concentrations when the free fraction of phenytoin is increased; possible permanent cerebellum damage may occur with chronic toxic serum concentrations; effects  with other sedative drugs or ethanol may be potentiated; use with caution in patients who are debilitated. Use with caution in diabetic patients; may cause hyperglycemia. Severe burning or pruritis and/or paresthesias, mostly perineal, may occur upon administration, usually at the maximum administration rate and last from minutes to hours; occurrence and intensity may be lessened by slowing or temporarily stopping the infusion.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1053047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Doses of fosphenytoin are always expressed as their phenytoin sodium equivalent (PE); thus phenytoin sodium: 1 mg = fosphenytoin 1 mg PE.  It is NOT appropriate to convert mg of fosphenytoin to mg of phenytoin.",
"     </b>",
"     Dosing errors have also occurred due to misinterpretation of vial concentrations resulting in two- or tenfold overdoses (some fatal); ensure correct volume of fosphenytoin is withdrawn from vial.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Fosphenytoin administration should not exceed 150 mg phenytoin equivalents (PE)/minute in patients",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Hypotension and severe cardiac arrhythmias (eg, heart block, ventricular tachycardia, ventricular fibrillation) may occur with rapid administration; adverse cardiac events have been reported at or below the recommended infusion rate; use with caution in patients with hypotension and/or severe myocardial insufficiency. In the treatment of status epilepticus in adults, the rate of administration is 150 mg PE/minute. Safety and efficacy of fosphenytoin in pediatric patients has not been established; based on experience with parenteral fosphenytoin, consider a maximum infusion rate in  pediatric patients of 1-3 mg PE/kg/minute. In a nonemergent situation, administer more slowly or use oral phenytoin. Cardiac monitoring is necessary during and after administration of intravenous fosphenytoin; reduction in rate of administration or discontinuation of infusion may be necessary.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Abrupt withdrawal of fosphenytoin may precipitate status epilepticus; do not discontinue abruptly; fosphenytoin should be withdrawn gradually, unless safety concerns (eg, allergic or hypersensitivity reaction) require a more rapid withdrawal.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Acute hepatotoxicity associated with a hypersensitivity syndrome characterized by fever, skin eruptions, and lymphadenopathy has been reported with phenytoin and occurs within the first 2 months of treatment; discontinue if skin rash or lymphadenopathy occur. Other reported manifestations of hepatotoxicity include jaundice, hepatomegaly, increased serum transaminase levels, leukocytosis, and eosinophilia. Serious skin reactions, including toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS), although rarely reported (with phenytoin), have resulted in fatalities; fosphenytoin should be discontinued if there are any signs of rash; and patient should be evaluated for signs and symptoms of drug reaction with eosinophilia and systemic symptoms (DRESS). Preliminary data suggests that patients testing positive for the human leukocyte antigen (HLA) allele HLA-B*1502 have an increased risk of developing SJS and/or TEN. The risk appears to be highest in the early months of therapy initiation. The presence of this genetic variant exists in up to 15% of people of Asian descent in China, Thailand, Malaysia, Indonesia, Taiwan, and the Philippines, and may vary from &lt;1% in Japanese and Koreans to 2% to 4% of South Asians and Indians. This variant is virtually absent in those of Caucasian, African-American, Hispanic, or European ancestry; consider avoiding fosphenytoin use in patients",
"     <i>",
"      HLA-B*1502",
"     </i>",
"     allele-positive if other therapeutic options are available.",
"     <b>",
"      Note:",
"     </b>",
"     Carbamazepine, another antiepileptic with a chemical structure similar to phenytoin, includes in the manufacturer labeling a  recommendation to screen patients of Asian descent for the",
"     <i>",
"      HLA-B*1502",
"     </i>",
"     allele prior to initiating therapy; this is not a current recommendation in the fosphenytoin or phenytoin manufacturer labeling.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A spectrum of hematologic effects have been reported with phenytoin use (eg, agranulocytosis, neutropenia, leukopenia, thrombocytopenia, pancytopenia, and anemias); patients with a previous history of adverse hematologic reaction to any drug may be at increased risk. Early detection of hematologic change is important; advise patients of early signs and symptoms including fever, infections, easy bruising, and petechial or purpuric hemorrhage.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The \"purple glove syndrome\" (ie, discoloration with edema and pain of distal limb) may rarely occur following peripheral I.V. administration of fosphenytoin; incidence may be less compared to phenytoin; symptoms may resolve spontaneously; however, skin necrosis and limb ischemia may occur.  In general, fosphenytoin has significantly less venous irritation and phlebitis compared with an equimolar dose of phenytoin (Jamerson, 1994).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F174587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (major), CYP2C9 (major), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Induces",
"     </b>",
"     CYP2B6 (strong), CYP2C19 (strong), CYP2C8 (strong), CYP2C9 (strong), CYP3A4 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F174528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: Anticonvulsants (Hydantoin) may increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the CNS depressant effect of Fosphenytoin. Alcohol (Ethyl) may decrease the serum concentration of Fosphenytoin. This may be particularly applicable with chronic, heavy alcohol consumption. Alcohol (Ethyl) may increase the serum concentration of Fosphenytoin. This may be particularly applicable with acute, heavy alcohol consumption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: May increase the serum concentration of Anticonvulsants (Hydantoin).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May increase the serum concentration of Fosphenytoin. Fosphenytoin may decrease the serum concentration of Amiodarone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of Anticonvulsants (Hydantoin).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): Fosphenytoin may decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the CNS depressant effect of Fosphenytoin. Barbiturates may decrease the serum concentration of Fosphenytoin. Fosphenytoin may increase the serum concentration of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines: May increase the serum concentration of Fosphenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <b>",
"      Exceptions:",
"     </b>",
"     ALPRAZolam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: Fosphenytoin may decrease the serum concentration of Boceprevir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Busulfan: Fosphenytoin may decrease the serum concentration of Busulfan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: May increase the serum concentration of Fosphenytoin. Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capecitabine: May increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Fosphenytoin. CarBAMazepine may increase the serum concentration of Fosphenytoin. Possibly by competitive inhibition at sites of metabolism. Fosphenytoin may decrease the serum concentration of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of Anticonvulsants (Hydantoin). Specifically, osteomalacia and rickets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CeFAZolin: May decrease the protein binding of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: May decrease the metabolism of Anticonvulsants (Hydantoin). Anticonvulsants (Hydantoin) may decrease the serum concentration of Chloramphenicol. Increased chloramphenicol concentrations have also been seen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May enhance the adverse/toxic effect of Anticonvulsants (Hydantoin). Cimetidine may increase the serum concentration of Anticonvulsants (Hydantoin). Management: Consider using an alternative H",
"     <sub>",
"      2",
"     </sub>",
"     -antagonist to avoid this interaction. Monitor for toxic effects of hydantoin anticonvulsants if cimetidine is initiated/dose increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ciprofloxacin (Systemic): May decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CISplatin: May decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Fosphenytoin may decrease the serum concentration of CloZAPine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: Fosphenytoin-Phenytoin may decrease the serum concentration of Cobicistat.  Management: Consider using an alternative antiepileptic when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Fosphenytoin may diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.  Management: Use of an alternative, nonhormonal means of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Fosphenytoin may diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.  Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Fosphenytoin may decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Substrates: CYP2B6 Inducers (Strong) may increase the metabolism of CYP2B6 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Moderate): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Strong): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inducers (Strong) may increase the metabolism of CYP2C19 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inducers (Strong) may increase the metabolism of CYP2C8 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inducers (Strong) may increase the metabolism of CYP2C9 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inducers (Strong) may increase the metabolism of CYP3A4 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: Fosphenytoin may decrease the serum concentration of Darunavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Fosphenytoin may decrease the serum concentration of Deferasirox.  Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: May increase the serum concentration of Fosphenytoin. Fosphenytoin may decrease the serum concentration of Delavirdine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: May increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May decrease the serum concentration of Fosphenytoin. Total phenytoin concentrations may be affected more than free phenytoin concentrations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diclofenac (Systemic): CYP2C9 Inducers (Strong) may decrease the serum concentration of Diclofenac (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: Fosphenytoin may decrease the serum concentration of Disopyramide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disulfiram: May increase the serum concentration of Fosphenytoin. Management: Avoid concomitant use of disulfiram and phenytoin when possible.  Phenytoin dose adjustment will likely be necessary when starting and/or stopping concurrent disulfiram.  Monitor phenytoin response and concentrations closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May decrease the serum concentration of Fosphenytoin. Fosphenytoin may decrease the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Doxycycline: Fosphenytoin may decrease the serum concentration of Doxycycline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May increase the serum concentration of Fosphenytoin. Fosphenytoin may decrease the serum concentration of Efavirenz.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: Fosphenytoin-Phenytoin may decrease the serum concentration of Elvitegravir.  Management: Consider using an alternative antiepileptic when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: May decrease the serum concentration of Fosphenytoin-Phenytoin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethosuximide: May enhance the CNS depressant effect of Fosphenytoin. Ethosuximide may increase the serum concentration of Fosphenytoin. Fosphenytoin may decrease the serum concentration of Ethosuximide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide: Fosphenytoin may decrease the serum concentration of Etoposide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide Phosphate: Fosphenytoin may decrease the serum concentration of Etoposide Phosphate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: Fosphenytoin may decrease the serum concentration of Etravirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.  Management: Avoid concurrent use of strong CYP3A4 inducers, but if strong CYP3A4 inducers cannot be avoided, consider gradually (in 5 mg increments) increasing the everolimus dose from 10 mg/day to 20 mg/day (adult doses).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Exemestane U.S. product labeling recommends using an increased dose (50 mg/day) in patients receiving concurrent strong CYP3A4 inducers. The Canadian product labeling does not recommend a dose adjustment  with concurrent use of strong CYP3A4 inducers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: May increase the serum concentration of Fosphenytoin. Fosphenytoin may decrease the serum concentration of Felbamate. Management: Decreased phenytoin dose will likely be needed when adding felbamate; some reports suggest an empiric 20% decrease in phenytoin dose. Additional reductions may be needed if felbamate dose is increased or as otherwise guided by monitoring.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floxuridine: May increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flunarizine: Fosphenytoin may decrease the serum concentration of Flunarizine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluorouracil (Systemic): May increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluorouracil (Topical): May increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FLUoxetine: May increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FluvoxaMINE: May increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Folic Acid: May decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: May decrease the serum concentration of Fosphenytoin. Fosphenytoin may increase the serum concentration of Fosamprenavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.  Management: In the absence of severe adverse drug reactions, consider increasing gefitinib dose to 500 mg daily in patients receiving strong CYP3A4 inducers.  Carefully monitor clinical response and development of adverse reactions.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Consider increasing the guanfacine dose by 2-fold when adding a strong CYP3A4 inducer.  Titrate the guanfacine dose up to a max of 8 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halothane: May increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Fosphenytoin may decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pitavastatin; Rosuvastatin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.  Management: Avoid concurrent use of imatinib with strong CYP3A4 inducers when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Irinotecan: Fosphenytoin may decrease the serum concentration of Irinotecan.  Management: Change to a non-enzyme inducing anticonvulsant, when clinically possible, at least 2 weeks prior to beginning irinotecan.  Dosage increases for irinotecan may be needed when used with phenytoin, but specific dosing guidelines are not available.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May increase the serum concentration of Fosphenytoin. Management: Consider alternatives. If concomitant therapy cannot be avoided, monitor for increased phenytoin concentrations/effects with isoniazid initiation/dose increase, or decreased concentrations/effects with isoniazid discontinuation/dose decrease.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (given as a 4-hour infusion), as tolerated, should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lacosamide: Fosphenytoin may decrease the serum concentration of Lacosamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: Fosphenytoin may decrease the serum concentration of LamoTRIgine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leucovorin Calcium-Levoleucovorin: May decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levodopa: Fosphenytoin may diminish the therapeutic effect of Levodopa.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levomefolate: May decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Fosphenytoin may enhance the adverse/toxic effect of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Fosphenytoin may diminish the diuretic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: Fosphenytoin may decrease the serum concentration of Lopinavir. Lopinavir may decrease the serum concentration of Fosphenytoin.  Management: The manufacturer of lopinavir/ritonavir recommends avoiding once-daily administration if used together with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice daily when used with strong CYP3A4 inducers. This does not apply to patients also receiving strong CYP3A4 inhibitors. Do not use maraviroc with strong CYP3A4 inducers in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mebendazole: Fosphenytoin may decrease the serum concentration of Mebendazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: Fosphenytoin may decrease the serum concentration of Meperidine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Fosphenytoin may decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylfolate: May decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: Fosphenytoin may decrease the serum concentration of MethylPREDNISolone.  Management: Consider an alternative corticosteroid. If this combination cannot be avoided, monitor for diminished methylprednisolone effects during phenytoin treatment, and increased methylprednisolone effects following phenytoin discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetroNIDAZOLE (Systemic): Fosphenytoin may decrease the serum concentration of MetroNIDAZOLE (Systemic). MetroNIDAZOLE (Systemic) may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrapone: Fosphenytoin may decrease the serum concentration of Metyrapone. The oral metyrapone test would thus be unreliable unless the metapyrone dosage was substantially increased (e.g., 750 mg every 2 hours).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mexiletine: Fosphenytoin may decrease the serum concentration of Mexiletine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Fosphenytoin-Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: Fosphenytoin may decrease the serum concentration of Nelfinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Fosphenytoin-Phenytoin may decrease serum concentrations of the active metabolite(s) of OXcarbazepine. Specifically, concentrations of the major active 10-monohydroxy metabolite may be reduced. OXcarbazepine may increase the serum concentration of Fosphenytoin-Phenytoin.  Management: Consider increasing the initial adult oxcarbazepine extended release tablet (Oxtellar XR) dose to 900 mg/day. No specific recommendations are available for other oxcarbazepine formulations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pazopanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: Fosphenytoin-Phenytoin may decrease the serum concentration of Perampanel.  Management: Increase the perampanel starting dose to 4 mg/day when perampanel is used with phenytoin/fosphenytoin.  Patients receiving this combination should be followed closely for response, especially with any changes to phenytoin/fosphenytoin therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.  Management: Avoid concomitant use of praziquantel with strong CYP3A4 inducers. Discontinue rifampin 4 weeks prior to initiation of praziquantel therapy. Rifampin may be resumed the day following praziquantel completion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PrednisoLONE (Systemic): Fosphenytoin may decrease the serum concentration of PrednisoLONE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PredniSONE: Fosphenytoin may decrease serum concentrations of the active metabolite(s) of PredniSONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: Fosphenytoin may increase the metabolism of Primidone. The ratio of primidone:phenobarbital is thus changed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Fosphenytoin.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dexlansoprazole; Esomeprazole; Lansoprazole; Pantoprazole; RABEprazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pyridoxine: May increase the metabolism of Fosphenytoin. This is most apparent in high pyridoxine doses (e.g., 80 mg to 200 mg daily)",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QUEtiapine: Fosphenytoin may decrease the serum concentration of QUEtiapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Fosphenytoin may decrease the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: Fosphenytoin may decrease the serum concentration of QuiNINE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Fosphenytoin may decrease the serum concentration of Rilpivirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: Fosphenytoin may decrease the serum concentration of Ritonavir. Ritonavir may decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast.  Management: Roflumilast U.S. prescribing information recommends against combining strong CYP3A4 inducers with roflumilast.  The Canadian product monograph makes no such recommendation but notes that such agents may reduce roflumilast therapeutic effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rufinamide: Fosphenytoin may decrease the serum concentration of Rufinamide. Rufinamide may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sertraline: Fosphenytoin may decrease the serum concentration of Sertraline. Sertraline may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Fosphenytoin may decrease the serum concentration of Sirolimus.  Management: Monitor for decreased sirolimus concentrations if fosphenytoin/phenytoin is initiated/dose increased. Monitor for increased sirolimus concentrations with phenytoin discontinuation/dose decrease. Sirolimus dose adjustments may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonamide Derivatives: May increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing sunitinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Fosphenytoin may decrease the serum concentration of Tacrolimus (Systemic). Tacrolimus (Systemic) may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.  Management: Erectile dysfunction: monitor for decreased effectiveness - no standard dose adjustments recommended.  Avoid use of tadalafil for pulmonary arterial hypertension in patients receiving a strong CYP3A4 inducer.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Fosphenytoin may decrease the serum concentration of Telaprevir. Telaprevir may decrease the serum concentration of Fosphenytoin. Telaprevir may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Fosphenytoin may decrease the serum concentration of Temsirolimus. Concentrations of the active metabolite, sirolimus, are also likely to be decreased (and maybe to an even greater degree).  Management: Temsirolimus prescribing information recommends against coadministration with strong CYP3A4 inducers such as phenytoin; however, if concurrent therapy is necessary, an increase in temsirolimus adult dose to 50 mg/week should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teniposide: Fosphenytoin may decrease the serum concentration of Teniposide.  Management: Consider alternatives to combined treatment with phenytoin and teniposide due to the potential for decreased teniposide concentrations.  If the combination cannot be avoided, monitor teniposide response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: May decrease the serum concentration of Fosphenytoin. Fosphenytoin may decrease the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Fosphenytoin may decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticlopidine: May increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: Fosphenytoin may decrease the serum concentration of Tipranavir. Tipranavir may decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.  Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Fosphenytoin may decrease the serum concentration of Topiramate. Topiramate may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraZODone: Fosphenytoin may decrease the serum concentration of TraZODone. TraZODone may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: CYP2C8 Inducers (Strong) may decrease the serum concentration of Treprostinil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Fosphenytoin may increase the metabolism of Valproic Acid. A hepatotoxic metabolite of valproic acid may result. Valproic Acid may decrease the serum concentration of Fosphenytoin. Continued therapy usually yields a normalization (or slight increase) of serum phenytoin concentrations.  Free phenytoin concentrations, however, tend to remain relatively stable (possibly increased with continued therapy).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vandetanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vecuronium: Fosphenytoin may diminish the therapeutic effect of Vecuronium. Fosphenytoin may enhance the therapeutic effect of Vecuronium. Fosphenytoin may decrease the serum concentration of Vecuronium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vigabatrin: May decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine: Fosphenytoin may decrease the serum concentration of VinCRIStine. VinCRIStine may decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Fosphenytoin may enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may increase the serum concentration of Fosphenytoin.  Management: Anticoagulant dose adjustment will likely be necessary when phenytoin is initiated or discontinued.  Monitor patients extra closely (INR and signs/symptoms of bleeding) when using this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zonisamide: Fosphenytoin may decrease the serum concentration of Zonisamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F174531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F174546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fosphenytoin is the prodrug of phenytoin. Refer to Phenytoin monograph for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1053055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, platelets, serum glucose, liver function. Serum phenytoin concentrations: If available, free phenytoin concentrations should be obtained in patients with hyperbilirubinemia, renal impairment, uremia, or hypoalbuminemia; in adult patients, if free phenytoin concentrations are unavailable, the adjusted total concentration may be determined based upon equations. Trough serum concentrations are generally recommended for routine monitoring. To ensure therapeutic concentration is attained, peak serum concentrations may be measured 1 hour after the end of an I.V. infusion (particularly after a loading dose).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Additional monitoring with I.V. use: Continuous cardiac monitoring (rate, rhythm, blood pressure) and clinical observation during administration is recommended; blood pressure and pulse should be monitored every 15 minutes for 1 hour after administration with nonemergency use (Meek, 1999); emergency use may require more frequent monitoring and for a longer time after administration; infusion site reactions",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1053059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Information based on experience with phenytoin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Timing of serum samples: The apparent serum half-life varies with the dosage and the drug follows Michaelis-Menten kinetics. In adults, the average apparent half-life is about 24 hours; in pediatric patients, the apparent half-life is age-dependent (longer in neonates). Steady-state concentrations are reached in 5-10 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toxicity is measured clinically and some patients may require levels outside the suggested therapeutic range.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Therapeutic range:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Total phenytoin:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Neonates: 8-15 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Pediatric patients &ge;1 month and Adults: 10-20 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Concentrations of 5-10 mcg/mL may be therapeutic for some patients, but concentrations &lt;5 mcg/mL are not likely to be effective",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     50% of adult patients show decreased frequency of seizures at concentrations &gt;10 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     86% of adult patients show decreased frequency of seizures at concentrations &gt;15 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Add another anticonvulsant if satisfactory therapeutic response is not achieved with a phenytoin concentration of 20 mcg/mL.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Free phenytoin: 1-2.5 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Total phenytoin:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Toxic:",
"     </i>",
"     &gt;30  mcg/mL (SI: &gt;119 micromole/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Lethal",
"     </i>",
"     : &gt;100 mcg/mL (SI: &gt;400 micromole/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     After  a loading dose: If rapid therapeutic serum concentrations are needed, initial concentrations may be drawn after 1 hour (after end of I.V. loading dose) to aid in determining maintenance dose or need to reload.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rapid achievement: Early assessment of serum concentrations: Draw within 2-3 days of therapy initiation to ensure that the patient's metabolism is not remarkably different from that which would be predicted by average literature-derived pharmacokinetic parameters; early serum concentrations should be used cautiously in design of new dosing regimens.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     See Phenytoin monograph for further information.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1053046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diphosphate ester salt of phenytoin which acts as a water soluble prodrug of phenytoin; after administration, plasma and tissue esterases convert fosphenytoin to phosphate, formaldehyde and phenytoin (as the active moiety); phenytoin works by stabilizing neuronal membranes and decreasing seizure activity by increasing efflux or decreasing influx of sodium ions across cell membranes in the motor cortex during generation of nerve impulses",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1053063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The pharmacokinetics of fosphenytoin-derived phenytoin are the same as those for phenytoin. Parameters listed below are for fosphenytoin (the prodrug) unless otherwise noted.",
"     <b>",
"      Note:",
"     </b>",
"     The pharmacokinetics of intravenous fosphenytoin in pediatric patients have been evaluated in two studies (n= 49, age range: 1 day to 16.7 years; n=8, age range: 5-18 years) and  have been found to be similar to the pharmacokinetics observed in young adults and the conversion rate of fosphenytoin to phenytoin to be consistent throughout childhood (Fischer, 2003; Pellock, 1996).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Bioavailability: I.M., I.V.: 100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 4.3-10.8 L; V",
"     <sub>",
"      d",
"     </sub>",
"     of fosphenytoin increases with dose and rate of administration (Fischer, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 95% to 99% primarily to albumin; binding of fosphenytoin to protein is saturable (the percent bound decreases as total concentration increases); fosphenytoin displaces phenytoin from protein binding sites; during the time fosphenytoin is being converted to phenytoin, fosphenytoin may temporarily increase the free fraction of phenytoin up to 30% unbound",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Each millimole of fosphenytoin is metabolized to 1 millimole of phenytoin, phosphate, and formaldehyde; formaldehyde is converted to formate, which is then metabolized by a folate-dependent mechanism; conversion of fosphenytoin to phenytoin increases with increasing dose and infusion rate, most likely due to a decrease in fosphenytoin protein binding",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Conversion of fosphenytoin to phenytoin:",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;text-align:justify;\">",
"     Pediatric patients (ages: 1 day to 16.7 years): 8.3 minutes (range: 2.5-18.5 minutes) (Fischer, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: Mean range: 7-15 minutes (Fischer, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Time for complete conversion to phenytoin:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M.: 4 hours after injection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 2 hours after the end of infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration (phenytoin):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Adults: 30-60 minutes from the beginning of fosphenytoin infusion (Fischer, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Neonates and Infants &le;6 months: 1-3 hours was reported in a case series (n=3; PNA: 15-47 days) (Fischer, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pediatric  patients &gt;7 months: Therapeutic concentrations within 30-40 minutes; time to maximum serum concentration not reported (Fischer, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 0% fosphenytoin excreted in urine",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1053065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosing equivalency: Fosphenytoin sodium 1.5 mg is equivalent to phenytoin sodium 1 mg which is equivalent to fosphenytoin 1 mg",
"     <b>",
"      PE",
"     </b>",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Fosphenytoin is water soluble and has a lower pH (8.8) than phenytoin (12), irritation at injection site or phlebitis is reduced.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Formaldehyde production from fosphenytoin is not expected to be clinically significant in adults with short-term use (eg, 1 week); potentially harmful amounts of phosphate and formaldehyde could occur with an overdose of fosphenytoin; fosphenytoin is more water soluble than phenytoin and, therefore, the injection does not contain propylene glycol; antiarrhythmic effects should be similar to phenytoin",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Overdose may result in: Lethargy, nausea, vomiting, hypotension, syncope, tachycardia, bradycardia, asystole, cardiac arrest, hypocalcemia, and metabolic acidosis; fatalities have also been reported",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Adams BD, Buckley NH, Kim JY, et al, \"Fosphenytoin May Cause Hemodynamically Unstable Bradydysrhythmias,\"",
"      <i>",
"       J Emerg Med",
"      </i>",
"      , 2006, 30(1):75-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/45/23258/abstract-text/16434340/pubmed\" id=\"16434340\" target=\"_blank\">",
"        16434340",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brophy GM, Bell R, Claassen J, et al, \"Guidelines for the Evaluation and Management of Status Epilepticus,\"",
"      <i>",
"       Neurocrit Care",
"      </i>",
"      , 2012, 17(1):3-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/45/23258/abstract-text/22528274/pubmed\" id=\"22528274\" target=\"_blank\">",
"        22528274",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fischer JH, Cwik MS, Luer MS, et al, &ldquo;Stability of Fosphenytoin Sodium With Intravenous Solutions in Glass Bottles, Polyvinyl Chloride Bags, and Polypropylene Syringes,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1997, 31(5):553-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/45/23258/abstract-text/9161647/pubmed\" id=\"9161647\" target=\"_blank\">",
"        9161647",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fischer JH, Patel TV, and Fischer PA, \"Fosphenytoin: Clinical Pharmacokinetics and Comparative Advantages in the Acute Treatment of Seizures,\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2003, 42(1):33-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/45/23258/abstract-text/12489978/pubmed\" id=\"12489978\" target=\"_blank\">",
"        12489978",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guerrini R, \"Epilepsy in Children,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2006, 367(9509):499-524.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/45/23258/abstract-text/16473127/pubmed\" id=\"16473127\" target=\"_blank\">",
"        16473127",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hegenbarth MA and American Academy of Pediatrics Committee on Drugs, \"Preparing for Pediatric Emergencies: Drugs to Consider,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(2):433-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/45/23258/abstract-text/18245435/pubmed\" id=\"18245435\" target=\"_blank\">",
"        18245435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jamerson BD, Dukes GE, Brouwer KL, et al, \"Venous Irritation Related to Intravenous Administration of Phenytoin Versus Fosphenytoin,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1994, 14(1):47-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/45/23258/abstract-text/8159601/pubmed\" id=\"8159601\" target=\"_blank\">",
"        8159601",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kochanek PM, Carney N, Adelson PD, et al, \"Guidelines for the Acute Medical Management of Severe Traumatic Brain Injury in Infants, Children, and Adolescents-Second Edition,\"",
"      <i>",
"       Pediatr Crit Care Med",
"      </i>",
"      , 2012, 13(Suppl 1):S1-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/45/23258/abstract-text/22217782/pubmed\" id=\"22217782\" target=\"_blank\">",
"        22217782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Koul R and Deleu D, \"Subtherapeutic Free Phenytoin Levels Following Fosphenytoin Therapy in Status Epilepticus,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2002, 58(1):147-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/45/23258/abstract-text/11781425/pubmed\" id=\"11781425\" target=\"_blank\">",
"        11781425",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kriel RL and Cifuentes RF, \"Fosphenytoin in Infants of Extremely Low Birth Weight,\"",
"      <i>",
"       Pediatr Neurol",
"      </i>",
"      , 2001, 24(3):219-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/45/23258/abstract-text/11301224/pubmed\" id=\"11301224\" target=\"_blank\">",
"        11301224",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lewis RJ, Yee L, Inkelis SH, et al, \"Clinical Predictors of Post-Traumatic Seizures in Children With Head Trauma,\"",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1993, 22(7):1114-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/45/23258/abstract-text/8517559/pubmed\" id=\"8517559\" target=\"_blank\">",
"        8517559",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McBryde KD, Wilcox J, and Kher KK, \"Hyperphosphatemia Due to Fosphenytoin in a Pediatric ESRD Patient,\"",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 2005, 20(8):1182-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/45/23258/abstract-text/15965770/pubmed\" id=\"15965770\" target=\"_blank\">",
"        15965770",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meek PD, Davis SN, Collins DM, et al, \"Guidelines for Nonemergency Use of Parenteral Phenytoin Products: Proceedings of an Expert Panel Consensus Process. Panel on Nonemergency Use of Parenteral Phenytoin Products,\"",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1999, 159(22):2639-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/45/23258/abstract-text/10597754/pubmed\" id=\"10597754\" target=\"_blank\">",
"        10597754",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morton LD, \"Clinical Experience With Fosphenytoin in Children,\"",
"      <i>",
"       J Child Neurol",
"      </i>",
"      , 1998, 13(Suppl 1):S19-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/45/23258/abstract-text/9796748/pubmed\" id=\"9796748\" target=\"_blank\">",
"        9796748",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ogutu BR, Newton CR, Muchohi SN, et al, \"Pharmacokinetics and Clinical Effects of Phenytoin and Fosphenytoin in Children With Severe Malaria and Status Epilepticus,\"",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 2003, 56(1):112-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/45/23258/abstract-text/12848783/pubmed\" id=\"12848783\" target=\"_blank\">",
"        12848783",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pellock JM, &ldquo;Fosphenytoin Use in Children,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1996, 46(6 Suppl 1):S14-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/45/23258/abstract-text/8649608/pubmed\" id=\"8649608\" target=\"_blank\">",
"        8649608",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pryor FM, Gidal B, Ramsay RE, et al, \"Fosphenytoin: Pharmacokinetics and Tolerance of Intramuscular Loading Doses,\"",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 2001, 42(2):245-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/45/23258/abstract-text/11240597/pubmed\" id=\"11240597\" target=\"_blank\">",
"        11240597",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Takeoka M, Krishnamoorthy KS, Soman TB, et al, \"Fosphenytoin in Infants,\"",
"      <i>",
"       J Child Neurol",
"      </i>",
"      , 1998, 13(11):537-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/45/23258/abstract-text/9853645/pubmed\" id=\"9853645\" target=\"_blank\">",
"        9853645",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Young KD, Okada PJ, Sokolove PE, et al, \"A Randomized, Double-Blinded, Placebo-Controlled Trial of Phenytoin for the Prevention of Early Posttraumatic Seizures in Children With Moderate to Severe Blunt Head Injury,\"",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 2004, 43(4):435-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/45/23258/abstract-text/15039684/pubmed\" id=\"15039684\" target=\"_blank\">",
"        15039684",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13327 Version 50.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.172.26-C9598D4138-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_45_23258=[""].join("\n");
var outline_f22_45_23258=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15795819\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174565\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053056\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442543\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053049\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174535\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174519\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053061\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174599\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053053\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053060\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174602\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174598\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053064\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053048\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053047\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174587\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174528\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174531\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174546\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053055\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053059\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053046\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053063\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053065\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13327\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13327|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/51/14138?source=related_link\">",
"      Fosphenytoin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/11/15540?source=related_link\">",
"      Fosphenytoin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_45_23259="Sulfonylurea with renally-eliminated active metabolites";
var content_f22_45_23259=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sulfonylureas with significant renally-eliminated, active metabolites",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Sulfonylurea",
"       </td>",
"       <td class=\"subtitle1\">",
"        Active, renally-eliminated metabolite",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acetohexamide",
"       </td>",
"       <td>",
"        Hydroxyhexamide, 65 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chlorpropamide",
"       </td>",
"       <td>",
"        <p>",
"         Chlorpropamide, 20 percent",
"        </p>",
"        <p>",
"         2-Hydroxychlorpropamide, 55 percent",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tolazamide",
"       </td>",
"       <td>",
"        <p>",
"         Hydroxytolazamide, 35 percent",
"        </p>",
"        <p>",
"         Tolazamide, 7 percent",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tolbutamide",
"       </td>",
"       <td>",
"        Hydroxytolbutamide, 30 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glimepiride",
"       </td>",
"       <td>",
"        Cyclohexylhydroxymethyl derivative, 63 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glyburide",
"       </td>",
"       <td>",
"        4-hydroxyglyburide, 36 percent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Bosse, GM. Antidiabetes and Hypoglycemics. In: Goldfrank's Toxicologic Emergencies, 8th Edition, Goldfrank, LR, Flomenbaum, NE, Hoffman, RS, et al (Eds), McGraw Hill, New York 2006. p. 749.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_45_23259=[""].join("\n");
var outline_f22_45_23259=null;
var title_f22_45_23260="Predisposing factors MDS";
var content_f22_45_23260=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F72951&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F72951&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Myelodysplastic syndromes: predisposing factors and epidemiologic associations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Heritable predisposition",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Constitutional genetic disorders",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Down syndrome (trisomy 21)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Trisomy 8 mosaicism",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Familial monosomy 7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Neurofibromatosis 1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Germ cell tumors (embryonal dysgenesis)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Congenital neutropenia (Kostmann's or Shwachman-Diamond syndrome)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       DNA repair deficiencies",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Fanconi's anemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Ataxia telangiectasia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Bloom's syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Xeroderma pigmentosum",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mutagen-detoxification (GSTq1-null)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Acquired",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Senescence",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Mutagen exposure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Genotoxic therapy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Alkylators",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Topoisomerase II interactive agents",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Beta-emitters (eg, radioactive P-32)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Hematopoietic cell transplantation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Environmental/occupational (eg, benzene)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Tobacco use",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Aplastic anemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Paroxysmal nocturnal hemoglobinuria (PNH)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Polycythemia vera",
"       </p>",
"       <p>",
"        Obesity",
"       </p>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: List AF, Doll DC. The Myelodysplastic Syndromes. Wintrobe's Clinical Hematology, 10th edition, Lee GR (Ed), Lippincott Williams &amp; Wilkins, Baltimore 1999. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_45_23260=[""].join("\n");
var outline_f22_45_23260=null;
var title_f22_45_23261="Biodegradeable soft tissue fillers";
var content_f22_45_23261=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F71066&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F71066&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Examples of biodegradable filling agents*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Filler type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Properties",
"       </td>",
"       <td class=\"subtitle1\">",
"        Uses",
"       </td>",
"       <td class=\"subtitle1\">",
"        Duration",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        Hyaluronic acid (HA)",
"       </td>",
"       <td>",
"        Restylane",
"        <sup>",
"         &reg;",
"        </sup>",
"        <br/>",
"        Restylane-L",
"        <sup>",
"         &reg;",
"        </sup>",
"        <br/>",
"        Perlane",
"        <sup>",
"         &reg;",
"        </sup>",
"        <br/>",
"        Perlane-L",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        Non-animal HA; cross-linked with BDDE",
"       </td>",
"       <td>",
"        Correction of moderate to severe wrinkles and folds (eg, nasolabial folds); lip enhancement",
"       </td>",
"       <td>",
"        6 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Juv&eacute;derm",
"        <sup>",
"         &reg;",
"        </sup>",
"        Ultra",
"        <br/>",
"        Juv&eacute;derm",
"        <sup>",
"         &reg;",
"        </sup>",
"        Ultra XC",
"        <br/>",
"        Juv&eacute;derm",
"        <sup>",
"         &reg;",
"        </sup>",
"        Ultra Plus",
"        <br/>",
"        Juv&eacute;derm",
"        <sup>",
"         &reg;",
"        </sup>",
"        Ultra Plus XC",
"        <br/>",
"        Juv&eacute;derm",
"        <sup>",
"         &reg;",
"        </sup>",
"        Voluma",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Non-animal, cross-linked HA; XC formulations contain lidocaine",
"       </td>",
"       <td>",
"        Correction of moderate to severe wrinkles and folds (eg, nasolabial folds)",
"       </td>",
"       <td>",
"        6 to 12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elevess&trade;",
"       </td>",
"       <td>",
"        Non-animal HA + lidocaine; cross-linked with BCDI, sodium metabisulfite preservative",
"       </td>",
"       <td>",
"        Correction of moderate to severe wrinkles and folds (eg, nasolabial folds)",
"       </td>",
"       <td>",
"        12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prevelle",
"        <sup>",
"         &reg;",
"        </sup>",
"        Silk",
"       </td>",
"       <td>",
"        Non-animal HA + lidocaine",
"       </td>",
"       <td>",
"        Correction of moderate to severe wrinkles and folds (eg, nasolabial folds)",
"       </td>",
"       <td>",
"        6 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Teosyal",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        Non-animal HA, cross-linked with BDDE; reduced protein and bacterial endotoxin level, no lidocaine",
"       </td>",
"       <td>",
"        Correction of fine lines to deeper rhytides and facial sculpting",
"       </td>",
"       <td>",
"        6 to 12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Revanesse",
"        <sup>",
"         &reg;",
"        </sup>",
"        Ultra",
"       </td>",
"       <td>",
"        Non-animal HA, cross-linked with BDDE",
"       </td>",
"       <td>",
"        Correction of moderate to deep rhytides, as well as lipoatrophy and facial wasting",
"       </td>",
"       <td>",
"        6 to 12 months",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Calcium hydroxylapatite microspheres (CaHA)",
"       </td>",
"       <td>",
"        Radiesse",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        Synthetic CaHA microspheres (25-45 &micro;m) suspended in an aqueous carboxymethylcellulose gel carrier",
"       </td>",
"       <td>",
"        For correction of moderate-to-severe facial wrinkles and folds (eg, nasolabial folds); for the correction of facial lipoatrophy",
"       </td>",
"       <td>",
"        12 months",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Poly-L-lactic acid (PLLA)",
"       </td>",
"       <td>",
"        Sculptra",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td rowspan=\"2\">",
"        Microparticles of PLLA induce fibroblastic activity; PLLA particles are eventually metabolized",
"       </td>",
"       <td>",
"        For restoration and/or correction of facial lipoatrophy",
"       </td>",
"       <td rowspan=\"2\">",
"        12 to 24 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sculptra",
"        <sup>",
"         &reg;",
"        </sup>",
"        Aesthetic",
"       </td>",
"       <td>",
"        For correction of shallow to deep nasolabial fold contour deficiencies and other facial wrinkles",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Autologous fat",
"       </td>",
"       <td>",
"        n/a",
"       </td>",
"       <td>",
"        Harvesting and reinjection of fat",
"       </td>",
"       <td>",
"        Dermal/lip augmentation",
"       </td>",
"       <td>",
"        Months to years",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Platelet-rich fibrin matrices (PRFM)",
"       </td>",
"       <td>",
"        SELPHYL",
"        <sup>",
"         &reg;",
"        </sup>",
"        System",
"       </td>",
"       <td>",
"        PRFM generated through collection and centrifugation of blood; stimulates cell proliferation and skin rejuvenation over time",
"       </td>",
"       <td>",
"        Glabellar lines, nasolabial folds, acne or post-operative scars, full-face contouring, and other dermal defects",
"       </td>",
"       <td>",
"        3 months to years",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BDDE: butanediol diglycidyl ether; BCDI: biscarbodiimide.",
"     <br/>",
"     * Collagen-based filling agents are additional biodegradeable fillers.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     The duration of filler effect tends to be longer in the upper face and mid face than in the perioral region.",
"     <br/>",
"     &Delta; Pending FDA approval as XC formulation.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_45_23261=[""].join("\n");
var outline_f22_45_23261=null;
var title_f22_45_23262="Contents: Immunology basic science";
var content_f22_45_23262=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?3/39/3710\">",
"       Rheumatology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Immunology basic science",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Immunology basic science",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Cell biology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/37/16986\">",
"           An overview of the innate immune system",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/49/22293\">",
"           Peptide hormone signal transduction and regulation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/54/13159\">",
"           Polymerase chain reaction",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cellular immunity",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/53/25432\">",
"           Antigen presenting cells",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/38/5735\">",
"           Apoptosis and autoimmune disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/41/17048\">",
"           Determinants of neutrophil movement",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/22/36201\">",
"           Immunology of the maternal-fetal interface",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/54/36711\">",
"           Leukocyte-endothelial adhesion in the pathogenesis of inflammation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/6/34921\">",
"           Mast cell derived mediators",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/22/44393\">",
"           Mast cells: Development, identification, and physiologic roles",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/28/20936\">",
"           Mast cells: Surface receptors and signal transduction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/31/6650\">",
"           Neutrophil functions other than movement",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/23/31098\">",
"           Normal B and T lymphocyte development",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/2/6185\">",
"           Normal neutrophil development and kinetics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/54/37733\">",
"           T cell receptor genetics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/58/41897\">",
"           T helper subsets: Differentiation and role in disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/58/6056\">",
"           The adaptive cellular immune response",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/54/23401\">",
"           Toll-like receptors: Roles in disease and therapy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Complement",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/59/11190\">",
"           Complement pathways",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/58/42920\">",
"           Inherited disorders of the complement system",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/25/10647\">",
"           Overview and clinical assessment of the complement system",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/38/10854\">",
"           Regulators and receptors of the complement system",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cytokines and inflammation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/42/38569\">",
"           Acute phase reactants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/22/16746\">",
"           Cytokine networks in rheumatic diseases: Implications for therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/37/28249\">",
"           Glucocorticoid effects on the immune system",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/57/3992\">",
"           Overview of autoimmunity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/50/10025\">",
"           Role of cytokines in rheumatic diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/8/4231\">",
"           Role of cytokines in the immune system",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         HLA",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/63/23546\">",
"           HLA and other susceptibility genes in rheumatoid arthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/38/24167\">",
"           Human leukocyte antigens (HLA): A roadmap",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/41/27283\">",
"           Major histocompatibility complex (MHC) structure and function",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Humoral immunity",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/53/40792\">",
"           Function and clinical applications of immunoglobulins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/52/37702\">",
"           Immunoglobulin genetics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/9/7318\">",
"           Structure of immunoglobulins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/62/27624\">",
"           The humoral immune response",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Transplantation immunology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/43/44729\">",
"           Biology of the graft-versus-tumor effect following hematopoietic cell transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/51/33590\">",
"           Gene therapy for primary immunodeficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/2/1066\">",
"           Hematopoietic cell transplantation for primary immunodeficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/24/18826\">",
"           Pathogenesis of graft-versus-host disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/27/10682\">",
"           Transplantation immunobiology",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-D54B02960D-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f22_45_23262=[""].join("\n");
var outline_f22_45_23262=null;
var title_f22_45_23263="Fibroid embolization 2a";
var content_f22_45_23263=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62884&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62884&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fibroid embolization 2a",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 331px; height: 303px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diagram showing superselective catheter position in the right uterine artery via left femoral arterial approach.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_45_23263=[""].join("\n");
var outline_f22_45_23263=null;
